{
    "pos": [
        [
            "The performance of method applied to both zero-shot and zero-shot-CoT base-lines",
            "Model  Llama-3.1-8B  Gemma-7/b  Mistral-7B-v0.3  Method  Zero-shot Zero-shot + Ours Zero-shot-CoT Zero-shot-CoT + Ours  Zero-shot Zero-shot + Ours Zero-shot-CoT Zero-shot-CoT + Ours  Zero-shot Zero-shot + Ours Zero-shot-CoT Zero-shot-CoT + Ours  Arithmetic  15.56% 50.56 % 77.22% 78.33 %  10.00% 15.00% 46.11% 73.33%  16.11% 27.78% 29.44% 37.22%  MultiArith GSM8&K  6.97% 34.57% 48.90 % 34.34%  48.98 % 45.26% 38.59% 44.81%  7.739% 15.31% 17.21% 15.39%  Commonsense  26.35% 30.13% 24.31% 45.27%  31.88% 34.79 % 19.36% 23.44%  23.58% 25.62 % 16.30% 36.83 %  36.00% 37.20% 32.00% 34.00%  10.80% 16.80% 34.00% 36.00%  34.40% 37.20% 13.20% 32.00%  Logical  StrategyQA DisambiguationQA Logical Deduction  28.40% 32.00% 16.80% 24.80%  24.80% 27.20% 18.80% 24.00%  14.80% 18.00% 28.80 % 20.40%  Avg  22.66% 36.90% 39.85% 43.35 %  25.29% 27.81% 31.37% 40.32%  19.32% 24.78 % 20.99% 28.37 % \f"
        ],
        [
            "The analysis of PTSD symptoms and PAIN follow-up",
            "PTSD 11 PTSD T2 PTSD T3 PAIN 11 PAIN T2 PAIN T3  PTSD T1  1.00  PTSD T2  fon 1.00  PTSD T3  1\" 88*** 1.00  PAIN 11  17  26\"  26\" 1.00  PAIN T2  22 Jo ae .61*** 1.00  PAIN T3  18  oO  Pe  Bo  80*** 1.00  PAIN follow-up  22 O1* A3\"\"\" A3\"\"\" 65*** 1™* \f"
        ],
        [
            "Helthcare Tools/methods and description",
            "Tool/Method  Iterative Improvement Cycles Plan-Do-Study-Act (PDSA) Cycle Plan-Do-Check-Act (PDCA) Cycle  Collaborative Problem-Solving Tools  Brainstorming Sessions  Description  A structured, iterative approach to testing and implementing changes [73].  Collaborative problem-solving methods to generate creative and actionable solutions [74]. \f"
        ],
        [
            "Categorical predictor variables, by sex and total",
            "   Variables        Women Total Xx? n % n % n % Sociodemographic: Sex 198 34.6 375 65.4 573 100 Marital status: Widower 17 8.6 120 32.0 137 23.9 X*=89.289, p=0.001 *“e Married 156 78.8 143 38.1 299 52.2 Never married 7 3.5 55 14.7 62 10.8 Divorced 18 9.1 57 15.2 75 82.5 Type of cohabitation (Who do you live with? ): Couple t 159 80.3 164 43.7 323 56.4 X*=70.461, p=0.001 *“e Children 94 47.5 170 45.3 264 46.1 X*=0.239, p=0.686 Parents 4 2.0 7 1.9 11 1.9 X*=0.016, p= 1.000 Siblings 6 3.0 26 6.9 32 5.6 X*=3.744, p=0.056 (Great)grandson 23 11.6 75 20.0 98 17.1 X*=6,.424, p=0.013 * Other 31 15.7 87 23.2 118 20.6 X*=4.060, p=0.0439 * Social participation: church 91 46.0 244 65.1 335 58.5 X*=19.481, p=0.001 *“e peer group (MAS program) 25 12.6 73 19.5 98 17.1 X*=4.277, p=0.063 In community group 74 374 205 54.7 279 48.7 X*=15.511, p=0.001 ms Caregiver of a family member 21 10.6 87 23.2 108 18.8 X*=13.437, p=0.001 “* Exposure to stressful events: 1. Own illness 51 25.8 104 27./ 155 27.1 X’=0.256, p=0.623 2. Illness of a family member 66 33.3 133 35.5 199 34.7 X*=0.260, p =0.647 3. Death of a loved one 8 40 16 4.3 24 42 X*=0.017, p=1.000 4, Death of a close friend 78 39.4 113 30.1 191 33.3 X*=5.001, p=0.027 * 5. Separation of the couple / 3.5 11 2.9 18 3.1 X*=0.154, p=0.800 6. Breakup of a stable relationship 5 2.5 6 1.6 11 1.9 X*=0.589, p=0.566 7. Serious problem with a friend or close friend 14 7.1 29 7./ 43 7.5 X?=0.082, p=0.861 8. Unemployment or unsuccessful job search 8 40 7 1.9 15 2.6 X*=2.402, p=0.182 9. You have been fired from your job t - - 2 0.5 2 0.3 X*=1.060, p=0.544 10. Serious economic crisis 24 12.1 51 13.6 /5 13.1 X*=0.249, p=0.708 11. Problems with the police or justice 4 2.0 8 2.1 12 2.1 X*=0.008, p= 1.000 12. Victim of theft 18 9.1 39 10.4 57 9.9 X’=0.248, p=0.666 13. Another type of problem 6 3.0 26 6.9 32 5.6 X*=3.744, p=0.049 * \f"
        ],
        [
            "Macroscopic features, Microscopic features and Reverse side for the fungi",
            "Isolates code  B2S3  B4S82  B3S4 b2  B2S2 al  B382 a  B3S3 bl  B4S4 b  B3S2 b  B3S2 A  B3S1 b  B3S3 b  B4S2  B3S4 b2  B3S1 A  B4S4  Accession no.  MZ569410  MZ569411  MZ569412  MZ569413  MZ569414  MZ569415  MZ569416  MZ569417  MZ569418  MZ569419  MZ569420  MZ569421  MZ569422  MZ569423  MZ569424  Macroscopic features  Greenish with white margin, fast growing, velvety  Greenish-gray, cottony, fast growing Grayish, fast growing, velvety  Grayish, powdery surface, fast growing  Greenish with white margin, powdery texture, fast growing  Grayish, powdery texture, fast growing  Greenish-gray, velvety, fast growing  Green with brown appearance at the center, fast growth, cottony  Green with white margin, fast growth, cottony  Brownish with white margin, wooly appearance, fast growing  Olive with shiny white margin, slow growing, velvety  Grayish with brown center, fast growing, powdery texture  Greenish, velvety, fast growth  Brownish, powdery texture, fast growth  Surface green with white periphery, slow growing, wooly  Microscopic features  Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore  Branching hyphae, septate, and hyaline club-shaped conidiophore  Branching hyphae, septate, and hyaline club-shaped conidiophore  Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore  Branching hyphae, septate, and hyaline club-shaped conidiophore     Reverse side  Cream  Cream  Cream  Cream  Cream  Cream  Cream  Cream  Cream  Brown  Brown  Cream  Brown  Brown  Cream \f"
        ],
        [
            "Task and result for each track",
            "Concepts ,  2,737| 3,298) 482] 673] 1,687| 3,297|1,516 FISH-ZOOPLANKTON | 145] 56 56] 34 7) 15 ALGAE-ZOOBENTHOS}] 108} 128 123} 24) 27| 18 Nell-DBpedia  Eee Yago-Wikidata  129 304 MI-EMMO MSE MI-MatOnto  232| 9536} 704} 63 114, 536) 793) 302     482 145  Puenorvrs [5] HP-MP____|12,7S6/11,928/4,387)/4,430]12,646|11,498) 606 64 \f"
        ],
        [
            "Risk estimated for incident cerebrovascular disease using the Cox proportional hazards model",
            "Variables  Patients  Comparison (ref.)  Kidney transplant recipients At different follow-up time In 6 months  Comparison (ref.)  Kidney transplant recipients In 1 year  Comparison (ref.)  Kidney transplant recipients In 3 years  Comparison (ref.)  Kidney transplant recipients In 5 years  Comparison (ref.)  Kidney transplant recipients  Cerebrovascular Disease  Adjusted HR  1 1.43  0.53  0.82  1.07  1.26  95% CI  1.23  0.28  0.52  0.81  1.01  1.68  0.99  1.30  1.41  1.57  p-value  <0.001  0.049  0.394  0.658  0.048 \f"
        ],
        [
            "The mean cosine similarity scores across our ensemble of five independently trained models. ",
            "Comparison Script Indus Proto-Cuneiform Proto-Elamite TYC 0.635 0.102 0.078 Naxi-Dongba 0.634 0.109 0.087  Old-Naxi 0.617 0.106 0.076 \f"
        ],
        [
            "Comparison with conventional algorithms",
            "Deception Series (N = 42) Non-Deception Series (N = 36)  Correct Incorrect Inconclusive Correct Incorrect Inconclusive PolyScore 17 6 19 15 5 16 OSS-3 24 18 0 28 7 1 This study (w/o PPG) at 0 5 35 0 1 This study 44 0 1 36 0 0  (w/PPG) \f"
        ],
        [
            "The outcomes of the Intensive BP control group, n (%) Standard BP control group, n (%) Risk ratio(95% CI)",
            "Efficacy outcomes All-cause mortality MACE Cardiovascular death Stroke  Myocardial infarction Heart failure  Safety outcomes Hypotension Syncope  Arrhythmia  Acute kidney injury Electrolyte abnormalities  Studies  [7, 8, [7, 8, [7, 8, [7, 8, [7, 8, [7, 8,  [7, 8, [7, 8, [7, 8, [7, 8, [7, 8,  15, 15, 16] 15, 15, 16]  16] 15, 16] 16] 16]  16] 16]  16] 16]  16]  Intensive BP control  group, n (%)  672/19,712 (3.4)  1458/19,712 (7.4)  220/19,079 (1.2 690/19,712 (3.5 383/19,712 (1  305/19,079 (1  Neer Ne ee  I .6  131/19,078 (0.7) 149/19,711 (0.8) 246/19,078 (1.3) 205/19,078 (1.1)  1,204/19,078 (6.3)  Standard BP control  group, n (%)  778/19,722 (3.9)  1765/19,722 (8.9)  305/19,092 (1.6) 851/19,722 (4.3) 462/19,722 (2.3) 386/ 19,092 (2.0)  63/19,092 (0.3)  100/19,722 (0.5) 211/19,092 (1.1) 123/19,092 (0.6) 950/ 19,092 (5.0)  Risk ratio (95% CI)  0.87 0.83 0.73 0.81 0.83 0.79  0.76-0.99) 0.77-0.88) 0.56-0.94) 0.74-0.90) 0.73-0.95) 0.68-0.92)  ee ee EE  3.34 (1.26-8.87) 1.56 (1.09-2.23} 1.17 (0.93-1.49) 1.66 (1.33-2.07) 1.26 (1.13-1.40) \f"
        ],
        [
            "completeness, conciseness, faithfulness, acceptance for TNH-Eval and Likert human evaluations ",
            "Note  Human Llama 3.1 70B Mistral Large V2  Completeness  TNH_Eval  29.5 (412.4) 39.7 (+7.9) 38.1 (47.5)  Likert  2.85 (41.09) 3.80 (+0.79) 4.01 (40.70)  Conciseness TN_Eval Likert 75.6 (414.9) 4.28 (40.89) 84.0 (412.1) 4.83 (40.35) 91.5 (47.1) 4.88 (40.35)  Faithfulness TNH_Eval Likert 87.0 (412.6) 4.43 (+0.81) 68.5 (415.1) 4.68 (+0.50) 71.8 (414.0) 4.90 (40.34)  Acceptance  Likert  2.34 (40.75) 3.34 (40.61) 3.73 (+£0.70) \f"
        ],
        [
            "Comparison of TURBOFUZZLLM versus GPTFuzzer (Yu et al., 2023) on 200 harmful behaviors from\nHarmBench (Mazeika et al., 2024) text standard dataset with a target model query budget of 4000",
            "ASR (%) Average Queries Per Jailbreak | Number of Jailbreaking Templates  Model (higher is better) (lower is better) (higher is better)  | GPTFuzzer TURBOFUZZLLM | GPTFuzzer TURBOFUZZLLM | GPTFuzzer TURBOFUZZLLM GPT-40 28 98 73.32 20.31 8 38 GPT-40 Mini 34 100 60.27 14.43 e 28 GPT-4 Turbo 58 100 34.79 13.79 10 26 GPT-3.5 Turbo 100 100 3.12 2.84 8 12 Gemma 7B 100 100 13.10 6.88 22 30  Gemma 2B 36 100 57.13 10.15 14 27 \f"
        ],
        [
            "The differents Parameters effects to the  Control, HFD + Vehicle, HFD + Lut50, HFD + Lut100, HFD + Met100",
            "Parameters  Fasting blood glucose (mg/dL) Fasting serum insulin (mg/dL) HOMA-IR index AUC of OGTT (mg/dL*min)  Control 98.33 + 0.92  103.31 + 11.64 23.82 + 1.18 22,170 + 311.94  HFD + Vehicle 127.17 £1.96 2  260.21 + 26.94 * 74.58 = 9.72 * 27,540 + 468.09 ?  HFD + Lut50 112.83 + 2.07 ?  190.04 + 32.63 51.47 + 9.69 26,047.5 + 291.98 °  HED + Lut100 99.57 + 1.46 >¢  161.47 + 14.72 > 39.72 + 3.78 6 24,147.5 + 392.73 abc  HED + Met100 100.33 + 3.83 Pc  163.01 £ 17.55 > 44.84 + 3.92 > 24,285 + 488.88 ab \f"
        ],
        [
            "OAEI tracks and records statistics for sources, targets, and alignments. \"MI\"\nrefers to the \"MaterialInformation\" ontology, while \"S\" and \"T\" denote the source and\ntarget ontologies, respectively.",
            "Concepts ,  2,737| 3,298) 482] 673] 1,687| 3,297|1,516 FISH-ZOOPLANKTON | 145] 56 56] 34 7) 15 ALGAE-ZOOBENTHOS}] 108} 128 123} 24) 27| 18 Nell-DBpedia  Eee Yago-Wikidata  129 304 MI-EMMO MSE MI-MatOnto  232| 9536} 704} 63 114, 536) 793) 302     482 145  Puenorvrs [5] HP-MP____|12,7S6/11,928/4,387)/4,430]12,646|11,498) 606 64 \f"
        ],
        [
            "components and prompt for clinical diagnostic processes",
            "specification description  DSM-5 Criteria  Output format Answer  Output format (Answer + reasoning)  Few-shot examples     Prompt You are a highly experienced psychiatrist specializing in trauma and mental health disorders.  Your task 1s to analyze patient transcripts—containing only the patient's speech—and classify whether the patient has PTSD or not.  According to the DSM-5 diagnostic criteria, PTSD is characterized by: a. Intrusion Symptoms: At least one symptom such as recurrent, involuntary, and intrusive distressing memories of the traumatic event(s); recurrent distressing dreams related to the event(s); dissociative reactions (e.g., flashbacks) in which the event seems to recur; intense or prolonged psychological distress at exposure to internal or external cues that symbolize or resemble the traumatic event(s); or marked physiological reactions to such cues. b. Avoidance: Persistent avoidance of stimuli associated with the traumatic event(s), evidenced by efforts to avoid distressing memories, thoughts, or feelings about or closely associated with the event(s) and/or avoidance of external reminders (people, places, conversations, activities, objects, or situations) that trigger these memories. c. Negative Alterations in Cognitions and Mood: Two or more symptoms such as inability to remember an important aspect of the traumatic event(s) (typically due to dissociative amnesia); persistent an exaggerated negative beliefs or expectations about oneself, others, or the world; persistent, distorted cognitions about the cause or consequences of the traumatic event(s) leading to self-blame or blaming others persistent negative emotional state (e.g., fear, horror, anger, guilt, or shame); markedly diminished interest ir significant activities; feelings of detachment or estrangement from others; or a persistent inability to experience positive emotions. d. Alterations in Arousal and Reactivity: Two or more symptoms such as irritable behavior and angry outbursts (with little or no provocation); reckless or self-destructive behavior; hypervigilance; exaggerated startle response; problems with concentration; or sleep disturbances.  Based on these criteria and your analysis of linguistic patterns, coherence, sentiment, and emotional expressions in the transcript, output 0 if there 1s no indication of PTSD and 1 if PTSD 1s present. Provide only the classification result (0 or 1) without any additional explanation.  Based on these criteria and your analysis of linguistic patterns, coherence, sentiment, and emotional expressions in the transcript, output O if there 1s no indication of PTSD and 1 if PTSD 1s present. Format Your Output as Follows: - The classification at the start in the format: \"Final Classification: 0\" or \"Final Classification: 1\". - Step-by-step reasoning for the classification in less than 100 words.  Here are two examples, one positive and one negative: Transcript for a participant with PTSD: xxx. Classification: 1; Transcript for a participant without PTSD: xxx. Classification: 0  —_ wa Saige — ais — | ‘gi Sa hagas —\" we > ee eee \f"
        ],
        [
            "Stability of liposomal formulations during 45-day storage at 37",
            "Storage (day) Size (nm) Zeta potential (mV)  Fi F2 Fi F2 Fi F2  78 + 6.5 77 + 5.5 0.26 + 0.20 0.22 + 0.11  77 + 4.4 75 + 4.7 0.29 + 0.60 0.27 + 0.33 7445.4 75 £54 0.29 + 0.17 0.30 + 0.20 72 te Sod 74 + 6.1 0.34 + 0.11 0.40 + 0.47                \f"
        ],
        [
            "Evaluation focus for different benchmark/framework",
            "Benchmark/Framework Evaluation Focus Program Evals Automated Gen Executable # Domains # Tasks  SysBench (Qin et al., 2024) System Prompt Following Response Generation x x = - 500 ComplexBench (Wen et al., 2024) Constraint Following Response Generation x x - - 1,150 RuleArena (Zhou et al., 2024) Rule-Following Reasoning x x - 3 816 T-Bench (Yao et al., 2024) Agent Action Policy Following v x v 2 165 ToolEmu (Ruan et al., 2023) Agent Action Safety x J x - 311 AgentOrca (Ours) Agent Action Routine and Constraint Following Jv Jv v 5 663* \f"
        ],
        [
            "Overview of training data. M: Music; I: Image;\nV: Video; T: Text",
            "   Dataset Used for In—out modality  COCO Train stage | I+TT Music4way Train stage 2 I+T—T Music4way Train stages 1&2 V+T-T Music4way Train stages 1&2 M+TT Alpaca Train stage 2 TT MusicQA Train stage 2 M+T-T MusicCaps Train stage 2 M+T-T Music4way-MI2T _ Train stage 2 M+I+T-T  Music4way-MV2T _ Train stage 2 M+V+T-T \f"
        ],
        [
            "Llama3-8B, Llama3-8B-IT for safety benchmarks",
            "Model  Llama3-8B  Llama3-8B-IT  Tuning  SFT  SFT + DPO Backtrack-SFT Backtrack ERPO-SFT ERPO  SFT  DPO Backtrack-SFT Backtrack C?-SYN ERPO-SFT ERPO     Harmful QA Lab Safety SciKE (1) SciSE())  LabSB (t) 41.68 97.40 6.74 58.59 97.20 18.09 56.72 96.20 6.38 51.53 93.80 7.09 40.75 84.40 32.62 6.66 36.20 36.28 37.15 97.60 57.45 18.51 91.40 60.99 13.45 99.20 62.77 30.63 92.80 60.99 21.97 89.20 63.12 29.03 95.00 58.87 10.25 72.40 65.43 1.86 54.20 68.00 \f"
        ],
        [
            "Baseline characteristics of patients with r-axSpA",
            "Variables  Age (years) Sex (male, N (%)) BMI (kg/m?) TNFi source Adalimumab SC Golimumab SC Golimumab IV Infliximab SC Disease duration (years) Previous treatment before TNFi Nonsteroidal anti-inflammatory drugs Sulfasalazine TNFi treatment duration (years) HLA-B27 positivity  r-axSpA (N=20)  31.0 (25.5; 42.5) 13 (65.0%) 24.2 (22.5; 28.5)  Disease activity and functional index at baseline  BASDAI ASDAS-ESR ASDAS BASFI  Laboratory finding at baseline ESR (mm/h) CRP (mg/dL) White blood cell count (/uL) Hemoglobin (g/dL) Platelet (10?/yL) AST (IU/L) ALT (IU/L) BUN (mg/dL) Creatinine (mg/dL)  AxSpA manifestation Peripheral arthritis Uveitis Psoriasis Dactylitis Inflammatory bowel disease  14 (70.0%)  4 (20.0%)  | (5.0%)  | (5.0%)  3.5 (1.4; 10.0) 20 (100%)  17 (85%)  0.5 (0.5; 2.5)  16 (80.0%)  1.1 (1.0; 1.3)  1.1 (0.9; 1.4) 1.0 (0.9; 1.2)  1.1 (0.4; 1.6) 6.0 (4.5;13.5)  0.1 (0.0; 0.2) 6715.0 (5610.0; 9090.0) 14.1 (13.1; 14.6)  252.0 (217.5; 295.0) 27.5 (21.0; 33.0) 22.5 (14.5; 42.0) 14.4 (12.4; 16.8) 0.7 (0.7; 0.9)  9 (45.0%) 4 (20.0%) | (5.0%) 0  | (5.0%)  TNFi tapering success (N= 12)  32.0 (28.0; 45.5) 9 (75.0%) 23.2 (22.0; 26.8)  11 (91.7%) | (8.3%)  0  0  4.0 (3.0; 10.0)  12 (100%) I! (91.7%) 1.0 (0.5; 3.0) 10 (83.3%)  1.0 (0.8; 1.2) 0.9 (0.7; 1.3) 0.9 (0.9; 1.1) 0.5 (0.3; 1.4)  5.0 (3.0; 9.5) 0.1 (0.0; 0.1)  6560.0 (5410.0; 8980.0) 14.1 (13.1; 14.9)  247.5 (201.5; 290.5) 27.5 (23.0; 32.0)  25.0 (17.5; 43.5)  14.2 (11.7; 17.1)  0.8 (0.7; 0.9)  5 (41.7%) 4 (33.3%) | (8.3%) 0  0  TNFi tapering failure (N=8)  27.0 (23.0; 42.0) 4 (50.0%) 27.7 (23.6; 31.6)  3 (37.5%) 3 (37.5%) | (12.5%) | (12.5%) 1.8 (1.1; 9.5)  8 (100%) 6 (75%)  0.5 (0.5; 2.0) 6 (75.0%)  1.2 (1.1; 14) 1.3 (1.1; 1.4) 1.1 (1.0; 1.2) 1.6 (1.2; 1.6)  12.0 (6.5; 16.5) 0.1 (0.1; 0.2)  8260.0 (6180.0; 9650.0) 13.8 (12.4; 14.6)  258.0 (235.5; 296.5) 25.0 (18.0; 34.5)  19.0 (14.0; 42.0)  14.4 (13.6; 15.9)  0.7 (0.6; 0.8)  4 (50.0%) 0 0 0 | (12.5%)  0.296 0.356  0.009  0.46!  | .000 0.701 0.472 | .000  0.079 0.105 0.074 0.121  0.088 0.215 0.270 0.643 0.440 0.643 0.643 | .000 0.418  | .000 0.117 | .000 | .000 0.400 \f"
        ],
        [
            " Bivariate correlation matrix",
            "Age BMI Time from diagnosis (y) Exam duration (min) ECSO before exam ECSO intra exam ECSO after exam ECSO total PSS Test performed last 24 months (n)  Age  NA 0.23 *** 0.2 EH 0.1 * —0.02 —0.05 —0.01 —0.02 0.01  —0.07  BMI  NA —0.02 0.02 —0.04 —0.02 0.01  —0.01 —0.04  Years Diagnosis  NA 0.07 0.1 * 0.05 0.02 0.09  —0.11 *  Exam Duration (min)  NA —0.02 —0.04  0.02 —0.01 —0.01  —Q.24 ***  ECSQ ECSQ Before During NA  0.79 *** NA  0.70 *** 0.78 ***  0.84 *** 0.81 *** —0.18 *** —0.24 ***  —0.02 —0.01  ECSO After  NA 0.82 *** —Q.24 ***  —0.02  ECSOQ Total  NA —Q.27 ***  —0.01  Test Performed Last 24 Months (n)  PSS  NA —0.02 NA \f"
        ],
        [
            "The Human written notes compare with each LLM notes ",
            "Note Source  Human Notes Claude 3 Sonnet Claude 3 Haiku Llama 3.1 (70B) Llama 3.1 (8B) Mistral Large V2 Mistral (7B)  S.  76 (+57) 73 (+23) 97 (+25) 65 (+15) 94 (+25) 88 (+23) 86 (+25)  O.  32 (+21) 41 (+10) 46 (+11) 37 (£13) 56 (+13) 51 (+9) 51 (+10)  A.  a7 (+41) 64 (+13) 77 (+16) 61 (+11) 77 (+17) 65 (+12) 66 (+12)  P.  29 (+14) 71 (+12) 94 (+22) 795 (+11) 82 (+15) 74 (+11) 75 (+11) \f"
        ],
        [
            "The performance between smaller and Larger LLM",
            "Metric (Avg.) | ELM (Mistral) | ELM (Llama) | ELM (Qwen)        \f"
        ],
        [
            " 52 HCC patients with plasma samples collected from the Ronald Reagan UCLA Medical Center.",
            "B wt bw Ew ae ZBEUWSE  Characteristic Median age (IQR) Sex, male (%) Etiology (%)  HCV  HBV  MASH  ALD  Others Median largest tumor size, cm (IQR) Multiple nodules present (%) Median prior AFP, ng/ml (IQR) Median MELD score (IQR) BCLC stage (%)  0  A  B  C Transplant criteria  1  2  3  A LRT and/or ST before sample collection, yes (%) LRT and/or ST after sample collection, yes (%) Events (%)  Death  Recurrence or progression Median follow-up, months  Sw EEG SE WS No SHE oem 6 le Oe rf SEWEE GG j\\VWFWREGE EF  Poe  wwe E  =e ee  No. 66.5 (60.8, 72.0) 39 (75%)  23 (44.2%)  7 (13.5%)  15 (28.8%)  3 (5.8%)  4 (7.7%)  3.4 (2.2, 6.4) 15 (28.8%) 10.3 (5.0, 29.1) 8 (6, 9)  2 (3.8%) 33 (63.5%) 6 (11.5%) 11 (21.2%)  29 (55.8%) 5 (9.6%) 13 (25%) 5 (9.6%) 16 (30.8%) 21 (40.4%)  15 (28.8%) 31 (59.6%) 44 \f"
        ],
        [
            "relationship between difficulty level, method and average performance",
            "Order  Random Topological  Reversed  Method  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8  MEND  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8  MEND  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8  MEND  Difficulty Level     |  100.0 100.0 100.0 100.0 100.0 97.5  99.0 100.0 99.0 100.0 100.0 97.5  995 100.0 993 100.0 100.0 97.5  2  99.0 98.5 82.5 94.5 100.0 09.5  65.5 62.5 Tie 96.5 99.5 99.5  45.0 30.5 85.0 97.0 100.0 98.5  3  79.5 87.0 16.0 28.5 49.5 88.5  10.5 13.0 15.0 26.0 38.5 85.5  5.5 0.5 20.5 30.0 42.5 86.0  4  32.0 33.0 1.5 3.5 9.0 D1 el  0.0  1.0  3.0  4.5  12.5 37.5  1.0 0.5 2.5 4.5 8.0 41.0  Avg.  77.6 79.6 (+2.0) 50.0 (-27.6) 56.6 (-21.0) 64.6 (-13.0) 80.8 (+3.2)  43.8 44.1 (40.3) 48.6 (44.8) 56.8 (+13.0) 62.6 (+18.8) 80.0 (+36.2)  37.8 32.9 (-4.9) 51.9 (+14.1) 57.9 (+20.1) 62.6 (+24.8) 80.8 (+43.0) \f"
        ],
        [
            "Comparison of fibrinolysis kinetic parameters in the absence or presence of CORM-2",
            "Parameter CGT  IMRL  MRL  CLI  Condition  tPA tPA+CORM-2  tPA tPA+CORM-2  tPA tPA+CORM-2  tPA tPA+CORM-2  Value  1.6 + 0.1 2.6 + 0.3*  12+ 0.2 3.4 + 0.3*  6.2 + 0.5 8.3 + 0.5*  2.7 + 0.3 5.9 + 0.4 * \f"
        ],
        [
            "Using smaller LLMs in ELM",
            "Metric (Avg.) | ELM (Mistral) | ELM (Llama) | ELM (Qwen)        \f"
        ],
        [
            "Portico, Navitor, p-Value of the Transcatheter Aortic Valve Type outcomes",
            "Mean gradient (mmHg) * EOAi (cm*/m7) * PVRS No/trace Mild >mild  New PPI 8  Transcatheter Aortic Valve Type  Portico Navitor 8.5 (7.3-10.0) 9.0 (5.5-11.5) 0.93 + 0.22 1.06 + 0.30 36.8% 80.0% 63.2% 20.0%  0 0  0 13.3%  p-Value 0.856 0.170  0.017  0.176 \f"
        ],
        [
            "Survival and Mortality Outcomes",
            "Survival Outcome 30-day Mortality 90-day Mortality 9-Year Median Survival  10-Year Median Survival  TABLE 4: Survival and Mortality Outcomes  Value  1 (6.7%) 2 (13.3%) 9 (60%)  5 (33%) \f"
        ],
        [
            "descriptioin and example for different four type of contstrains",
            "l'ype single  And Or  Chain  Description  Only one constraint that must be satisfied before executing the action.  Multiple constraints that must all be simul- taneously satisfied.  A set of constraints where satisfying any one is sufficient to enable the action.  A sequence of constraints that all must be satisfied and verified in a specific order.  Example  To renew the vehicle, please verify the vehicle has valid insurance.  To schedule a driving test, please verify that the user is at least 16 years old AND has passed the knowledge test.  To verify the identification at the DMV, the user must provide either correct account password OR social security number.  To renew vehicle insurance, please first verify that the user has a regis- tered vehicle, THEN verify that the vehicle currently has insurance. \f"
        ],
        [
            "Information about dataet used for training ",
            "   Dataset Used for In—out modality  COCO Train stage | I+TT Music4way Train stage 2 I+T—T Music4way Train stages 1&2 V+T-T Music4way Train stages 1&2 M+TT Alpaca Train stage 2 TT MusicQA Train stage 2 M+T-T MusicCaps Train stage 2 M+T-T Music4way-MI2T _ Train stage 2 M+I+T-T  Music4way-MV2T _ Train stage 2 M+V+T-T \f"
        ],
        [
            "Time, Gender, Age, Sleep quality and parameters estimates for the model",
            "Mean Intercept Meditation Positive affect Sleep quality Meditation * sleep quality Time Gender Age  Meditation Positive affect Sleep quality Meditation * sleep quality Time Gender Age  Random intercept Residual variance  Within-level Between-level  Within-level Between-level  Within-level Between-level  AIC BIC —2LL Sample size  Model 1 Model 1 Mediator (PA) Dependent (Vitality) Within-person effects 6.64 *** —0.20 1.15 ** 0.07 - 0.84 *** —0.36 ** - —0.00 0.01 Between-person effects —0.24 0.23 *** - 0.79 *** —1.27 ** - 0.26 - —0.24 *** —0.00 0.41 * 0.20 * 0.05 0.06 Variance of random components 0.15 ** 0.00 0.21 *** 0.16 ***  Direct effect  0.07 CI 95% [—0.04, 0.18] 0.23 *** CI 95% [0.10, 0.35]  Indirect effect  Model 2  Model 2 Mediator (PA) Dependent (MH) 6.65 *** 0.54 1.15 ** —0.01 - 0.62 *** —0.36 ** - —0.00 0.00 —0.24 0.08 - 0.81 *** —1.27 ** - 0.25 - —0.24 *** 0.04 0.41 * 0.01 0.00 0.05 0.15 ** 0.04 ** 0.21 *** 0.10 ***  —0.01 CI 95% [—0.09, 0.09] 0.08 CI 95% [—0.08, 0.24]  0.96 ** CI 95% [0.19, 1.78] —0.19 CI 95% [—0.98, 0.58]  Conditional indirect effect —0.31 ** CI 95% [—0.57, —0.05] 0.20 CI 95% [—0.04, 0.46] Model fit statistics 533.11  548.64 925.11  0.72 ** CI 95% [0.14, 1.32] —0.19 CI 95% [—1.01, 0.60]  —0.23 ** CI 95% [—0.43, —0.04] 0.21 CI 95% [—0.04, 0.47]  477.79 493.32 469.79  L1 = 440; Ly = 44 \f"
        ],
        [
            "Age, gender, BMI, History of disease, Biomarkers of population",
            "YIVYyyeuY Vy PITSUUT y VI UIOWVE LEO        Characteristics All Non-DM DM P n 6737 6434 303 Age, years 58.4+8.8 58.4+8.8 58.8 + 8.0 0.458 Male, n(%) 3088(45.9)  2975(46.2) 113(37.3) 0.002 Height, m 1.6+0.1 1.6+0.1 1.6+0.1 0.561 Weight, kg 5884115 5854113 6384141 < 0.001 BMI, kg/m? 2344411 23.4+4.0 254+5.1 < 0.001 Waist, cm 85.1+9.9 84.8+9.8 90.8+9.9 < 0.001 BRI 42+14 42414 49414 < 0.001 CMI lat22 1242.1 1.94+3.3 < 0.001 Education level, n(%) Elementary 6087(90.4)  5821(90.5) 266(87.8) 0.282 school or below Secondary 570(8.5) 537(8.3) 33(10.9) school College and 77(1.1) 73(1.1) A(1.3) above History of disease, n(%) HTN 1391(20.7) 1253(19.5) 138(45.5) < 0.001 Dyslipidemia 475(7.2) 382(5.9) 93(30.7) < 0.001 CVD at 1481(22.0) 1369(21.3) 112(37) < 0.001 follow-up Personal history, n(%) Smoking 2577(38.3)  2483(38.6) 94(31) 0.008 Drinking 1747(25.9) 1692(26.3) 55(18.2) 0.002 Physical activity 2589(38.4)  2476(38.5) 113(37.3) 0.676 Biomarkers WBC(x107/L) 6.3+1.9 6.2+1.9 6.5+1.9 0.030 Plt (x107/L) 212.0+73.0 2120+73.2  2114+70.1 0.893 FBG (mg/dL) 109.5+35.2 10684284 165.2+84.7 <0.001 Cr (umol/L) 0.8+0.2 0.8+0.2 0.8+0.2 0.863 TC (mg/dL) 194.2+38.7 19404387 1979+439.1 0.084 TG (mg/dL) 133.0041114 1314+4109.5 167.34142.1 <0.001 HDL-C (mg/dL) 5154154 5184154 462+154 <0.001 LDL-C (mg/dL) 116.7+34.7 11664346 11834362 0.398 CRP (mg/L) 24+6.5 24+6.5 28453 0.276 HbA1c (%) 5.3+0.8 5.2+0.6 6.6+1.8 < 0.001 HCT (%) 41.5+63 41.5+63 41.3458 0.521 Hb (g/L) 144422 144422 14.2+2.0 0.279    \f"
        ],
        [
            "Results in a zero-shot scenario on IEMOCAP.",
            "zero-shot zero-shot + Behavior Acc. w-Fl Acc. w-Fl     GPT-40-mini 53.72 51.39 54.09 52.73 Gemini 55.63 55.10 55.88 55.28 Qwen-2.5-72B | 56.07 54.77 59.03 57.92 Phi-4-14B 55.21 53.20 55.67 55.18 \f"
        ],
        [
            "comparison between Llama 3.3 w/style,w/instr, w/topics",
            "Llama 3.3 70B Instruct w/STYLE Ww/INSTR w/TOPICS wW/STYLE wW/TOPICS W/INSTR W/TOPICS  Q-shot 0.175 0.184 0.210 0.226 0.225 0.230  3-shot 0.210 0.215 0.223 0.227 0.225 0.230  RI +20% +17%  +6% +0% +0% +0% \f"
        ],
        [
            "Trends in hemoglobin levels, serum M-spike, free light chain ratio, and bone marrow plasma cell percentage during treatment",
            "Laboratory Hemoglobin  o/dL  Serum  IgG lambda, M-spike:  o/dL  Free light chain ratio (0.26—1.65)  % Of plasma cell in the bone marrow  Prior to Cl” 4.2  2.56  45.5  15%  End of Cl 10.1  0.95  6.12  End of C3 14.8  0.52  1.94  End of C5 14.2  0.35  1.96  End of C7 14.7  1.56  End of C9 13.9  1.37  End of C12 15  1.27  1%, MRD negative \f"
        ],
        [
            "Size, Zeta potential, EE,PDI of liposomal",
            "Storage (day) Size (nm) Zeta potential (mV)  Fi F2 Fi F2 Fi F2  78 + 6.5 77 + 5.5 0.26 + 0.20 0.22 + 0.11  77 + 4.4 75 + 4.7 0.29 + 0.60 0.27 + 0.33 7445.4 75 £54 0.29 + 0.17 0.30 + 0.20 72 te Sod 74 + 6.1 0.34 + 0.11 0.40 + 0.47                \f"
        ],
        [
            "Main experimental results compared to baselines on four benchmarks",
            "Category  In-context  Vanilla RAG  Advanced  RAG  Ours  Model  GLM-4-9B (128k) GLM-4-32B(128k) GLM-4-9B(128k) GLM-4-32B(128k) QwQ-32B Self-RAG(Llama2-7b) SearChain(GPT-40) Search-o | (QwQ-32B) ReaRAG-9B  MuSiQue  ACC; EM  23.50 15.00 33.50 17.00 25.50 14.00 29.00 17.00 36.00 20.00 24.00 13.00 S150 33.00 40.50 32.00 66.00 40.00  Multi-hop HotpotQA  ACC, 58.00 65.50 68.00 67.50 67.00 45.50 69.00 55.50 75.50  EM 47.00 50.00 52.00 52.00 47.00 31.00 49.00 38.00 56.00  IRC  ACC, 20.50 25.00 28.25 28.25 38.25 25.00 40.50 32.25 42.75  EM 18.00 16.00 23.00 17.00 32.00 13.00 20.50 27.00 29.00  Single-hop  NQ  ACC, 45.50 52.50 49.00 53.00 48.00 40.00 54.00 43.00 52.00  EM 26.00 24.00 32.00 39.00 26.00 28.00 25.00 28.00 25.00 \f"
        ],
        [
            "Disease response, as-treated population",
            "PONIN B LLU EBDY LESVPULIOY, GAD°UUAWY PUPUIalYit  Parameter  Best overall response,*(“) CR PR mCR SD PD Transformation to AML Non-PR/Non-PD Non-evaluable OR (confirmed CR+mCR+ PR),1(“%) 95% CI HI, n/m(%)P HI-E HI-P HI-N Progression/relapse after HI, n/m(%)° HI-E HI-P HI-N PFS,“months, median (80% CI)  6-month PFS rate,“(80% CI) OS,‘months, median (80% Cl)  6-month OS rate,“(80% CI)  Part 1: durvalumab monotherapy  Low/int-1 (n=18)  0 0  3 (17)  8 (44)  0  0  5 (28)  2 (11)  3 (17) (3.6, 41.4) 5/18 (28) 3/18 (17) 1/10 (10) 3/11 (27) 2/5 (40) 1/3 (33) 0/1 (0)  1/3 (33) 22.3 (11.9, 24.3)  88.5 (74.0, 95.2)  23.8 (15.5, 27.7)  88.9 (74.7, 95.4)  Int-2/high (n=22)  0 0  3 (14)  6 (27)  3 (14)  0  9 (41)  1 (5)  3 (14) (2.9, 34.9) 9/22 (41) 2/22 (9) 3/18 (17) 4/19 (21) 1/9 (11) 0/2 (0) 0/3 (0) 1/4 (25)  6.0 (4.0, 7.4)  50.0 (35.8, 62.7)  8.0 (5.5, 9.3)  59.1 (44.5, 71.1)  Total (N=40)  0 0  6 (15)  14 (35)  3 (8)  0  14 (35)  3 (8)  6 (15) (5.7, 29.8) 14/40 (35) 5/40 (13) 4/28 (14) 7/30 (23) 3/14 (21) 1/5 (20) 0/4 (0)  2/7 (29) 9.0 (7.4, 11.4)  66.5 (55.8, 75.2)  11.8 (9.2, 14.1)  71.7 (61.3, 79.8)  Part 2: durvalumab combination therapy  Durva  + treme 25 mg  (n=3)  1 (33)  1 (33)  1 (33) (0.8, 90.6) 0/3 (0)  0/3 (0)  0/2 (0)  0/2 (0)  0/0  0/0  0/0  0/0  9.3 (2.2, 11.5)  66.7 (22.9, 89.4)  9.3 (2.2, 11.5)  66.7 (22.9, 89.4)  Durva  + treme 75 mg  (n=17)  0 0  2 (12)  1 (6)  2 (12)  1 (6)  8 (47)  4 (24)  2 (12) (1.5, 36.4) 7/17 (41) 1/17 (6) 4/17 (24) 5/15 (33) 0/7 (0)  0/1 (0) 0/4 (0)  0/5 (0)  3.7 (3.6, 4.1)  25.5 (12.1, 41.2)  5.3 (3.7, 6.8)  43.2 (27.0, 58.4)  Durva  + treme 75 mg  + aza (1=7)  0  0  1 (14)  1 (14)  0  0  1 (14)  4 (57)  1 (14) (0.4, 57.9) 1/7 (14) 0/7 (0) 0/7 (0)  1/6 (17) 0/1 (0) 0/0  0/0  0/1 (0) NR (NE, NE)  60.0 (27.9, 81.5)  NR (NE, NE)  60.0 (27.9, 81.5)  Total (N=27)  0 0  4 (15)  2 (7)  2 (7)  I (4)  10 (37)  9 (33)  4 (15) (4.2, 33.7) 8/27 (30) 1/27 (4) 4/26 (15) 6/23 (26) 0/8 (0)  0/1 (0) 0/4 (0)  0/6 (0)  3.8 (3.7, 6.6)  38.1 (24.9, 51.2)  5.3 (3.7, 7.6)  49.9 (36.0-62.2)    \f"
        ],
        [
            "Parameter estimates for the multilevel moderated mediation models",
            "Mean Intercept Meditation Positive affect Sleep quality Meditation * sleep quality Time Gender Age  Meditation Positive affect Sleep quality Meditation * sleep quality Time Gender Age  Random intercept Residual variance  Within-level Between-level  Within-level Between-level  Within-level Between-level  AIC BIC —2LL Sample size  Model 1 Model 1 Mediator (PA) Dependent (Vitality) Within-person effects 6.64 *** —0.20 1.15 ** 0.07 - 0.84 *** —0.36 ** - —0.00 0.01 Between-person effects —0.24 0.23 *** - 0.79 *** —1.27 ** - 0.26 - —0.24 *** —0.00 0.41 * 0.20 * 0.05 0.06 Variance of random components 0.15 ** 0.00 0.21 *** 0.16 ***  Direct effect  0.07 CI 95% [—0.04, 0.18] 0.23 *** CI 95% [0.10, 0.35]  Indirect effect  Model 2  Model 2 Mediator (PA) Dependent (MH) 6.65 *** 0.54 1.15 ** —0.01 - 0.62 *** —0.36 ** - —0.00 0.00 —0.24 0.08 - 0.81 *** —1.27 ** - 0.25 - —0.24 *** 0.04 0.41 * 0.01 0.00 0.05 0.15 ** 0.04 ** 0.21 *** 0.10 ***  —0.01 CI 95% [—0.09, 0.09] 0.08 CI 95% [—0.08, 0.24]  0.96 ** CI 95% [0.19, 1.78] —0.19 CI 95% [—0.98, 0.58]  Conditional indirect effect —0.31 ** CI 95% [—0.57, —0.05] 0.20 CI 95% [—0.04, 0.46] Model fit statistics 533.11  548.64 925.11  0.72 ** CI 95% [0.14, 1.32] —0.19 CI 95% [—1.01, 0.60]  —0.23 ** CI 95% [—0.43, —0.04] 0.21 CI 95% [—0.04, 0.47]  477.79 493.32 469.79  L1 = 440; Ly = 44 \f"
        ],
        [
            "Attribute description for stocks",
            "Attribute Investment Budget Investment Term Risk Tolerance Market Environment  Category  Description ‘[ have {budget} US dollars to invest.’ ‘My investment term is {term}’ ‘My risk tolerance is {risk}.’ ‘The market environment is {env}.  ‘I tend to invest in {category} stocks.’ \f"
        ],
        [
            "Llama-2, Llama-3, Mistral, Qwen 2.5 perfromance comparison",
            "Models  Llama-2 7B  Llama-3 8B  Mistral 7B  Qwen 2.5 7B  Datasets > Method | Naive AbsInst M:  Ma Naive AbsInst M:  Ma Naive AbsInst M:  Ma Naive AbsInst Mt  Ma  Acc  0.6194 0.5425 ().7243 0.5968  0.6218 0.5312 ().7549 0.6792  0.6270 0.6149 ().7546 0.5940  0.5870 0.4672 0.6250 0.5174  TriviaQA  Truth  0.6194 0.7015 0.7243 0.8943  0.6218 0.7643 0.7550 0.8471  0.6270 0.7123 0.7547 (0.8954  0.5901 0.8261 0.6251 0.7747  Rely  0.6194 0.6762 0.7243 0.8058  0.6218 0.7100 0.7550 0.8189  0.6270 0.7028 0.7547 0.8045  0.5900 0.6973 0.6251 0.7085  Acc  0.4177 0.3309 0.5742 0.4889  0.4443 0.4200 0.6013 0.5141  0.4444 0.3304 0.6104 0.4899  0.4523 0.3788 0.5023 0.4467  NQ Truth  0.4177 0.7112 0.5746 0.7908  0.4444 0.7322 0.6013 0.7931  0.4444 0.6929 0.6105 0.8311  0.4529 0.8023 0.5028 0.7144  Rely  0.4177 0.5665 0.5746 (0.6996  0.4444 0.6347 0.6013 0.7153  0.4444 0.5615 0.6105 0.7147  0.4529 0.6230 0.5028 0.6427  Acc  0.4342 0.3591 0.4619 0.3767  0.4529 0.3590 0.4712 0.4367  0.4586 0.3459 0.4736 0.3611  0.4413 0.3759 0.4222 0.3730  HotpotQA  Truth  0.4342 0.4828 0.4621 0.8359  0.4529 0.5193 0.4712 0.7015  0.4586 0.6251 0.4736 0.8390  0.4451 ().7932 0.4222 0.7095  Rely  0.4342 0.4675 0.4621 0.6251  0.4529 0.4936 0.4712 0.6314  0.4586 0.5471 0.4736 0.6106  0.4450 0.6191 0.4222 0.5963  Acc  0.5402 0.3849 0.5811 0.3999  0.5656 0.4914 0.6313 0.5563  0.5911 0.4634 0.6499 0.4372  0.5735 0.4487 0.5197 0.4415  BioASQ  Truth  0.5402 0.6456 0.5818 0.8723  0.5656 0.6815 0.6313 ().7679  0.5911 0.7496 0.6499 0.8788  0.5742 0.8361 0.5204 0.7898  Rely  0.5402 0.5776 0.5818 (0.6492  0.5656 0.6454 0.6313 0.7232  0.5911 0.6677 0.6499 0.6838  0.5742 0.6860 0.5204 0.6685 \f"
        ],
        [
            "GPT-4o,OpenAI o1,DeepSeek-V3,Qwen 2.5-Max  performance result",
            "Top wall lm/s > jvetoaty | amis” |v | fw |v Top wall Im /s > ssineag)| x |v | x | Cavity Mov! seston | ase |v | |v | resolution —+ x15xl1l | v Vv  [endTime | 35 [v| |v |v  ‘Turbulence [Model |RNGKepitoy v || x | ‘Turbulence “ode! |komegessr| v | | v | ‘Turbulence [nodal | witiomega | x |v | x | ‘Turbulence node | urr_[v| | x | 10m/s > niet vetocty| “20mys fv | |v | x PitzDaily | ‘Turbulence Model [uOmegassr| v || x | Turbulence |Smagorinsky nodal | aes) |v | |v | HOT_WALL 310K > [iotroom | temperature| 320 |v | |v |v Liquid inside all [ole membrane | water — oil Dambreak ‘Turbulence cv] fe]  Velocity of the lm/s > fluid/particles _2m /s  Particle : Particle [pe oF Raid | A> CO TV [v7  Turbulence model KEpsilon x x x  Angular 20rad/s —> 15rad/s v x x v x  x x  \\ \\             speed of Mixed rotation vessel ‘Turbulence Model      KEpsilon    \f"
        ],
        [
            "Accuracy (Acc), truthfulness (Truth), and reliability (Rely) scores across in-domain (TriviaQA and NQ)\nand out-of-domain (HotpotQA and BioASQ) datasets",
            "Models  Llama-2 7B  Llama-3 8B  Mistral 7B  Qwen 2.5 7B  Datasets > Method | Naive AbsInst M:  Ma Naive AbsInst M:  Ma Naive AbsInst M:  Ma Naive AbsInst Mt  Ma  Acc  0.6194 0.5425 ().7243 0.5968  0.6218 0.5312 ().7549 0.6792  0.6270 0.6149 ().7546 0.5940  0.5870 0.4672 0.6250 0.5174  TriviaQA  Truth  0.6194 0.7015 0.7243 0.8943  0.6218 0.7643 0.7550 0.8471  0.6270 0.7123 0.7547 (0.8954  0.5901 0.8261 0.6251 0.7747  Rely  0.6194 0.6762 0.7243 0.8058  0.6218 0.7100 0.7550 0.8189  0.6270 0.7028 0.7547 0.8045  0.5900 0.6973 0.6251 0.7085  Acc  0.4177 0.3309 0.5742 0.4889  0.4443 0.4200 0.6013 0.5141  0.4444 0.3304 0.6104 0.4899  0.4523 0.3788 0.5023 0.4467  NQ Truth  0.4177 0.7112 0.5746 0.7908  0.4444 0.7322 0.6013 0.7931  0.4444 0.6929 0.6105 0.8311  0.4529 0.8023 0.5028 0.7144  Rely  0.4177 0.5665 0.5746 (0.6996  0.4444 0.6347 0.6013 0.7153  0.4444 0.5615 0.6105 0.7147  0.4529 0.6230 0.5028 0.6427  Acc  0.4342 0.3591 0.4619 0.3767  0.4529 0.3590 0.4712 0.4367  0.4586 0.3459 0.4736 0.3611  0.4413 0.3759 0.4222 0.3730  HotpotQA  Truth  0.4342 0.4828 0.4621 0.8359  0.4529 0.5193 0.4712 0.7015  0.4586 0.6251 0.4736 0.8390  0.4451 ().7932 0.4222 0.7095  Rely  0.4342 0.4675 0.4621 0.6251  0.4529 0.4936 0.4712 0.6314  0.4586 0.5471 0.4736 0.6106  0.4450 0.6191 0.4222 0.5963  Acc  0.5402 0.3849 0.5811 0.3999  0.5656 0.4914 0.6313 0.5563  0.5911 0.4634 0.6499 0.4372  0.5735 0.4487 0.5197 0.4415  BioASQ  Truth  0.5402 0.6456 0.5818 0.8723  0.5656 0.6815 0.6313 ().7679  0.5911 0.7496 0.6499 0.8788  0.5742 0.8361 0.5204 0.7898  Rely  0.5402 0.5776 0.5818 (0.6492  0.5656 0.6454 0.6313 0.7232  0.5911 0.6677 0.6499 0.6838  0.5742 0.6860 0.5204 0.6685 \f"
        ],
        [
            "Characteristics of the baseline population in 2011,\ngrouped by history of diabetes",
            "YIVYyyeuY Vy PITSUUT y VI UIOWVE LEO        Characteristics All Non-DM DM P n 6737 6434 303 Age, years 58.4+8.8 58.4+8.8 58.8 + 8.0 0.458 Male, n(%) 3088(45.9)  2975(46.2) 113(37.3) 0.002 Height, m 1.6+0.1 1.6+0.1 1.6+0.1 0.561 Weight, kg 5884115 5854113 6384141 < 0.001 BMI, kg/m? 2344411 23.4+4.0 254+5.1 < 0.001 Waist, cm 85.1+9.9 84.8+9.8 90.8+9.9 < 0.001 BRI 42+14 42414 49414 < 0.001 CMI lat22 1242.1 1.94+3.3 < 0.001 Education level, n(%) Elementary 6087(90.4)  5821(90.5) 266(87.8) 0.282 school or below Secondary 570(8.5) 537(8.3) 33(10.9) school College and 77(1.1) 73(1.1) A(1.3) above History of disease, n(%) HTN 1391(20.7) 1253(19.5) 138(45.5) < 0.001 Dyslipidemia 475(7.2) 382(5.9) 93(30.7) < 0.001 CVD at 1481(22.0) 1369(21.3) 112(37) < 0.001 follow-up Personal history, n(%) Smoking 2577(38.3)  2483(38.6) 94(31) 0.008 Drinking 1747(25.9) 1692(26.3) 55(18.2) 0.002 Physical activity 2589(38.4)  2476(38.5) 113(37.3) 0.676 Biomarkers WBC(x107/L) 6.3+1.9 6.2+1.9 6.5+1.9 0.030 Plt (x107/L) 212.0+73.0 2120+73.2  2114+70.1 0.893 FBG (mg/dL) 109.5+35.2 10684284 165.2+84.7 <0.001 Cr (umol/L) 0.8+0.2 0.8+0.2 0.8+0.2 0.863 TC (mg/dL) 194.2+38.7 19404387 1979+439.1 0.084 TG (mg/dL) 133.0041114 1314+4109.5 167.34142.1 <0.001 HDL-C (mg/dL) 5154154 5184154 462+154 <0.001 LDL-C (mg/dL) 116.7+34.7 11664346 11834362 0.398 CRP (mg/L) 24+6.5 24+6.5 28453 0.276 HbA1c (%) 5.3+0.8 5.2+0.6 6.6+1.8 < 0.001 HCT (%) 41.5+63 41.5+63 41.3458 0.521 Hb (g/L) 144422 144422 14.2+2.0 0.279    \f"
        ],
        [
            "Roughness characteristic of all the prepared membranes",
            "Membrane Code  PO Pl p2 p3 p4 P5 1% FP4 2% FPA  Average Surface Roughness (Ra) nm  64.76 66.96 81.53 93.94 95.93 56.17 156.3 175  Root Mean Square (Rq) nm  78.68 83.28 100.2 115.2 115.1 69.56 196.3 212.7  Maximum Height (Rz) nm  455.6 499.9 641.6 706.3 600 466.2 1294 1122 \f"
        ],
        [
            "Prompt Structure for PTSD prediction",
            "specification description  DSM-5 Criteria  Output format Answer  Output format (Answer + reasoning)  Few-shot examples     Prompt You are a highly experienced psychiatrist specializing in trauma and mental health disorders.  Your task 1s to analyze patient transcripts—containing only the patient's speech—and classify whether the patient has PTSD or not.  According to the DSM-5 diagnostic criteria, PTSD is characterized by: a. Intrusion Symptoms: At least one symptom such as recurrent, involuntary, and intrusive distressing memories of the traumatic event(s); recurrent distressing dreams related to the event(s); dissociative reactions (e.g., flashbacks) in which the event seems to recur; intense or prolonged psychological distress at exposure to internal or external cues that symbolize or resemble the traumatic event(s); or marked physiological reactions to such cues. b. Avoidance: Persistent avoidance of stimuli associated with the traumatic event(s), evidenced by efforts to avoid distressing memories, thoughts, or feelings about or closely associated with the event(s) and/or avoidance of external reminders (people, places, conversations, activities, objects, or situations) that trigger these memories. c. Negative Alterations in Cognitions and Mood: Two or more symptoms such as inability to remember an important aspect of the traumatic event(s) (typically due to dissociative amnesia); persistent an exaggerated negative beliefs or expectations about oneself, others, or the world; persistent, distorted cognitions about the cause or consequences of the traumatic event(s) leading to self-blame or blaming others persistent negative emotional state (e.g., fear, horror, anger, guilt, or shame); markedly diminished interest ir significant activities; feelings of detachment or estrangement from others; or a persistent inability to experience positive emotions. d. Alterations in Arousal and Reactivity: Two or more symptoms such as irritable behavior and angry outbursts (with little or no provocation); reckless or self-destructive behavior; hypervigilance; exaggerated startle response; problems with concentration; or sleep disturbances.  Based on these criteria and your analysis of linguistic patterns, coherence, sentiment, and emotional expressions in the transcript, output 0 if there 1s no indication of PTSD and 1 if PTSD 1s present. Provide only the classification result (0 or 1) without any additional explanation.  Based on these criteria and your analysis of linguistic patterns, coherence, sentiment, and emotional expressions in the transcript, output O if there 1s no indication of PTSD and 1 if PTSD 1s present. Format Your Output as Follows: - The classification at the start in the format: \"Final Classification: 0\" or \"Final Classification: 1\". - Step-by-step reasoning for the classification in less than 100 words.  Here are two examples, one positive and one negative: Transcript for a participant with PTSD: xxx. Classification: 1; Transcript for a participant without PTSD: xxx. Classification: 0  —_ wa Saige — ais — | ‘gi Sa hagas —\" we > ee eee \f"
        ],
        [
            "AlpacaEval 2 and Arena-Hard results under the four settings",
            "Method  SFT  DPO IPO CPO KTO ORPO R-DPO SimPO  LMPO  Method  SFT  DPO IPO CPO KTO ORPO R-DPO SimPO  LMPO  Mistral-Base (7B)  AlpacaEval 2 LC(%) WR(%) 6.2 4.6 15.1 12.5 11.8 9.4 9.8 8.9 13.1 9.1 14.7 12.2 17.4 12.8 17.7 16.5 20.9 14.9  Length  1082  1477 1380 1827 1144 1475 1335 1803  1351]  Llama-3-Base (8B)  AlpacaEval 2 LC(%) WR(%) 8.4 6.2 18.2 15.5 14.4 14.2 12.3 13.7 14.2 12.4 12.2 10.6 17.6 14.4 21.6 20.0 21.3 17.7  Length  914  1585 1856 2495 1646 1628 1529 1818  1601  Arena-Hard WR(%) ~~ Length 3.3 437 10.4 628 7.5 674 5.8 823 5.6 475 7.0 764 9.9 528 14.3 709 13.8 458 Arena-Hard WR(%) Length 1.3 521 15.9 563 17.8 608 11.6 SOO 12.5 519 10.8 639 17.2 527 26.9 877 30.1 1114  AlpacaEval 2 Arena-Hard LC (%) WR (%) Length WR (%)  17.1 14.7 1676 12.6 26.8 24.9 1808 16.3 20.3 20.3 2024 16.2 23.8 28.8 3245 22.6 24.5 23.6 1901 17.9 24.5 24.9 2022 20.8 27.3 24.5 1784 16.1 29.7 31.7 2350 22.3 29.8 28.0 1881 23.5  Llama-3-Instruct (8B)  AlpacaEval 2 Arena-Hard LC (%) WR(%) Length WR (%)  26.0 25.3 1920 22.3 40.3 37.9 1883 32.6 35.6 35.6 1983 30.5 28.9 32.2 2166 28.8 33.1 31.8 1909 26.4 28.5 27.4 1888 25.8 41.1 37.8 1854 33.1 43.9 39.0 1788 33.8 43.7 39.0 1791 34.3  Mistral-Instruct (7B)  Length 486  518 740 812 496 527 495 572  485  Length 596  528 554 624 536 535 522 502  AT] \f"
        ],
        [
            "Pass Rate of Models Across Five Domains. Overall score is averaged across all tasks from five domains.Large reasoning models are highlighted, which were evaluated only on the healthcare domain due to high costs",
            "Model  GPT-40 (FC)  GPT-40-mini (FC) Claude-3-5-Sonnet (FC) Gemini-2.0-Flash (FC) Gemini-1.5-Pro (FC) Qwen2.5-72B-Instruct (FC) Llama3.1-70B-Instruct (FC)  ol (FC) Gemini-2.0-Flash-Thinking (ReAct) Deepseek-R1 (ReAct)  Bank  64.71 34.64 71.90 56.86 54.25 36.60 38.56  DMV  80.87 70.43 50.43 54.78 60.00 45.22 41.74  Library  65.38 46.15 33.33 26.92 26.92 30.77 37.18  Healthcare  73.85 26.15 39,23 23.08 18.46 28.46 25.38 91.54 83.08 54.69  Market  63.64 45.99 43.32 40.11 34.22 22.99 19.79  Overall  69.08 43.74 49.17 41.63 39.37 31.98 31.07 \f"
        ],
        [
            "Owners’ agreement with statements relating to experiences of caring for their cats with CKD (n = 100)",
            "Statement  My daily routine has changed a lot since my cat was diagnosed with CKD  The care of my cat has negatively impacted/restricted my life  | feel Supported by my veterinary practice with regard to my cat's care  | feel comfortable making decisions with a veterinarian about my cat's care  | feel comfortable making decisions with a veterinary nurse about my cat's care  | feel | am knowledgeable about CKD in cats  | am able to determine/assess my cat’s quality of lite  | feel confident | am able to monitor the progression of my cat’s CKD  | feel my cat’s condition has improved since starting treatment  Being a caregiver to my cat has given me ourpose and a sense of accomplishment  strongly agree  31 (31) 14 (14) 42 (42) 39 (39) 26 (26) 28 (28) 26 (26) 28 (28) 22 (22)  26 (26)  Agree  35 (35) 23 (23) 28 (28) 41 (41) 22 (22) 50 (50) 54 (54) ee 30 (30)  ZO) Z5))  Neither agree nor disagree  14 (14) 20 (20) 20 (20) 15 (15) 38 (38) 12 (12) 12 (12) 25 (25) 30 (30)  33 (33)  Disagree  strongly disagree \f"
        ],
        [
            "Macro F1 between the human majority vote and evaluators. F1 scores are converted to binary using a τ = 0.5",
            "Candidate  GPT-3.5  GPT-40  Gemini  Task  AmbigQA HotpotQA  AmbigQA HotpotQA  AmbigQA HotpotQA  EM  0.758 0.790  0.733 0.763  0.772 0.732  Fl  0.828 0.877  0.774 0.830  0.783 0.829  GPT-3.5  0.611 0.527  0.591 0.532  0.582 0.553  Judge w/o Tool GPT-40  0.697 0.609  0.683 0.669  0.668 0.617  Gemini  0.792 0.665  0.780 0.675  0.614 0.619  GPT-3.5  0.784 0.706  0.802 0.770  0.819 0.816  TALE  GPT-40  0.898 0.779  0.957 0.850  0.873 0.846  Gemini  0.830 0.762  0.957 0.839  0.835 0.797 \f"
        ],
        [
            "Ablation analysis of R3Mem on  PG9, arXiv, C4",
            "Model | PG19 arXiv C4 (4K+)  Fine-tuned Base 8.10 4.31 19.04 R°Mem-context-only 7.15 3.69 17.16 R°Mem-short-context 7.44 3.83 17.60  R°Mem-w/o-backward | 6.41 = 3.21 15.83  R°Mem-w/o-cycle 5.91 2.87 14.80  R°Mem 5.21 2.39 13.38    \f"
        ],
        [
            "Unstandardized and standardized SEM regression weights for longitudinal moderation by resolution in non-treatment groups (model 8)",
            "Model 8: Non-treatment groups Maternal age — T3 Sensitivity  Verbal ability — T3 Sensitivity Neglect history — T3 Sensitivity Resolution — T3 Sensitivity  Neglect x Resolution — T3 Sensitivity  B -.009  040 —.019 035  051  SE  007 014 053 019  018  —129 264 —.040 204  287  005 721  005  164  0597  ** \f"
        ],
        [
            "comparison between AILS-NTUA, YNU, ZJUKLAB ",
            "Environment  Online  Local  Algorithm AILS-NTUA  YNU  Mr.Snuffleupagus ZJUKLAB (ours)  NPO+GDR+KLR (model; ) NPO+GDR+KLR (model?)  Ours  Aggregate  (0.706 0.470 0.376 0.487  0.481 0.504 (0.806  Task Aggregate  0.827 0.834 0.387 0.944  0.968 0.659 0.939  MIA Score/MIA AUC MMLU Avg.  0.847 / — 0.139 /- 0.256 / — 0.048 / —  0.045 / 0.022* 0.364 / 0.8184 0.997 / 0.501\"  0.443 0.436 0.485 0.471  0.431 0.491 0.480 \f"
        ],
        [
            "The isotherm models and error functions used in the study",
            "Isotherm  Freundlich  Langmuir  Abbreviation  SSE  RMSE  Isotherm Models  Nonlinear Form Linear Form           q = Kp-Coql!™ logq = logKp- j;l0gCeq _ 4maxKtCeq Cog __ Ceg 1 q — 1+K,Ceg Q  Qmax KL max  Error functions  Definition / expression  it 2 L (Fe, cal — Jeexp); i=l 7 decal The adsorption capacity value obtained from calculations. E » (qe, exp — Ye cal ); de,exp— The adsorption capacity value measured experimentally. i=] n—The total number of data points in the experimental observations. 2 \" (Geexp —4e,cal) y wee | Ae cal  Parameters  Kr—Freundlich constant associated with  the system’s adsorption capacity and intensity, expressed in units of mg/g(L/mg)!/\"\". 1/n—Represents the adsorption favorability and is a dimensionless parameter.  Qmax—The maximum capacity of adsorption, measured in mg/g. K,—The Langmuir constant, reflecting the binding site affinity and the adsorption energy, with units of L/mg.  Parameters  Ref.  [54]  [55]  Ref.  [53] \f"
        ],
        [
            "model performance comparison on ASR, Average Queries Per Jailbreak, Number of Jailbreaking Templates",
            "ASR (%) Average Queries Per Jailbreak | Number of Jailbreaking Templates  Model (higher is better) (lower is better) (higher is better)  | GPTFuzzer TURBOFUZZLLM | GPTFuzzer TURBOFUZZLLM | GPTFuzzer TURBOFUZZLLM GPT-40 28 98 73.32 20.31 8 38 GPT-40 Mini 34 100 60.27 14.43 e 28 GPT-4 Turbo 58 100 34.79 13.79 10 26 GPT-3.5 Turbo 100 100 3.12 2.84 8 12 Gemma 7B 100 100 13.10 6.88 22 30  Gemma 2B 36 100 57.13 10.15 14 27 \f"
        ],
        [
            "Ozone water screening experiment treatment conditions",
            "Z, s  he  Pretreatment Method  Ozone water 1 Ozone water 2 Ozone water 3 Ozone water 4 Ozone water 5 Ozone water 6 Ozone water 7 Ozone water 8 Ozone water 9 Ozone water 10 Ozone water 11 Ozone water 12  Description  Continuous immersion of 10 mg/L ozone water for 60 s Continuous immersion of 10 mg/L ozone water for 90 s Continuous immersion of 10 mg/L ozone water for 120s Continuous immersion of 10 mg/L ozone water for 150 s Continuous immersion of 15 mg/L ozone water for 60 s Continuous immersion of 15 mg/L ozone water for 90 s Continuous immersion of 15 mg/L ozone water for 120s Continuous immersion of 15 mg/L ozone water for 150s Continuous immersion of 20 mg/L ozone water for 60 s Continuous immersion of 20 mg/L ozone water for 90 s Continuous immersion of 20 mg/L ozone water for 120s Continuous immersion of 20 mg/L ozone water for 150s \f"
        ],
        [
            "Effect of luteolin treatment on glucose homeostasis in HFD-induced MAFLD rats",
            "Parameters  Fasting blood glucose (mg/dL) Fasting serum insulin (mg/dL) HOMA-IR index AUC of OGTT (mg/dL*min)  Control 98.33 + 0.92  103.31 + 11.64 23.82 + 1.18 22,170 + 311.94  HFD + Vehicle 127.17 £1.96 2  260.21 + 26.94 * 74.58 = 9.72 * 27,540 + 468.09 ?  HFD + Lut50 112.83 + 2.07 ?  190.04 + 32.63 51.47 + 9.69 26,047.5 + 291.98 °  HED + Lut100 99.57 + 1.46 >¢  161.47 + 14.72 > 39.72 + 3.78 6 24,147.5 + 392.73 abc  HED + Met100 100.33 + 3.83 Pc  163.01 £ 17.55 > 44.84 + 3.92 > 24,285 + 488.88 ab \f"
        ],
        [
            "Comparison of used large language models",
            "Top wall lm/s > jvetoaty | amis” |v | fw |v Top wall Im /s > ssineag)| x |v | x | Cavity Mov! seston | ase |v | |v | resolution —+ x15xl1l | v Vv  [endTime | 35 [v| |v |v  ‘Turbulence [Model |RNGKepitoy v || x | ‘Turbulence “ode! |komegessr| v | | v | ‘Turbulence [nodal | witiomega | x |v | x | ‘Turbulence node | urr_[v| | x | 10m/s > niet vetocty| “20mys fv | |v | x PitzDaily | ‘Turbulence Model [uOmegassr| v || x | Turbulence |Smagorinsky nodal | aes) |v | |v | HOT_WALL 310K > [iotroom | temperature| 320 |v | |v |v Liquid inside all [ole membrane | water — oil Dambreak ‘Turbulence cv] fe]  Velocity of the lm/s > fluid/particles _2m /s  Particle : Particle [pe oF Raid | A> CO TV [v7  Turbulence model KEpsilon x x x  Angular 20rad/s —> 15rad/s v x x v x  x x  \\ \\             speed of Mixed rotation vessel ‘Turbulence Model      KEpsilon    \f"
        ],
        [
            "Results for the YELP, IHS, and DIALOCONAN (DC) datasets",
            "Ours Baselines  Metries SSVAE  Similarity + 45.8  IHS Strength + 41.1 ; ; 43.8 Fluency | ; 130.7 ; 77.3  GM + 40.7 . . , ; 35.9  HM + 34.9 : , , ; 34.0  Similarity + , , 69.2 ‘ , 33.5  Yelp Strength + . ; 88.0 76.6 Fluency | ; 161.5 : ; ; 42.4  GM + : : ; 48.2 40.9  HM + , 38.9 : , 37.3  Similarity + ‘ 73.1 , , 36.6  DC Strength + ; 63.5 , , 55.5  Fluency | ; . 91.4 ; ; 36.4 GM + ; 46.0 ‘ , , 38.4 HM + ; 38.9 : ’ , 36.9    \f"
        ],
        [
            "MM,  DLBCL,  AML,  FL, ALL,  AA, CML, MDS, ATL,  and MCL for patients",
            "Patients Samples Positive (> 0.5) Positive Positive (>1.0) Positive Samples (>0.5) Rate Samples (>1.0) Rate Total 330 2155 540 25% 235 10.9% MM 77 453 279 61.3% 111 24.5% DLBCL 74 313 63 20% 29 9.3% AML 52 533 54 10.1% 23 4.3% teell 16 73 5 6.8% 3 4.1% lymphoma FL 12 51 15 29% 4 7.8% ALL 12 91 6 6.6% 0 0 AA 12 75 5 6.7% 4 5.3% CML 10 145 7 4.8% 2 1.4% MDS 10 70 14 20% 6 8.6% ATL 9 56 5 8.9% 0 0 MCL 6 61 23 37.7% 12 19.7% Others 40 234 64 27.6% 61 26.1%    \f"
        ],
        [
            "Survival Outcome for patients",
            "Survival Outcome 30-day Mortality 90-day Mortality 9-Year Median Survival  10-Year Median Survival  TABLE 4: Survival and Mortality Outcomes  Value  1 (6.7%) 2 (13.3%) 9 (60%)  5 (33%) \f"
        ],
        [
            "Benchmark Statistics",
            "Statistic  Scientific Paper  - Avg./Max. Pages  - Avg./Max. Number of Options - Average Size (px)  - Maximum Size (px)  Subject  - 2D Object Recognition  - Efficient Al  - Multimodal Learning  - Datasets and Evaluation  - 3D from Multi-View and Sensors - Large Language Model  - Robotics  Total Questions  - Figure Comprehension  - Multi-Figure Comprehension - Figure-Table Comprehension - Figure-Text Comprehension - Figure-Formula Comprehension - Table Comprehension  - Multi-Table Comprehension - Text Comprehension  - Formula Comprehension  - Pseudocode Comprehension  Number  31 19/35 5/5 1573 x 1210 1584 x 1224  7  4 (12.90%) 2 (6.45%) 15 (48.39%) 4 (12.90%) 1 (3.23%) 2 (6.45%) 3 (9.68%)  276 43 (15.58%) 20 (7.25%) 26 (9.42%) 53 (19.20%) 13 (4.71%) 62 (22.46%) 10 (3.62%) 35 (12.68%) 9 (3.26%) 5 (1.81%) \f"
        ],
        [
            "Do LMPO, and AlpacaEval 2 and Arena-Hard algorithms improve over the SFT baseline",
            "Method  SFT  DPO IPO CPO KTO ORPO R-DPO SimPO  LMPO  Method  SFT  DPO IPO CPO KTO ORPO R-DPO SimPO  LMPO  Mistral-Base (7B)  AlpacaEval 2 LC(%) WR(%) 6.2 4.6 15.1 12.5 11.8 9.4 9.8 8.9 13.1 9.1 14.7 12.2 17.4 12.8 17.7 16.5 20.9 14.9  Length  1082  1477 1380 1827 1144 1475 1335 1803  1351]  Llama-3-Base (8B)  AlpacaEval 2 LC(%) WR(%) 8.4 6.2 18.2 15.5 14.4 14.2 12.3 13.7 14.2 12.4 12.2 10.6 17.6 14.4 21.6 20.0 21.3 17.7  Length  914  1585 1856 2495 1646 1628 1529 1818  1601  Arena-Hard WR(%) ~~ Length 3.3 437 10.4 628 7.5 674 5.8 823 5.6 475 7.0 764 9.9 528 14.3 709 13.8 458 Arena-Hard WR(%) Length 1.3 521 15.9 563 17.8 608 11.6 SOO 12.5 519 10.8 639 17.2 527 26.9 877 30.1 1114  AlpacaEval 2 Arena-Hard LC (%) WR (%) Length WR (%)  17.1 14.7 1676 12.6 26.8 24.9 1808 16.3 20.3 20.3 2024 16.2 23.8 28.8 3245 22.6 24.5 23.6 1901 17.9 24.5 24.9 2022 20.8 27.3 24.5 1784 16.1 29.7 31.7 2350 22.3 29.8 28.0 1881 23.5  Llama-3-Instruct (8B)  AlpacaEval 2 Arena-Hard LC (%) WR(%) Length WR (%)  26.0 25.3 1920 22.3 40.3 37.9 1883 32.6 35.6 35.6 1983 30.5 28.9 32.2 2166 28.8 33.1 31.8 1909 26.4 28.5 27.4 1888 25.8 41.1 37.8 1854 33.1 43.9 39.0 1788 33.8 43.7 39.0 1791 34.3  Mistral-Instruct (7B)  Length 486  518 740 812 496 527 495 572  485  Length 596  528 554 624 536 535 522 502  AT] \f"
        ],
        [
            "Summarizes the obtained MIC values",
            "OF WN FH  Code  DTA * DTThr DTTyr10 DY Tyr1 DT4F  Structure  FLPLIGRVLSGILNH> FLPLIGRVLTGILNH> FLPLIGRVLYGILNH> YLPLIGRVLSGILNH>  Phe(4F)LPLIGRVLSGILNH>  B. subtilis 3562  80 pe /mL 160 ug /mL 320 ug/mL 160 ug /mL 80 ue /mL  E. coli 8785  320 ug/mL NI +E NI + NI +E NI +  A. oxydans 9333  80 ug/mL 320 ug/mL 320 ug/mL 320 ug/mL 160 ug/mL  P. aeruginosa  3700  320 ug/mL 320 ug/mL 320 ug/mL 320 ug/mL 80 ug/mL  C. albicans 74  320 ug /mL NI +E NI +E NI +E NI ** \f"
        ],
        [
            "The correlation from Characteristic to the Age, ER, PR, HER2, UGCG, BTG2, TNFRSF21, MYB, Ki-67, Lymph Nodes",
            "— Lymph Nodes Characteristic Age ER PR HER2 UGCG BTG2 TNFRSF21 MYB Ki-67 Metastasis  —0.061 —0.153 —0.095 0.021 0.332 —0.346 0.305 —0.346 0.105 —0.323 p 0.657 0.259 0.486 0.879 0.013 * 0.009 * 0.022 * 0.009 * 0.439 0.015 *  ey \f"
        ],
        [
            "Accuracy (%) of LLaMA-3.1-8B, Mistral-7B-v0.3, and Gemma-7B models across a wide range of reasoning tasks. We compared four settings: Zero-shot, Zero-shot + Ours, Zero-shot-CoT, and Zero-shot-CoT + Ours.",
            "Model  Llama-3.1-8B  Gemma-7/b  Mistral-7B-v0.3  Method  Zero-shot Zero-shot + Ours Zero-shot-CoT Zero-shot-CoT + Ours  Zero-shot Zero-shot + Ours Zero-shot-CoT Zero-shot-CoT + Ours  Zero-shot Zero-shot + Ours Zero-shot-CoT Zero-shot-CoT + Ours  Arithmetic  15.56% 50.56 % 77.22% 78.33 %  10.00% 15.00% 46.11% 73.33%  16.11% 27.78% 29.44% 37.22%  MultiArith GSM8&K  6.97% 34.57% 48.90 % 34.34%  48.98 % 45.26% 38.59% 44.81%  7.739% 15.31% 17.21% 15.39%  Commonsense  26.35% 30.13% 24.31% 45.27%  31.88% 34.79 % 19.36% 23.44%  23.58% 25.62 % 16.30% 36.83 %  36.00% 37.20% 32.00% 34.00%  10.80% 16.80% 34.00% 36.00%  34.40% 37.20% 13.20% 32.00%  Logical  StrategyQA DisambiguationQA Logical Deduction  28.40% 32.00% 16.80% 24.80%  24.80% 27.20% 18.80% 24.00%  14.80% 18.00% 28.80 % 20.40%  Avg  22.66% 36.90% 39.85% 43.35 %  25.29% 27.81% 31.37% 40.32%  19.32% 24.78 % 20.99% 28.37 % \f"
        ],
        [
            "Statistical comparisons of the correlation with Age, BMI, Years Diagnosis,etc",
            "Age BMI Time from diagnosis (y) Exam duration (min) ECSO before exam ECSO intra exam ECSO after exam ECSO total PSS Test performed last 24 months (n)  Age  NA 0.23 *** 0.2 EH 0.1 * —0.02 —0.05 —0.01 —0.02 0.01  —0.07  BMI  NA —0.02 0.02 —0.04 —0.02 0.01  —0.01 —0.04  Years Diagnosis  NA 0.07 0.1 * 0.05 0.02 0.09  —0.11 *  Exam Duration (min)  NA —0.02 —0.04  0.02 —0.01 —0.01  —Q.24 ***  ECSQ ECSQ Before During NA  0.79 *** NA  0.70 *** 0.78 ***  0.84 *** 0.81 *** —0.18 *** —0.24 ***  —0.02 —0.01  ECSO After  NA 0.82 *** —Q.24 ***  —0.02  ECSOQ Total  NA —Q.27 ***  —0.01  Test Performed Last 24 Months (n)  PSS  NA —0.02 NA \f"
        ],
        [
            "Vaccination coverage by type of vaccine, dose and year of evaluation",
            "Vaccine Administered According to Schedule  BCGO  2018 Total: 18,268  N°  Yo  2019 Total: 17,422  N°  ‘Yo  Vaccination Coverage  Year of Evaluation  2020 Total: 11,430  N°  ‘Yo  2021 Total: 17,956  N°  Yo  2022 Total: 17,626  N°  ‘Yo  xX? p  —— BCGO.s—“‘«‘:™*«SdA«95.AT~— 16,702 95.87 10,617 92.89 16,647 92.71 16,514 93.69 0.001 |  95.47  16,702  95.87  10,617  92.89  16,647  92.71  16,514  93.69  0.001  - ANTI-HEPATITISO. ——15,806 86.52 15,323 87.95 9884 8647 15,659 87.21 15,708 89.12 0.001  PENTAVALENT2  15,806 17,248  86.52 94.42  15,323 16,546  87.95 94.97  9884 10,399  86.47 90.98  15,659 16,584  87.21 92.36  15,708 16,442  89.12 93.28  0.001 0.001  _ PENTAVALENT4  —16,382. 89.68 15,704 90.14 9823 85.94 15,868 88.37 15,620 88.62 0.001  16,382  89.68  15,704  90.14  9823  85.94  15,868  88.37  15,620  88.62  0.001  _ PENTAVALENT6 =——s‘15,253 83.50 14,568 83.62 9160 80.14 14,649 81.58 14,411 81.76 0.001  ANTI-POLIO2  15,253 17,539  83.50 96.01  14,568 16,753  83.62 96.16  9160 10,570  80.14 92.48  14,649 16,805  81.58 93.59  14,411 16,420  81.76 93.16  0.001 0.001  - ANTEPOLIO4 ~=——s«16,598 90.86 15,898 91.25 9988 87.38 16,044 89.35 15,740 89.30 0.001  ANTI-POLIO6 ANTI-PNEUMOCOCCUS2  16,598 15,412 17,915  90.86 84.37 95.88  15,898 14,734 16,696  91.25 84.57 95.83  9988 9303 10,327  87.38 81.39 90.35  16,044 14,815 16,444  89.35 82.51 91.58  15,740 14,464 16,288  89.30 82.06 92.41  0.001 0.001 0.001  ~ ANTI-PNEUMOCOCCUS4 16,576 90.74 15,791 90.64 9772 85.49 15,737 87.64 15,456 87.69 0.001  16,576 13,098  90.74 71.70  15,791 12,220  90.64 70.14  9772 7923  89.49 69.32  15,737 12,154  87.64 67.69  15,456 11,963  87.69 67.87  0.001 0.001   ANTI-PNEUMOCOCCUS12 13,098 71.70 12,220 70.14 7923 69.32 12,154 67.69 11,963 67.87 0.001  ANTI-ROTAVIRUS2 ANTI-ROTAVIRUS4 ANTI-INFLUENZA6  17,087 15,405 14,196  93.54 84.33 77.71  16,316 14,870 13,248  93.65 89.35 76.04  10,103 9227 86/7  88.39 80.73 79.91  15,956 14,561 13,568  88.86 81.09 79.96  15,825 14,349 13,323  89.78 81.41 79.99  0.001 0.001 0.001  _ ANTLINFLUENZA7 —:12,011. 65.75—-:10,897 62.55 7225 63.21 10,906 60.74 10,780 61.16 0.001  12,011  65.75  10,897  62.55  7225  63.21  10,906  60.74  10,780  61.16  0.001  - ANTEYELLOW15 —s'10,549 57.75 10,103 57.99 6629 58.00 9955 55.44 9666 54.84 0.001  SPR12  10,549 13,608  57.75 74.49  10,103 12,885  57.99 73.96  6629 8364  58.00 73.18  9955 12,702  99.44 70.74  9666 12,430  54.84 70.52  0.001 0.001  — SPRI8. «93861 51.24 9326 «53.53 6238 «454.58 9021 50.24 8915 50.58 0.001  9361  51.24  9326  53.93  6238  54.58  9021  50.24  8915  50.58  0.001 \f"
        ],
        [
            "Adjusted HR, 95% CI, p-value of differents variabes estimate risk",
            "Variables  Patients  Comparison (ref.)  Kidney transplant recipients At different follow-up time In 6 months  Comparison (ref.)  Kidney transplant recipients In 1 year  Comparison (ref.)  Kidney transplant recipients In 3 years  Comparison (ref.)  Kidney transplant recipients In 5 years  Comparison (ref.)  Kidney transplant recipients  Cerebrovascular Disease  Adjusted HR  1 1.43  0.53  0.82  1.07  1.26  95% CI  1.23  0.28  0.52  0.81  1.01  1.68  0.99  1.30  1.41  1.57  p-value  <0.001  0.049  0.394  0.658  0.048 \f"
        ],
        [
            "Comparison of different benchmarks and framework.",
            "Benchmark/Framework Evaluation Focus Program Evals Automated Gen Executable # Domains # Tasks  SysBench (Qin et al., 2024) System Prompt Following Response Generation x x = - 500 ComplexBench (Wen et al., 2024) Constraint Following Response Generation x x - - 1,150 RuleArena (Zhou et al., 2024) Rule-Following Reasoning x x - 3 816 T-Bench (Yao et al., 2024) Agent Action Policy Following v x v 2 165 ToolEmu (Ruan et al., 2023) Agent Action Safety x J x - 311 AgentOrca (Ours) Agent Action Routine and Constraint Following Jv Jv v 5 663* \f"
        ],
        [
            "BMI, TNFi, SC, IV, HLA, BASDAI, ASDAS, BASFI, ESR, CRP,  AST,  ALT, BUN, axSpA for patients",
            "Variables  Age (years) Sex (male, N (%)) BMI (kg/m?) TNFi source Adalimumab SC Golimumab SC Golimumab IV Infliximab SC Disease duration (years) Previous treatment before TNFi Nonsteroidal anti-inflammatory drugs Sulfasalazine TNFi treatment duration (years) HLA-B27 positivity  r-axSpA (N=20)  31.0 (25.5; 42.5) 13 (65.0%) 24.2 (22.5; 28.5)  Disease activity and functional index at baseline  BASDAI ASDAS-ESR ASDAS BASFI  Laboratory finding at baseline ESR (mm/h) CRP (mg/dL) White blood cell count (/uL) Hemoglobin (g/dL) Platelet (10?/yL) AST (IU/L) ALT (IU/L) BUN (mg/dL) Creatinine (mg/dL)  AxSpA manifestation Peripheral arthritis Uveitis Psoriasis Dactylitis Inflammatory bowel disease  14 (70.0%)  4 (20.0%)  | (5.0%)  | (5.0%)  3.5 (1.4; 10.0) 20 (100%)  17 (85%)  0.5 (0.5; 2.5)  16 (80.0%)  1.1 (1.0; 1.3)  1.1 (0.9; 1.4) 1.0 (0.9; 1.2)  1.1 (0.4; 1.6) 6.0 (4.5;13.5)  0.1 (0.0; 0.2) 6715.0 (5610.0; 9090.0) 14.1 (13.1; 14.6)  252.0 (217.5; 295.0) 27.5 (21.0; 33.0) 22.5 (14.5; 42.0) 14.4 (12.4; 16.8) 0.7 (0.7; 0.9)  9 (45.0%) 4 (20.0%) | (5.0%) 0  | (5.0%)  TNFi tapering success (N= 12)  32.0 (28.0; 45.5) 9 (75.0%) 23.2 (22.0; 26.8)  11 (91.7%) | (8.3%)  0  0  4.0 (3.0; 10.0)  12 (100%) I! (91.7%) 1.0 (0.5; 3.0) 10 (83.3%)  1.0 (0.8; 1.2) 0.9 (0.7; 1.3) 0.9 (0.9; 1.1) 0.5 (0.3; 1.4)  5.0 (3.0; 9.5) 0.1 (0.0; 0.1)  6560.0 (5410.0; 8980.0) 14.1 (13.1; 14.9)  247.5 (201.5; 290.5) 27.5 (23.0; 32.0)  25.0 (17.5; 43.5)  14.2 (11.7; 17.1)  0.8 (0.7; 0.9)  5 (41.7%) 4 (33.3%) | (8.3%) 0  0  TNFi tapering failure (N=8)  27.0 (23.0; 42.0) 4 (50.0%) 27.7 (23.6; 31.6)  3 (37.5%) 3 (37.5%) | (12.5%) | (12.5%) 1.8 (1.1; 9.5)  8 (100%) 6 (75%)  0.5 (0.5; 2.0) 6 (75.0%)  1.2 (1.1; 14) 1.3 (1.1; 1.4) 1.1 (1.0; 1.2) 1.6 (1.2; 1.6)  12.0 (6.5; 16.5) 0.1 (0.1; 0.2)  8260.0 (6180.0; 9650.0) 13.8 (12.4; 14.6)  258.0 (235.5; 296.5) 25.0 (18.0; 34.5)  19.0 (14.0; 42.0)  14.4 (13.6; 15.9)  0.7 (0.6; 0.8)  4 (50.0%) 0 0 0 | (12.5%)  0.296 0.356  0.009  0.46!  | .000 0.701 0.472 | .000  0.079 0.105 0.074 0.121  0.088 0.215 0.270 0.643 0.440 0.643 0.643 | .000 0.418  | .000 0.117 | .000 | .000 0.400 \f"
        ],
        [
            "Ra1,Ra2, Ra3 for derived units",
            "Unit 1 min 1 kg lm K  1 mL 1 cal 1 atm 1V  1 MHz 1N 1kW 1T  l ha 1 lx  1 ly 1B  Derived unit Actual value  seconds (sec) grams (gr) centimeter (cm) Celsius degrees (°C) cubic centimeter (cm?) Joule (J)  Pascal (Pa) milivolt (mV) Hertz (Hz) millinewton (mN) Watt (W) millitesla (mT) Square meter (m7) lumen per m7 (Im/m7) Trillion/Billion km bit (b)  60sec 1000gr 100cm  °C + 273.15  lem? 4.184/ 101, 325Pa LO00mV  10° Hz  1000mN 1000W 1000mT 10, 000m? lm /m? 9.461Tkm 8b     Ral LOOsec 900gr 60cm  °C’ + 300  215,000Pa 900mV 10° Hz 900m N 1500W 600mT  10, 500m”  0.5lm/m?  9.461Bkm  106  Ra2 5 x 10°sec 10~**gr 310'0cm °C +1 10000cm? 1500J 0.55Pa A10°mV 2H z 210'5mN 510°-°W 10°3mT 31074*m? 1000lm/m? 10m 610°b  Ra3 —90sec —100gr  —200cm  100 * °C’ + 500  —10cem? —5J —5000Pa —10mV —10°Hz —3000mN —30W —90mT —25m? —19Im/m?* —2Tkm —Ab \f"
        ],
        [
            "Key Findings and Study Limitations of current studies of the Malignant mesenchymal tumors of the breast",
            "Study (Year)  Holm et al. [5] (2015)  Confavreux et al. [3] (2006)  McGowan et al. [4] (2000)  Global Cohort  (Number of  Patients)  42  70  78  5y-OS  49%  49%  57%  5y-DFS  48%  28%  47%  5y-LRR  24%  26%  Median Follow-Up  (Period of Study)  50.4  (1979-2014)  31.7 (1966-2004)  114 (1958-1990)  Key Findings  - Tumor size and grade are significant prognostic factors  - Negative surgical margins (RO) significantly  improve survival (72% vs.  38%) - Angiosarcomas have the worst DES (7%)  - Negative surgical margins (RO) improve local relapse-free survival (80% vs. 33%)  - Radiation dose >48 Gy improves 5-year OS (91% vs. 50%)  Study Limitations  - Retrospective study  - Single institution  - Small and disomogeneous cohort - Missing data  - Retrospective study - Small and disomogeneous cohort  - Lack of uniform treatment protocols  - Retrospective study  - Single institution,  - Small and disomogeneous cohort - Missing or incomplete data \f"
        ],
        [
            "results of the baselines\nwith 60K data for DeepSeekMath, Llama3-8B, Mistral-7B",
            "IVIUUCL TT OALLIPICS  MATH GSM8K_ College DM Olympiad Theorem AVG DeepSeekMath (7B Math-Specialized Base Model)  DeepSeekMath-7B-RFT 590K 53.0 88.2 41.9 60.2 19.1 Zi 48.3 DeepSeekMath-7B-DART-Math 590K 53.6 86.8 40.7 61.6 21.7 32.2 49.4 DeepSeekMath-7B-Instruct 780K 46.9 82.7 37.1 52.2 14.2 28.1 43.5 DeepSeekMath-7B-MMIQC 2.3M 45.3 79.0 35.3 52.9 13.0 23.4 41.5 ~DeepSeekMath-7B-Standard st” ISK 306 £663 £227 286 #56 — 11.0 27.5 DeepSeekMath-7B-RefAug 30K 32.1 71.2 26.0 38.4 10.1 14.4 32.0 MathFusion-DSMath-7B (Sequential) 30K 49.9 76.6 38.8 64.6 21.6 22.8 45.7 MathFusion-DS Math-7B (Parallel) 30K 50.9 76.7 38.9 62.2 19.0 23.8 AS MathFusion-DS Math-7B (Conditional) 30K 48.5 74.6 37.0 Ny 19.3 19.0 42.3 DeepSeekMath-7B-MetaMath! 60K 40.0 79.0 33.2 45.9 9.5 18.9 37.8 DeepSeekMath-7 B-MMIQC! 60K 26.3 60.6 19.2 41.5 10.4 6.8 27.5 DeepSeekMath-7B-RefAug! 60K 33.1 71.6 26.2 35.4 10.5 14.0 31.8 DeepSeekMath-7 B-DART-Math! 60K 51.4 82.9 39.1 62.8 21.0 27.4 47.4 MathFusion-DS Math-7B 60K 53.4 779 39.8 65.8 23.3 24.6 47.5 Mistral-7B (7-8B General Base Model) Mistral-7B-MetaMath 400K 29.8 76.5 19.3 28.0 5.9 14.0 28.9 Mistral-7B-WizardMath-V 1.1 418K 32.3 80.4 23.1 38.4 7.7 16.6 33.1 Mistral-7B-RFT 590K 38.7 82.3 24.2 35.6 8.7 16.2 34.3 Mistral-7B-DART-Math 590K 45.5 81.1 29.4 45.1 14.7 17.0 38.8 Mistral-7B-MathScale 2.0M 35.2 74.8 21.8 — — — — Mistral-7 B-MMIQC 2.3M 37.4 75.4 28.5 38.0 9.4 16.2 34.2 -Mistral-7B-Standard sts ISK 124 603 84 #170 #22 °° © 76 18.0. Mistral-7B-RefAug 30K 15.1 61.1 10.4 15.4 3.1 11.0 19.4 MathFusion-Mistral-7B (Sequential) 30K 327 73.9 18.9 29.3 9.3 15.5 29.9 MathFusion-Mistral-7B (Parallel) 30K 30.9 75.1 20.9 26.5 11.0 15.2 29.9 MathFusion-Mistral-7B (Conditional) 30K 26.3 73.0 15.6 2 inal 7.3 12.8 26.1 Mistral-7B-MetaMath' 60K 22.7 70.8 14.1 27.2 5.0 12.2 25.3 Mistral-7B-MMIQC' 60K 17.3 61.4 11.1 813.5 5.0 5.9 19.0 Mistral-7B-Ref Aug! 60K 17.4 63.1 12.5 18.1 3.9 11.1 21.0 Mistral-7B-DART-Math! 60K 34.1 77.2 23.4 36.0 8.7 18.2 32.9 MathFusion-Mistral-7B 60K 41.6 79.8 24.3 39.2 13.6 18.1 36.1 Llama3-8B (7-8B General Base Model) Llama3-8B-MetaMath 400K 32.5 77.3 20.6 35.0 5.5 13.8 30.8 Llama3-8B-RFT 590K 39.7 81.7 23.9 41.7 9.3 14.9 35.2 Llama3-8B-MMIQC 2.3M 39.5 77.6 29.5 41.0 9.6 16.2 35.6 Llama3-8B-DART-Math 590K 46.6 81.1 28.8 43.0 14.5 19.4 39.7 -Llama3-8B-Standard i sis ISK 175 £4654 £129 216 47 © 10.9 22.2. Llama3-8B-RefAug 30K 20.8 67.3 15.7 25.9 4.7 13.6 24.7 MathFusion-Llama3-8B (Sequential) 30K 38.8 77.9 25.1 42.0 12.6 17.0 35.6 MathFusion-Llama3-8B (Parallel) 30K 38.1 75.4 25.5 41.9 11.9 18.9 35.3 MathFusion-Llama3-8B (Conditional) 30K 34.7 76.9 21.2 27.4 11.9 15.5 31.3 Llama3-8B-MetaMath! 60K 28.7 78.5 19.7 31.3 5.3 16.1 29.9 Llama3-8B-MMIQCT 60K 24.4 69.7 13.4 30.9 5.2 10.6 25.7 Llama3-8B-RefAug! 60K 20.3 68.6 15.5 29.1 5.5 13.0 25.3 Llama3-8B-DART-Math! 60K 39.6 82.2 27.9 39.9 12.9 22.9 37.6  MathFusion-Llama3-8B 60K 46.5 79.2 27.9 43.4 17.2 20.0 39.0 \f"
        ],
        [
            "Composition of the dataset. The dataset is broken down by language, source,type, and task",
            "#Samples  Total tokens  Source Type  Language  LIMO Single-turn  English French French French  Dolphin R1 Single-turn  English English English French French French French  Tulu 3 (SFT) Long context  Pensez-2k  Math Reasoning OpenR1 Math Single-turn SLAK Single-turn Daily Tasks  Magpie Align Single-turn Tulu 3 (SFT) Multi-turn Tulu 3 (SFT) Long context Magpie Align Single-turn Tulu 3 (SFT) Single-turn Tulu 3 (SFT) Multi-turn  700 358 142 200  179 9] 30 88 100 8/7 25  2,000  4,596,147 1,825,706 1,197,929 799,873  270,614 388,958 250,941 115,321 143,409 180,734 159,883  9,967,320 \f"
        ],
        [
            "All 18 emotions used in the study and how they were represented in words, emojis, and Valence-Arousal-Dominance (VAD) scores with values represented lexically and numerically (in parentheses). The category of the emotions were used when selecting which emotions to use but were not integrated into the generation nor shown to participants.",
            "Group Words Emoji | Valence Arousal Dominance     Grateful - Very High (+2. ° Moderate (0.0) Low (-2.5) Happy Joyful Very High ( High (+1.0) High (+1.0) Content Very a ( Moderate (0.0) Very High (+4.0)        Excited Very i — 5) Very no = 0) | High (+1.0) Proud Very Mek 40 High ( 1 } Very High (+2.5) Low (-1.0)           Anxious High (+2. ; Low (-2.5) Fear Afraid High (+2.5) Very Low (-4.0) Terrified Very High (+4.0) | Very Low (-4.0) Annoyed Moderate (0.0) Moderate (-1.0) Anger Angry High (2.5) Moderate (0.0)             oS e9 Furious q Very High (4.0) | High (1.0) Sad é Low (-2.5) Very Low (-4.0) Paciness Devastated ® High (1.0) Low (-2.5) Ashamed ® Moderate (-1.0) | Very Low (-4.0) Shame | Embarrassed a High (2.5) Low (-2.5) Guilty é) Moderate (0.0) Very Low (-4.0) \f"
        ],
        [
            "The Statistic data of the Scientific Paper, Subject, Total Questions ",
            "Statistic  Scientific Paper  - Avg./Max. Pages  - Avg./Max. Number of Options - Average Size (px)  - Maximum Size (px)  Subject  - 2D Object Recognition  - Efficient Al  - Multimodal Learning  - Datasets and Evaluation  - 3D from Multi-View and Sensors - Large Language Model  - Robotics  Total Questions  - Figure Comprehension  - Multi-Figure Comprehension - Figure-Table Comprehension - Figure-Text Comprehension - Figure-Formula Comprehension - Table Comprehension  - Multi-Table Comprehension - Text Comprehension  - Formula Comprehension  - Pseudocode Comprehension  Number  31 19/35 5/5 1573 x 1210 1584 x 1224  7  4 (12.90%) 2 (6.45%) 15 (48.39%) 4 (12.90%) 1 (3.23%) 2 (6.45%) 3 (9.68%)  276 43 (15.58%) 20 (7.25%) 26 (9.42%) 53 (19.20%) 13 (4.71%) 62 (22.46%) 10 (3.62%) 35 (12.68%) 9 (3.26%) 5 (1.81%) \f"
        ],
        [
            "MIC values of Temporin A novel analogues [µg/mL].",
            "OF WN FH  Code  DTA * DTThr DTTyr10 DY Tyr1 DT4F  Structure  FLPLIGRVLSGILNH> FLPLIGRVLTGILNH> FLPLIGRVLYGILNH> YLPLIGRVLSGILNH>  Phe(4F)LPLIGRVLSGILNH>  B. subtilis 3562  80 pe /mL 160 ug /mL 320 ug/mL 160 ug /mL 80 ue /mL  E. coli 8785  320 ug/mL NI +E NI + NI +E NI +  A. oxydans 9333  80 ug/mL 320 ug/mL 320 ug/mL 320 ug/mL 160 ug/mL  P. aeruginosa  3700  320 ug/mL 320 ug/mL 320 ug/mL 320 ug/mL 80 ug/mL  C. albicans 74  320 ug /mL NI +E NI +E NI +E NI ** \f"
        ],
        [
            "Macroscopic and microscopic features of fungal isolates",
            "Isolates code  B2S3  B4S82  B3S4 b2  B2S2 al  B382 a  B3S3 bl  B4S4 b  B3S2 b  B3S2 A  B3S1 b  B3S3 b  B4S2  B3S4 b2  B3S1 A  B4S4  Accession no.  MZ569410  MZ569411  MZ569412  MZ569413  MZ569414  MZ569415  MZ569416  MZ569417  MZ569418  MZ569419  MZ569420  MZ569421  MZ569422  MZ569423  MZ569424  Macroscopic features  Greenish with white margin, fast growing, velvety  Greenish-gray, cottony, fast growing Grayish, fast growing, velvety  Grayish, powdery surface, fast growing  Greenish with white margin, powdery texture, fast growing  Grayish, powdery texture, fast growing  Greenish-gray, velvety, fast growing  Green with brown appearance at the center, fast growth, cottony  Green with white margin, fast growth, cottony  Brownish with white margin, wooly appearance, fast growing  Olive with shiny white margin, slow growing, velvety  Grayish with brown center, fast growing, powdery texture  Greenish, velvety, fast growth  Brownish, powdery texture, fast growth  Surface green with white periphery, slow growing, wooly  Microscopic features  Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore  Branching hyphae, septate, and hyaline club-shaped conidiophore  Branching hyphae, septate, and hyaline club-shaped conidiophore  Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore Branching hyphae, septate, and hyaline club-shaped conidiophore  Branching hyphae, septate, and hyaline club-shaped conidiophore     Reverse side  Cream  Cream  Cream  Cream  Cream  Cream  Cream  Cream  Cream  Brown  Brown  Cream  Brown  Brown  Cream \f"
        ],
        [
            "M-spike;  C1, C3, C5,  C7,  C9, \nC12, MRD",
            "Laboratory Hemoglobin  o/dL  Serum  IgG lambda, M-spike:  o/dL  Free light chain ratio (0.26—1.65)  % Of plasma cell in the bone marrow  Prior to Cl” 4.2  2.56  45.5  15%  End of Cl 10.1  0.95  6.12  End of C3 14.8  0.52  1.94  End of C5 14.2  0.35  1.96  End of C7 14.7  1.56  End of C9 13.9  1.37  End of C12 15  1.27  1%, MRD negative \f"
        ],
        [
            "Results on specialized safety benchmarks: Sci-\nKnowEval (SciKE), SciSafeEval (SciSE) and LabSafety\nBench (LabSB)",
            "Model  Llama3-8B  Llama3-8B-IT  Tuning  SFT  SFT + DPO Backtrack-SFT Backtrack ERPO-SFT ERPO  SFT  DPO Backtrack-SFT Backtrack C?-SYN ERPO-SFT ERPO     Harmful QA Lab Safety SciKE (1) SciSE())  LabSB (t) 41.68 97.40 6.74 58.59 97.20 18.09 56.72 96.20 6.38 51.53 93.80 7.09 40.75 84.40 32.62 6.66 36.20 36.28 37.15 97.60 57.45 18.51 91.40 60.99 13.45 99.20 62.77 30.63 92.80 60.99 21.97 89.20 63.12 29.03 95.00 58.87 10.25 72.40 65.43 1.86 54.20 68.00 \f"
        ],
        [
            "The comparative analysis results of the Deception Series (N = 42) and Non-Deception Series (N = 36)",
            "Deception Series (N = 42) Non-Deception Series (N = 36)  Correct Incorrect Inconclusive Correct Incorrect Inconclusive PolyScore 17 6 19 15 5 16 OSS-3 24 18 0 28 7 1 This study (w/o PPG) at 0 5 35 0 1 This study 44 0 1 36 0 0  (w/PPG) \f"
        ],
        [
            "Experiments were carried out to measure the fluidity and loss of fluidity of cement pastes using national standard reference cements.",
            "   Chemical Composition Composition SiO, AloO3 FeO; CaO MgO SO3 Na,Oeq f—CaO Loss Cl— Cement (wt%) 20.94 4.31 3.28 63.46 2.76 2.23 0.56 0.80 2.31 0.036 \f"
        ],
        [
            "The detailed information of Typographic Visual Prompt Injection (TVPI) Dataset",
            "Datacet Clean Factor Modification (FM) Different Target Threat (DTT) Total  VLP Size Opacity — Position Sub || |” 1° 1\" | factors) (4 factors) (4 factors) “ee scale |500 500 500 500; 8000 SOOO SOOO 10000 10000 | 10000 10000 | 10000 10000; 86000  LI TI 19 Size Opacity Position Harmful Bias Neutral 12] Total Sub (4 factors) (4 factors) (4 factors)|naked bloody     scale 500 500 A000 4000 4000 2000 2000 2000 2000 | 2000 2000 | 25000 \f"
        ],
        [
            "The Math Reasoning and Daily Tasks dataset of different Language, Source, Type, #Samples and Total tokens",
            "#Samples  Total tokens  Source Type  Language  LIMO Single-turn  English French French French  Dolphin R1 Single-turn  English English English French French French French  Tulu 3 (SFT) Long context  Pensez-2k  Math Reasoning OpenR1 Math Single-turn SLAK Single-turn Daily Tasks  Magpie Align Single-turn Tulu 3 (SFT) Multi-turn Tulu 3 (SFT) Long context Magpie Align Single-turn Tulu 3 (SFT) Single-turn Tulu 3 (SFT) Multi-turn  700 358 142 200  179 9] 30 88 100 8/7 25  2,000  4,596,147 1,825,706 1,197,929 799,873  270,614 388,958 250,941 115,321 143,409 180,734 159,883  9,967,320 \f"
        ],
        [
            "This study selected 15 HRV features listed in Table that might have potential in mated to predict mental workload,  including 4 time domain features, 8 in the frequency domain, and 3 non-linear features.",
            "HRV Feature Time-domain features mRR  SDRR RMSSD  PNN5S0O  Frequency-domain features VLE  LF  HF  TP  pVLEF  pLF  pHEFE  LF/HF  nLF  nHF  Non-linear features SD2/SD1  ApEn  SampEn  WN NI  WN NI  WN  BBB BS  N  el bed  o Oo © bd  el —  | —  cog  rel —  Description (Equation)  N The mean of RR intervals (Hie Ri) )  N _ 2 The standard deviation of RR intervals ( din RR MRR)\" )  The square root of the mean squared differences between successive RR  intervals (\\/mean(RRji1 — RR;)°) Number of interval differences in successive RR intervals greater than 50 ms count(|RRj+1—RRj|) s 50 ms <x 100%)  ( N=I  Absolute powers of very low frequency band (0—0.04 Hz) Absolute powers of low frequency band (0.04—0.15 Hz) Absolute powers of high frequency band (0.15-0.4 Hz) The total energy of RR intervals  Relative powers of VLF (VLF [ms*]/TP [ms7] x 100%) Relative powers of LF (LF [ms*]/TP [ms*] x 100%) Relative powers of HF (HF [ms*]/TP [ms] x 100%)  The ratio between LF and HF band powers  Normalized low frequency power  Normalized high frequency power  Ratio between SD2 and SD1 Approximate entropy Sample entropy \f"
        ],
        [
            "The globally ASMRs and ASDRs of kidney dysfunction-attributed stroke and subtypes and temporal trends in 1990–2021",
            "               1990 2021 AAPC ASMRs ASDRs ASMRs ASDRs ASMRs ASDRs ASMRs ASDRs (95%UI) (95%UI) (95%UI) (95%UI) (95%Cl) P value (95%Cl) P value Stroke Both sex 13.6 283.6 8.1 174.6 -1.67 < 0.001 -1.55 < 0.001 (9.2 to 18.3) (207.2 to 361.9) (5.6 to 10.7) (127.0 to 222.8) (-1.84 to -1.5) (-1.72 to -1.39) Men 14.4 305.5 9.2 200.8 -1.42 <0.001 -1,33 <0.001 (9.9 to 19.2) (223.2 to 395.3) (6.4 to 12.1) (146.0 to 255.0) (-1.6 to -1.24) (-1.48 to -1.18) Women 12.9 263.1 72 150.6 -1.87 < 0.001 -1.78 <0.001 (8.7 to 17.2) (192.6 to 335.0) (4.8 to 9.7) (107.2 to 195.0) (-2.07 to -1.67) (-1.93 to -1.62) IS Both sex 7.3 130.3 AD 82.1 -1.73 <0.001 -1.47 <0.001 (4.7 to 10.1) (90.4 to 172.7) (2.8 to 5.8) (57.6 to 108.5) (-1.95 to -1.51) (-1.69 to -1.25) Men 74 136.9 47 924 -1.45 <0.001 -1,24 <0.001 (4.9 to 10.2) (96.3 to 185.0) (3.1 to 6.3) (65.2 to 119.8) (-1.68 to -1.22) (-1.43 to -1.05) Women 7.1 123.7 3.8 729 -1.94 < 0.001 -1.68 <0.001 (4.4 to 9.9) (84.5 to 164.1) (2.5 to 5.4) (50.9 to 97.0) (-2.17 to -1.71) (-1.9 to -1.47) ICH Both sex 6.3 153.2 3.9 92.5 -1.6 <0,.001 -1.61 <0.001 (4.5 to 8.2) (115.4 to 192.4) (2.7 to 5.0) (68.5 to 117.1) (-1.74 to -1.47) (-1.76 to -1.45) Men 6.9 168.6 45 108.4 -14 <0.001 -1,.39 <0.001 (5.0 to 9.1) (126.9 to 216.8) (3.2 to 5.8) (80.6 to 138.1) (-1.53 to -1.27) (-1.52 to -1.26) Women 5.8 139.4 3.3 777 -1.79 <0.001 -1.87 <0.001 (4.2 to 7.5) (105.6 to 174.7) (2.3 to 4.5) (57.5 to 100.7) (-1.9 to -1.68) (-1.99 to -1.75) \f"
        ],
        [
            "Sociodemographic, Marital status,Exposure to stressful events of interviewers",
            "   Variables        Women Total Xx? n % n % n % Sociodemographic: Sex 198 34.6 375 65.4 573 100 Marital status: Widower 17 8.6 120 32.0 137 23.9 X*=89.289, p=0.001 *“e Married 156 78.8 143 38.1 299 52.2 Never married 7 3.5 55 14.7 62 10.8 Divorced 18 9.1 57 15.2 75 82.5 Type of cohabitation (Who do you live with? ): Couple t 159 80.3 164 43.7 323 56.4 X*=70.461, p=0.001 *“e Children 94 47.5 170 45.3 264 46.1 X*=0.239, p=0.686 Parents 4 2.0 7 1.9 11 1.9 X*=0.016, p= 1.000 Siblings 6 3.0 26 6.9 32 5.6 X*=3.744, p=0.056 (Great)grandson 23 11.6 75 20.0 98 17.1 X*=6,.424, p=0.013 * Other 31 15.7 87 23.2 118 20.6 X*=4.060, p=0.0439 * Social participation: church 91 46.0 244 65.1 335 58.5 X*=19.481, p=0.001 *“e peer group (MAS program) 25 12.6 73 19.5 98 17.1 X*=4.277, p=0.063 In community group 74 374 205 54.7 279 48.7 X*=15.511, p=0.001 ms Caregiver of a family member 21 10.6 87 23.2 108 18.8 X*=13.437, p=0.001 “* Exposure to stressful events: 1. Own illness 51 25.8 104 27./ 155 27.1 X’=0.256, p=0.623 2. Illness of a family member 66 33.3 133 35.5 199 34.7 X*=0.260, p =0.647 3. Death of a loved one 8 40 16 4.3 24 42 X*=0.017, p=1.000 4, Death of a close friend 78 39.4 113 30.1 191 33.3 X*=5.001, p=0.027 * 5. Separation of the couple / 3.5 11 2.9 18 3.1 X*=0.154, p=0.800 6. Breakup of a stable relationship 5 2.5 6 1.6 11 1.9 X*=0.589, p=0.566 7. Serious problem with a friend or close friend 14 7.1 29 7./ 43 7.5 X?=0.082, p=0.861 8. Unemployment or unsuccessful job search 8 40 7 1.9 15 2.6 X*=2.402, p=0.182 9. You have been fired from your job t - - 2 0.5 2 0.3 X*=1.060, p=0.544 10. Serious economic crisis 24 12.1 51 13.6 /5 13.1 X*=0.249, p=0.708 11. Problems with the police or justice 4 2.0 8 2.1 12 2.1 X*=0.008, p= 1.000 12. Victim of theft 18 9.1 39 10.4 57 9.9 X’=0.248, p=0.666 13. Another type of problem 6 3.0 26 6.9 32 5.6 X*=3.744, p=0.049 * \f"
        ],
        [
            "Factor of Average age (years), Average body mass index (kg/m2), Sex (Male/Female)",
            "Demographic Factor  Average age (years) 22.0 Average body mass index (kg/m7) 20.17 Sex (Male/Female) 1 (10%) /9 (90%) \f"
        ],
        [
            "The SQuAD accuracy results",
            "Model  LLAMA3  LLAMA2 7B  GEMMA 9B  GEMMA 27B  MISTRAL 7B  BASE  KVD KVD  HoA Hol Hol  DODO BASE  KVD KVD  HoA  HoA  Hol ICAE BASE  KVD KVD  BASE  KVD KVD  BASE  KVD KVD  % KV 100%  25% 20%  25% 20% 25% 20%  20% 100%  25% 20%  25% 20% 25% 20%  57% 100%  25% 20%  100%  25% 20%  100%  25% 20%  0-Shot Acc. 87.6 + .6%  86.6 + .7% 86.0 + .7%  84.0 + .7% 83.0 + .7% 96.6 + .9% ol.7 + 1%  73.3 + .8% 82.5 + .7%  79.1 + .8% 77.6 + .8%  19 .7% 16.7 + .7% 90.2 + .9% 90.3 + 1%  79.0 + .8% 89.15 + .7%  84.55 + .7% Baek se. t 7a  85.3 + .87%  83.1+1% 82.2 +1%  87.1 + .6%  84.1 + .7% 82.5 + .7% \f"
        ],
        [
            "recent studies based on using the Wavelet transform-based model during solar radiation prediction",
            ": ;     Wavelet transform (WT) ANN Turkey =e = 54,38-78.40 208 Wavelet transform (WT) LightGBM (LGB) | Greece RMSE = 135.68 2024 \f"
        ],
        [
            "Categorized Distribution of Absolute Rotation Data",
            "[wie [ww ome [am] wee [we om [me | TSC*idSSCCS wee [ww oe [am CdTSSC*idSS woe [ow wef CdSCdS EO EO Ea not [ww ome [am dCi Ea sew [ww om | oe | om || new [wo em | om) ae | Cd new [ww em | me |e new [ow] om | am TSC~dSCS nee [wv om | om | = | iS wow [wel as | osm) TC new [wo] am | m= | ae | if neo [ww] em | om | om | ww [ww [me [| \f"
        ],
        [
            "The Awareness, Selection, Capability of different Model and Type LLM and LRM",
            "Type  LLM  LRM  Model  LLaMA3.1-70B GPT-40 Claude3.5-sonnet  DeepSeek-R1 Claude3.7-sonnet Gemini-2.0-Flash  100.00 98.18 100.00  100.00 100.00 98.18  Awareness L3.1-70B GPT-4o0  98.18 96.36 100.00  100.00 90.91 100.00  CL3.5  94.55 96.36 100.00  98.18 100.00 100.00  70.91 78.18 80.00  78.18 76.36 78.18  Selection  L3.1-70B GPI-40  70.91 78.18 78.18  76.36 76.36 76.36  CL3.5  70.91 76.36 78.18  76.36 76.36 76.36  Capability L3.1-70B GPT-40  90.09 89.19 89.19  89.19 88.29 88.29  CL3.5  89.19 89.19 90.09  90.99 88.29 89.19 \f"
        ],
        [
            "Performance of the Lamoid with and without norms across the metrics",
            "Precision Recall F1Score  No Violation 1 0.85 0.92 Quantity Violation 0.63 1 0.77 Quality Violation 1 1 1 Relation Violation 1 1 1 Manner Violation 1 1 1 \f"
        ],
        [
            "the performance of seven LLMs with native function calling support and three large reasoning models",
            "Model  GPT-40 (FC)  GPT-40-mini (FC) Claude-3-5-Sonnet (FC) Gemini-2.0-Flash (FC) Gemini-1.5-Pro (FC) Qwen2.5-72B-Instruct (FC) Llama3.1-70B-Instruct (FC)  ol (FC) Gemini-2.0-Flash-Thinking (ReAct) Deepseek-R1 (ReAct)  Bank  64.71 34.64 71.90 56.86 54.25 36.60 38.56  DMV  80.87 70.43 50.43 54.78 60.00 45.22 41.74  Library  65.38 46.15 33.33 26.92 26.92 30.77 37.18  Healthcare  73.85 26.15 39,23 23.08 18.46 28.46 25.38 91.54 83.08 54.69  Market  63.64 45.99 43.32 40.11 34.22 22.99 19.79  Overall  69.08 43.74 49.17 41.63 39.37 31.98 31.07 \f"
        ],
        [
            "Overall, the Lamoid with norms outperformed the Lamoid without norms across all metrics",
            "Accuracy in Understanding Response Experiment Task Options Mean Length Mean Options Relevance Clarity  Norms 95.27 % 97.74% 227.73 2.99 96.36 % 96.82 % Without Norms 74.73% 90.74 % 400.84 2.70 76.36 % 80.91 % \f"
        ],
        [
            "Average Surface Roughness, Root Mean Square and Maximum Heigh shown in the table",
            "Membrane Code  PO Pl p2 p3 p4 P5 1% FP4 2% FPA  Average Surface Roughness (Ra) nm  64.76 66.96 81.53 93.94 95.93 56.17 156.3 175  Root Mean Square (Rq) nm  78.68 83.28 100.2 115.2 115.1 69.56 196.3 212.7  Maximum Height (Rz) nm  455.6 499.9 641.6 706.3 600 466.2 1294 1122 \f"
        ],
        [
            "Univariate analysis of clinicopathological characteristics associated with DFS and OS",
            "Characteristics  Age at diagnosis <55 >55 Menopausal status Premenopausal Postmenopausal T stage Tl T2 T3 T4 N stage NO N1 N2 N3 Ki-67 index <30 % >30 % HER2 status 0 Low NAT regimens Anthracyclines + Taxanes Platinum-based regimens Other regimens* Type of surgery Mastectomy Breast-conserving MP grade 142 3 4+5 Radiation therapy No Yes Capecitabine No Yes  Total  Zoe 63  178 118  19 220 41 16  80 133 16 67  20 271  126 170  251 33 12  233 63  93 94 109  o1 245  144 152  No-DFS events  N(%)  173 (79.4) 45 (20.6)  130 (59.6) 88 (40.4)  12 (5.5) 168 (77.1) 32 (14.7) 6 (2.8)  76 (34.9) 111 (50.9) 7 (3.2) 24 (11.0)  21 (9.6) 197 (90.4)  95 (43.6) 123 (56.4)  183 (83.9) 25 (11.5) 10 (4.6)  166 (76.1) 52 (23.9)  56 (25.7) 68 (31.2) 94 (43.1)  39 (17.9) 179 (82.1)  98 (45.0) 120 (55.0)  DFS events N(%)  60 (76.9) 18 (23.1)  48 (61.5) 30 (38.5)  7 (9.0) 52 (66.7)  9 (11.5) 10 (12.8)  4 (5.1) 22 (28.2)  9 (11.5) 43 (55.1)  4 (5.1) 74 (94.9)  31 (39.7) 47 (60.3)  68 (87.2) 8 (10.3) 2 (2.6)  67 (85.9) 11 (14.1)  37 (47.4) 26 (33.3) 15 (19.2)  12 (15.4) 66 (84.6)  46 (59.0) 32 (41.0)  Univariate Analysis  p-Value 0.65  0.77  0.004  <0.001  0.22  0.56  0.70  0.07  <0.001  0.62  0.033  No-OS events  N(%)  210 (79.8) 53 (20.2)  159 (60.5) 104 (39.5)  15 (5.7) 201 (76.4)  35 (13.3)  12 (4.6)  78 (29.7) 127 (48.3) 11 (4.2) 47 (17.9)  24 (9.1) 239 (90.9)  113 (43.0) 150 (57.0)  220 (83.7) 32 (12.2) 11 (4.2)  202 (76.8) 61 (23.2)  78 (29.7) 79 (30.0) 106 (40.3)  45 (17.1) 218 (82.9)  122 (46.4) 141 (53.6)  OS events N(%)  23 (69.7) 10 (30.3)  19 (57.6) 14 (42.4)  4 (12.1) 19 (57.6) 6 (18.2) 4 (12.1)  2 (6.1)  6 (18.2)  5 (15.2) 20 (60.6)  1 (3.0) 32 (97.0)  13 (39.4) 20 (60.6)  31 (93.9) 1 (3.0) 1 (3.0)  31 (93.9) 2 (6.1)  15 (45.5) 15 (45.5) 3 (9.1)  6 (18.2) 27 (81.8)  22 (66.7) 11 (33.3)  Univariate Analysis p-Value 0.18  0.75  0.047  <0.001  0.39 0.70  0.31  0.023  0.002  0.88  0.028 \f"
        ],
        [
            "results  for LLama3-8B, NarrativeQA, Qasper, hotpotQA, Musique",
            "| Full | Duo  NarrativeQA 27.3 | 17.4 Qasper 28.9 | 16.4 MultiFieldQA-en 52.3 | 35.8 MultiFieldQA-zh 50.9 | 37.9  HotpotQA 40.6 | 26.8 2WikiQA 29.3 | 22.2 Musique 24.4 | 12.0 DuReader (zh) 30.2 | 26.3 GovReport 34.1 | 22.4 QMSum 24.5 | 20.9 MultiNews 27.7 | 24.0 VCSUM (zh) 11.3 | 4.8  TREC 71.0 | 53.5 TriviaQA 87.7 | 77.8 SAMSum 42.5 | 41.0 LSHT 38.0 | 21.5 Passage Count 1.0 | 2.09  PassageRetrieval-en | 80.5 | 46.5 PassageRetrieval-zh | 61.2 | 29.4 LCC 37.5 | 36.2 RepoBench-P 38.0 | 39.1  SLLM  22.1 13.0 40.6 34.4 28.1 Zak 17.9 31.3 28.8 21.5 24.4 10.6 61.5 82.8 39.4 25.0 2.0  25.5 14.0 43.5 42.0  H20  25.75 16.9 29.1 28.2 32.8 24.4 18.1 17.7 24.1 21.4 22.4 13.14 55.5 84.9 38.8 Ddoite 2.0 47.0 34.2 44.74 41.9  NAtS  23.09(13%) 29.01(26%) 48.72(22%) 46.03(27%) 41.7(17%) 27.39(20%) 21.0(16%) 28.44(20%) 33.47(20%) 23.88(15%) 27.77(32%) 9.4(19%) 68.5(22%) 87.42(18%) 41.78(14%) 35.5(20%) 1.59(23%) 67.0(15%) 41.07(24%) 40.11(35%) 42.63(25%) \f"
        ],
        [
            "Efficacy and safety outcomes",
            "Efficacy outcomes All-cause mortality MACE Cardiovascular death Stroke  Myocardial infarction Heart failure  Safety outcomes Hypotension Syncope  Arrhythmia  Acute kidney injury Electrolyte abnormalities  Studies  [7, 8, [7, 8, [7, 8, [7, 8, [7, 8, [7, 8,  [7, 8, [7, 8, [7, 8, [7, 8, [7, 8,  15, 15, 16] 15, 15, 16]  16] 15, 16] 16] 16]  16] 16]  16] 16]  16]  Intensive BP control  group, n (%)  672/19,712 (3.4)  1458/19,712 (7.4)  220/19,079 (1.2 690/19,712 (3.5 383/19,712 (1  305/19,079 (1  Neer Ne ee  I .6  131/19,078 (0.7) 149/19,711 (0.8) 246/19,078 (1.3) 205/19,078 (1.1)  1,204/19,078 (6.3)  Standard BP control  group, n (%)  778/19,722 (3.9)  1765/19,722 (8.9)  305/19,092 (1.6) 851/19,722 (4.3) 462/19,722 (2.3) 386/ 19,092 (2.0)  63/19,092 (0.3)  100/19,722 (0.5) 211/19,092 (1.1) 123/19,092 (0.6) 950/ 19,092 (5.0)  Risk ratio (95% CI)  0.87 0.83 0.73 0.81 0.83 0.79  0.76-0.99) 0.77-0.88) 0.56-0.94) 0.74-0.90) 0.73-0.95) 0.68-0.92)  ee ee EE  3.34 (1.26-8.87) 1.56 (1.09-2.23} 1.17 (0.93-1.49) 1.66 (1.33-2.07) 1.26 (1.13-1.40) \f"
        ],
        [
            "For each type of claim, we report the percent of those claims for which all three annotators agree on the faithfulness label",
            "Summary writer:  Human LLM  Synthetic claim type:  Objective Subjective  % Agree  79.93 72.74  55.56** 26.56 \f"
        ],
        [
            "Patients’ demographic data",
            "Demographic Factor  Average age (years) 22.0 Average body mass index (kg/m7) 20.17 Sex (Male/Female) 1 (10%) /9 (90%) \f"
        ],
        [
            "Descriptions of HRV features employed",
            "HRV Feature Time-domain features mRR  SDRR RMSSD  PNN5S0O  Frequency-domain features VLE  LF  HF  TP  pVLEF  pLF  pHEFE  LF/HF  nLF  nHF  Non-linear features SD2/SD1  ApEn  SampEn  WN NI  WN NI  WN  BBB BS  N  el bed  o Oo © bd  el —  | —  cog  rel —  Description (Equation)  N The mean of RR intervals (Hie Ri) )  N _ 2 The standard deviation of RR intervals ( din RR MRR)\" )  The square root of the mean squared differences between successive RR  intervals (\\/mean(RRji1 — RR;)°) Number of interval differences in successive RR intervals greater than 50 ms count(|RRj+1—RRj|) s 50 ms <x 100%)  ( N=I  Absolute powers of very low frequency band (0—0.04 Hz) Absolute powers of low frequency band (0.04—0.15 Hz) Absolute powers of high frequency band (0.15-0.4 Hz) The total energy of RR intervals  Relative powers of VLF (VLF [ms*]/TP [ms7] x 100%) Relative powers of LF (LF [ms*]/TP [ms*] x 100%) Relative powers of HF (HF [ms*]/TP [ms] x 100%)  The ratio between LF and HF band powers  Normalized low frequency power  Normalized high frequency power  Ratio between SD2 and SD1 Approximate entropy Sample entropy \f"
        ],
        [
            "various cell types and the number of cells in the dataset",
            "usc [s [| 55 [7 [x [x [200  pemcoo [wos st foe fam io Px ff    \f"
        ],
        [
            "electrochemically grown nanostructures on copper were found to be key materials in numerous applications, including electro-catalysis",
            "Passivation System and Procedure  otentiostat; 1.0 M KOH, —0.06 V vs. Hg! HgO, 10-100 s  Potentiostat; 0.01-6.0 M KOH, 0.864 V vs. RHE  NA; 3 M KOH, 10 mA/cm/2, 60s  Potentiostat; 1.0-3.0 M NaOH, 0 or 100 mV vs. Hg! HgO, RT, 20 min  otentiostat; 200 g/L of NaCl + 4 g/L of NaOH; pulse passivation (0.2 mA/cm? for 10 s followed by 0 mA/cm7? for 2s), 2160s  NA; 2 M KOH, 4 mA/cm2,0°C, 30 min  Two-electrode; 3 M NaOH, 10 mA/cm? (cupric hydroxide), or 0.2-5.0 mA/cm? (cuprous oxide) 25 °C, 30 min  Two-electrode; 10 V, 5 °C, 3 min  Remarks/A pplications  At 0.60 V (methanol oxidation) vs. Hg! HgO, after passivation, current density increased over 10 times—methanol oxidation  It was found that the greater the pH the faster the nanostructures grow, and the greater the Cu(OH)»2 to CuO ratio; for the samples obtained in the highest pH, the highest value of methanol oxidation current density oxidation was registered—methanol oxidation  It was found that selectivity towards ethylene formation is much greater than for the plain foil, accompanied by great stability—electrochemical CO» reduction into ethylene  Cu was electrochemically oxidized at various operating conditions. It was found that the greater the electrolyte concentration, the greater the ECSA (electrochemical surface area) and the higher the current densities recorded during the carbon dioxide reduction reaction—electrochemical CO, reduction  Performance of electrochemically grown nanostructures vs. plain copper plate in carbon dioxide reduction into formic acid, methane, and ethene was compared: it was shown that selectivity toward carbon on low-oxidation-state products is much better for the electrochemically grown nanostructures, even after 9 h of reaction—electrochemical CO> reduction  Electrochemically grown copper oxides served in Gas Diffusion Electrodes (GDE) as an active material for CO» reduction; scalable technology has been reported; selectivity to C5, products was as high as 87%—electrochemical CO, reduction  Photocorrosion performance of catalysts for Hz generation: CuOx nanostructures were coated with carbonized glucose, which improved stability—hydrogen generation (water splitting)  Various electrolytes were applied: 0.1% NH4F in ethylene glycol with 10%, 5% HO, or 1% H2O0 with 0.1 M KOH or 0.1 M NaOH. The greater the water content in the electrolyte, the longer the nanoneedles. Methylene blue (MB) was subjected  to photodegradation on the formed materials; the longer nanoneedles composed of both CuzO and CuO were found to provide the highest degradation efficiency, equal to 88%  Reference  [82]  [83]  [84]  [85]  [86]  [87]  [89] \f"
        ],
        [
            "Accuracy (%) evaluation on datasets with different\npermutation order and base model as Llama-3.2-3B",
            "Order  Random Topological  Reversed  Method  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8  MEND  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8  MEND  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8  MEND  Difficulty Level     |  100.0 100.0 100.0 100.0 100.0 97.5  99.0 100.0 99.0 100.0 100.0 97.5  995 100.0 993 100.0 100.0 97.5  2  99.0 98.5 82.5 94.5 100.0 09.5  65.5 62.5 Tie 96.5 99.5 99.5  45.0 30.5 85.0 97.0 100.0 98.5  3  79.5 87.0 16.0 28.5 49.5 88.5  10.5 13.0 15.0 26.0 38.5 85.5  5.5 0.5 20.5 30.0 42.5 86.0  4  32.0 33.0 1.5 3.5 9.0 D1 el  0.0  1.0  3.0  4.5  12.5 37.5  1.0 0.5 2.5 4.5 8.0 41.0  Avg.  77.6 79.6 (+2.0) 50.0 (-27.6) 56.6 (-21.0) 64.6 (-13.0) 80.8 (+3.2)  43.8 44.1 (40.3) 48.6 (44.8) 56.8 (+13.0) 62.6 (+18.8) 80.0 (+36.2)  37.8 32.9 (-4.9) 51.9 (+14.1) 57.9 (+20.1) 62.6 (+24.8) 80.8 (+43.0) \f"
        ],
        [
            "The capabilities of FeRG-LLM are compared with those of other recent models including CAAFE (Holl-mann et al., 2024) and FeatLLM (Han et al., 2024). A ✓ indicates that a criterion is met while a ✗ indicates that it is not",
            "Criteria | CAAFE  FeatLLM | FeRG-LLM  Create contextual features by understanding the dataset and modeling objectives? J Operate without explicitly specifying operators such as inequalities in the prompt? J Applicable to tasks beyond classification (e.g., regression)? x x v Produce features at the point of generation without external API like GPT-4? J Generate features without requiring specific variable values in the prompt? J \f"
        ],
        [
            "GPT-4o, GPT-4o mini, DeepSeek-V3, ERNIE, Roberta performance comparison",
            "Model | CrossDial-Dougen(ACC) | CrossDial-Penggen(ACC) | HumorWB(ACC) GPT-40 79.67 73.88 83.41 GPT-40 mini 74.14 67.45 $4.78 DeepSeek-V3 83.66 78.16 85.15 ERNIE 84.54 - - RoBERTa - 76.19 - Qwen2.5-7B-Instruct 24.74 20.87 79.56 CFunModel(ours) 91.70 $8.99 $5.98 \f"
        ],
        [
            "Parameter, Condition and Value of CORM-2",
            "Parameter CGT  IMRL  MRL  CLI  Condition  tPA tPA+CORM-2  tPA tPA+CORM-2  tPA tPA+CORM-2  tPA tPA+CORM-2  Value  1.6 + 0.1 2.6 + 0.3*  12+ 0.2 3.4 + 0.3*  6.2 + 0.5 8.3 + 0.5*  2.7 + 0.3 5.9 + 0.4 * \f"
        ],
        [
            "comparison between our model and the baselines",
            "Ours Baselines  Metries SSVAE  Similarity + 45.8  IHS Strength + 41.1 ; ; 43.8 Fluency | ; 130.7 ; 77.3  GM + 40.7 . . , ; 35.9  HM + 34.9 : , , ; 34.0  Similarity + , , 69.2 ‘ , 33.5  Yelp Strength + . ; 88.0 76.6 Fluency | ; 161.5 : ; ; 42.4  GM + : : ; 48.2 40.9  HM + , 38.9 : , 37.3  Similarity + ‘ 73.1 , , 36.6  DC Strength + ; 63.5 , , 55.5  Fluency | ; . 91.4 ; ; 36.4 GM + ; 46.0 ‘ , , 38.4 HM + ; 38.9 : ’ , 36.9    \f"
        ],
        [
            "Compare the capabilities of FeRG-LLM with other models",
            "Criteria | CAAFE  FeatLLM | FeRG-LLM  Create contextual features by understanding the dataset and modeling objectives? J Operate without explicitly specifying operators such as inequalities in the prompt? J Applicable to tasks beyond classification (e.g., regression)? x x v Produce features at the point of generation without external API like GPT-4? J Generate features without requiring specific variable values in the prompt? J \f"
        ],
        [
            "Onwer's feeling or opinion towards caring for their cats",
            "Statement  My daily routine has changed a lot since my cat was diagnosed with CKD  The care of my cat has negatively impacted/restricted my life  | feel Supported by my veterinary practice with regard to my cat's care  | feel comfortable making decisions with a veterinarian about my cat's care  | feel comfortable making decisions with a veterinary nurse about my cat's care  | feel | am knowledgeable about CKD in cats  | am able to determine/assess my cat’s quality of lite  | feel confident | am able to monitor the progression of my cat’s CKD  | feel my cat’s condition has improved since starting treatment  Being a caregiver to my cat has given me ourpose and a sense of accomplishment  strongly agree  31 (31) 14 (14) 42 (42) 39 (39) 26 (26) 28 (28) 26 (26) 28 (28) 22 (22)  26 (26)  Agree  35 (35) 23 (23) 28 (28) 41 (41) 22 (22) 50 (50) 54 (54) ee 30 (30)  ZO) Z5))  Neither agree nor disagree  14 (14) 20 (20) 20 (20) 15 (15) 38 (38) 12 (12) 12 (12) 25 (25) 30 (30)  33 (33)  Disagree  strongly disagree \f"
        ],
        [
            "Current evidence on malignant mesenchymal tumors of the breast - focus on sarcomas and phyllodes tumors",
            "Study (Year)  Holm et al. [5] (2015)  Confavreux et al. [3] (2006)  McGowan et al. [4] (2000)  Global Cohort  (Number of  Patients)  42  70  78  5y-OS  49%  49%  57%  5y-DFS  48%  28%  47%  5y-LRR  24%  26%  Median Follow-Up  (Period of Study)  50.4  (1979-2014)  31.7 (1966-2004)  114 (1958-1990)  Key Findings  - Tumor size and grade are significant prognostic factors  - Negative surgical margins (RO) significantly  improve survival (72% vs.  38%) - Angiosarcomas have the worst DES (7%)  - Negative surgical margins (RO) improve local relapse-free survival (80% vs. 33%)  - Radiation dose >48 Gy improves 5-year OS (91% vs. 50%)  Study Limitations  - Retrospective study  - Single institution  - Small and disomogeneous cohort - Missing data  - Retrospective study - Small and disomogeneous cohort  - Lack of uniform treatment protocols  - Retrospective study  - Single institution,  - Small and disomogeneous cohort - Missing or incomplete data \f"
        ],
        [
            "Wanda, SliceGPT, SLEB performance comparison",
            "OPT-13b Llama-2-13b  OPT-30b  Methods  Dense Wanda (2:4)  SliceGPT SLEB EvoP  Dense Wanda (2:4)  SliceGPT SLEB EvoP  Dense Wanda (2:4)  SliceGPT SLEB  EvoP  O% SO% 10% 20% 10% 20% 10% 20%  O% SO% 10% 20% 10% 20% 10% 20%  O% SO% 10% 20% 10% 20% 10% 20%  1.00x 1.00x 0.99x 1.10x 1.10x 1.23x 1.10x 1.23x  1.00x 1.00x 0.93x 1.01x 1.11x 1.24x 1.11x 1.24x  1.00x 1.00x 0.95x 1.01x 1.12x 1.26x 1.12x 1.26x  0.82 0.71 0.65 0.44 0.77 0.73 0.77 0.73  0.71 0.63 0.67 0.60 0.70 0.65 0.70 0.67  0.72 0.64 0.69 0.63 0.71 0.69 0.72 0.70  0.53 0.35 0.34 0.24 0.43 0.39 (0.46 0.40  0.35 0.28 0.32 0.31 0.34 0.30 0.35 0.33  0.37 0.29 0.34 0.32 0.36 0.35 0.38 0.34  0.61 0.43 0.44 0.34 0.56 0.50 0.57 0.52  0.52 0.42 0.49 0.44 0.52 0.47 0.52 0.50  0.55 0.42 0.51 0.47 0.53 0.50 (55 0.51  0.80 0.72 0.69 0.60 0.78 0.77 0.79 0.77  0.76 0.71 0.74 0.69 0.76 0.74 0.76 0.75  0.77 0.70 0.75 0.72 0.77 0.75 0.77 0.76  Sparsity SpeedUp ARC_E ARC_C HellaSwag PIQA Winogrande  0.75 0.62 0.70 0.62 0.69 0.65 0.71 0.68  0.67 0.60 0.65 0.63 0.67 0.64 0.67 0.66  0.69 0.61 0.68 0.65 0.68 0.65 ().69 0.66  Avg  0.70 0.57 0.56 0.45 0.65 0.61 ().66 0.62  0.60 0.53 0.57 0.53 (0.60 0.56 (0.60 0.58  0.62 0.53 0.59 0.56 0.61 0.59 0.62 0.59 \f"
        ],
        [
            "MemoryLLM，CAMELoT，RMT，MELODI，MemoRAG performance comparison",
            "Model | PG19 arXiv C4 (4K+)  MemoryLLM | 7.65 = 4.00 18.14 CAMELoT 7.10 3.60 -  RMT 7.04 3.56 17.67 MELODI 6.21 - 15.25 MemoRAG 5.92 3.35 15.37     R°Mem 5.21 8 2.39 13.38 \f"
        ],
        [
            "Model performance for SALMONN, MU-LLaMA, OpenMU",
            "MusicQA MusicCaps Music4way-MusicCaps B-1 R-L BERTS B-1 R-L BERTS B-1 R-L BERTS  Model     SALMONN (Tang et al., 2024a) 128.7 135.4 190.3 | 119.7 119.1 186.9 | 19.1 20.0 87.0 MU-LLaMA (Liu et al., 2024) 129.7 133.1 189.9 | *196 *116.2 *T868} 15.1 27.6 88.3 OpenMU (Zhao et al., 2024) 124.5 125.5 188.6 | 123.9 119.4 186.6 _ - - MusiLingo sft. w/ MusicCaps (Deng et al., 2024) _ _ _ — 121.7 186.8 _ = _ NExT-GPT (Wu et al., 2024) 23.3 26.0 876 | 165 14. 840} 166 17.2 86.7 M2UGen (Hussain et al., 2023) 129.1 137.9 190.5 | *114.4 *716.4  *'86.5 | *T13.1 *126.0 = *187.6 NExT-GPT w/ M?UGen 134.0 139.6 91.2) 124 16.1 86.9 | *123.2 *136.7 = *791.3 NExT-GPT w/ Music4way 134.1 139.2 191.3 | 125.0 121.0 187.2 | 139.1 146.8 193.0 DeepResonance-a (ours) 135.1 140.8 191.6 | 126.0 121.6 187.3 | 140.9 148.4 193.3  DeepResonance- (ours) 135.6 ‘41.1 191.6 | 125.8 121.6 187.3 | 139.9 147.8 193.2 \f"
        ],
        [
            "Perplexity Comparison Across Models and Fine-Tuning Formats",
            "Model Data Type Base Perplexity Finetuned Perplexity  Tb treatment 12.66 12.76 Tb control 12.66 12.81 Tb-chat treatment 17.04 15.36  Tb-chat control 17.03 15.85 \f"
        ],
        [
            "The comparison between frequency and distress",
            "Distress  Chronicity  Distress  Frequency Not Lonely 523 (94.23%) 141 (60.00%)  Lonely  32 (5.77%) 94 (40.00%) 126  Not Lonely  Lonely  ©) ©) me  Frequency  Not Lonely 570 (89.62%) 94 (61.04%)  Lonely  66 (10.38%) 60 (38.96%) 126  Not Lonely  Lonely  ©) ©) me  Chronicity Not Lonely 544 (98.02%) 92 (39.15%)  Lonely  11 (1.98%) 143 (60.90%) 154  Not Lonely Lonely  O) oO O) \f"
        ],
        [
            "The immunohistochemistry group’s patients exhibited certain clinical baseline characteristics",
            "Characteristic Low expression group (” = 30) High expression group (” = 20) p-value  Sex (Male %) 85% 85% 0.75 Age (mean + SD) 55.6 + 11.4 60.2 + 10.1 0.09 Weight (kg) 73.2 + 10.9 64.7 + 84 <0.01 Height (cm) 168.3 + 6.8 167.1 + 6.3 0.45 Alcohol consumption (%) 30% 30% 1.00 Differentiation 2.5+0.5 2.6 + 0.6 0.52 Fatty liver (%) 10% 5% 0.50  Tumor size (cm) 3.64 2.8 4.9 + 2.7 0.06 \f"
        ],
        [
            "compare ReaRAG-9B result with other models",
            "Category  In-context  Vanilla RAG  Advanced  RAG  Ours  Model  GLM-4-9B (128k) GLM-4-32B(128k) GLM-4-9B(128k) GLM-4-32B(128k) QwQ-32B Self-RAG(Llama2-7b) SearChain(GPT-40) Search-o | (QwQ-32B) ReaRAG-9B  MuSiQue  ACC; EM  23.50 15.00 33.50 17.00 25.50 14.00 29.00 17.00 36.00 20.00 24.00 13.00 S150 33.00 40.50 32.00 66.00 40.00  Multi-hop HotpotQA  ACC, 58.00 65.50 68.00 67.50 67.00 45.50 69.00 55.50 75.50  EM 47.00 50.00 52.00 52.00 47.00 31.00 49.00 38.00 56.00  IRC  ACC, 20.50 25.00 28.25 28.25 38.25 25.00 40.50 32.25 42.75  EM 18.00 16.00 23.00 17.00 32.00 13.00 20.50 27.00 29.00  Single-hop  NQ  ACC, 45.50 52.50 49.00 53.00 48.00 40.00 54.00 43.00 52.00  EM 26.00 24.00 32.00 39.00 26.00 28.00 25.00 28.00 25.00 \f"
        ],
        [
            "LLM-as-a-judge without access to tools or reference answers shows competitive macro F1 scores",
            "Candidate  GPT-3.5  GPT-40  Gemini  Task  AmbigQA HotpotQA  AmbigQA HotpotQA  AmbigQA HotpotQA  EM  0.758 0.790  0.733 0.763  0.772 0.732  Fl  0.828 0.877  0.774 0.830  0.783 0.829  GPT-3.5  0.611 0.527  0.591 0.532  0.582 0.553  Judge w/o Tool GPT-40  0.697 0.609  0.683 0.669  0.668 0.617  Gemini  0.792 0.665  0.780 0.675  0.614 0.619  GPT-3.5  0.784 0.706  0.802 0.770  0.819 0.816  TALE  GPT-40  0.898 0.779  0.957 0.850  0.873 0.846  Gemini  0.830 0.762  0.957 0.839  0.835 0.797 \f"
        ],
        [
            "Total number of various cells and their corresponding counts in the RSLI, LISC, WBCDD, and BCCD datasets",
            "usc [s [| 55 [7 [x [x [200  pemcoo [wos st foe fam io Px ff    \f"
        ],
        [
            "Mean Cosine Similarity Between Comparison and Target Scripts",
            "Comparison Script Indus Proto-Cuneiform Proto-Elamite TYC 0.635 0.102 0.078 Naxi-Dongba 0.634 0.109 0.087  Old-Naxi 0.617 0.106 0.076 \f"
        ],
        [
            "All standardized and unstandardized regression weights are presented in Table",
            "Model 8: Non-treatment groups Maternal age — T3 Sensitivity  Verbal ability — T3 Sensitivity Neglect history — T3 Sensitivity Resolution — T3 Sensitivity  Neglect x Resolution — T3 Sensitivity  B -.009  040 —.019 035  051  SE  007 014 053 019  018  —129 264 —.040 204  287  005 721  005  164  0597  ** \f"
        ],
        [
            "LongBench Results with 25% Budget Allocation for full\nattention (Full), DuoAttention (Duo), Streaming LLM (SLLM),\nH2O and NAtS on the LLama8B model.",
            "| Full | Duo  NarrativeQA 27.3 | 17.4 Qasper 28.9 | 16.4 MultiFieldQA-en 52.3 | 35.8 MultiFieldQA-zh 50.9 | 37.9  HotpotQA 40.6 | 26.8 2WikiQA 29.3 | 22.2 Musique 24.4 | 12.0 DuReader (zh) 30.2 | 26.3 GovReport 34.1 | 22.4 QMSum 24.5 | 20.9 MultiNews 27.7 | 24.0 VCSUM (zh) 11.3 | 4.8  TREC 71.0 | 53.5 TriviaQA 87.7 | 77.8 SAMSum 42.5 | 41.0 LSHT 38.0 | 21.5 Passage Count 1.0 | 2.09  PassageRetrieval-en | 80.5 | 46.5 PassageRetrieval-zh | 61.2 | 29.4 LCC 37.5 | 36.2 RepoBench-P 38.0 | 39.1  SLLM  22.1 13.0 40.6 34.4 28.1 Zak 17.9 31.3 28.8 21.5 24.4 10.6 61.5 82.8 39.4 25.0 2.0  25.5 14.0 43.5 42.0  H20  25.75 16.9 29.1 28.2 32.8 24.4 18.1 17.7 24.1 21.4 22.4 13.14 55.5 84.9 38.8 Ddoite 2.0 47.0 34.2 44.74 41.9  NAtS  23.09(13%) 29.01(26%) 48.72(22%) 46.03(27%) 41.7(17%) 27.39(20%) 21.0(16%) 28.44(20%) 33.47(20%) 23.88(15%) 27.77(32%) 9.4(19%) 68.5(22%) 87.42(18%) 41.78(14%) 35.5(20%) 1.59(23%) 67.0(15%) 41.07(24%) 40.11(35%) 42.63(25%) \f"
        ],
        [
            "Assessment of the ChatGPT-4o-generated exercise plans: safety issues",
            "Safety Criteria Exercise Plan 1 Exercise Plan 2 (According to ElSayed et al. (Patient 1, (Patient 2, [16]; Kanaley et al. [1]) Prompt 1) Prompt 1) Advice for a medical check-up prior to the start of the training program (for individuals who are older than 40 years of age, have any secondary complications, intend to undertake high-intensity workouts, intend to undertake high-intensity physical activities and are currently sedentary adults or have a diabetes duration > 10 years) No conflicts with possible contraindications (e.g., high-intensity training for patients with proliferative retinopathy or weight-bearing exercises for patients with diabetic foot ulcers) Additional safety instructions (e.g., for patients with insulin treatment: regularly check glucose values before/ during /after exercise; for all patients with diabetes: stay hydrated; for patients with hypertension: do not hold breath during strength exercises)  Exercise Plan 3 (Patient 3, Prompt 1)  Exercise Plan 4 (Patient 1, Prompt 2)  Exercise Plan 5 (Patient 2, Prompt 2)  Exercise Plan 6 (Patient 3, Prompt 2)  Exercise Plan 7 (Patient 1, Prompt 3)  Exercise Plan 8 (Patient 2, Prompt 3)  Exercise Plan 9 (Patient 3, Prompt 3)    \f"
        ],
        [
            "The full list of emotions, their grouping, and their VAD values accordingly",
            "Group Words Emoji | Valence Arousal Dominance     Grateful - Very High (+2. ° Moderate (0.0) Low (-2.5) Happy Joyful Very High ( High (+1.0) High (+1.0) Content Very a ( Moderate (0.0) Very High (+4.0)        Excited Very i — 5) Very no = 0) | High (+1.0) Proud Very Mek 40 High ( 1 } Very High (+2.5) Low (-1.0)           Anxious High (+2. ; Low (-2.5) Fear Afraid High (+2.5) Very Low (-4.0) Terrified Very High (+4.0) | Very Low (-4.0) Annoyed Moderate (0.0) Moderate (-1.0) Anger Angry High (2.5) Moderate (0.0)             oS e9 Furious q Very High (4.0) | High (1.0) Sad é Low (-2.5) Very Low (-4.0) Paciness Devastated ® High (1.0) Low (-2.5) Ashamed ® Moderate (-1.0) | Very Low (-4.0) Shame | Embarrassed a High (2.5) Low (-2.5) Guilty é) Moderate (0.0) Very Low (-4.0) \f"
        ],
        [
            "Results on MusicQA, MusicCaps, and Music4way-MusicCaps",
            "MusicQA MusicCaps Music4way-MusicCaps B-1 R-L BERTS B-1 R-L BERTS B-1 R-L BERTS  Model     SALMONN (Tang et al., 2024a) 128.7 135.4 190.3 | 119.7 119.1 186.9 | 19.1 20.0 87.0 MU-LLaMA (Liu et al., 2024) 129.7 133.1 189.9 | *196 *116.2 *T868} 15.1 27.6 88.3 OpenMU (Zhao et al., 2024) 124.5 125.5 188.6 | 123.9 119.4 186.6 _ - - MusiLingo sft. w/ MusicCaps (Deng et al., 2024) _ _ _ — 121.7 186.8 _ = _ NExT-GPT (Wu et al., 2024) 23.3 26.0 876 | 165 14. 840} 166 17.2 86.7 M2UGen (Hussain et al., 2023) 129.1 137.9 190.5 | *114.4 *716.4  *'86.5 | *T13.1 *126.0 = *187.6 NExT-GPT w/ M?UGen 134.0 139.6 91.2) 124 16.1 86.9 | *123.2 *136.7 = *791.3 NExT-GPT w/ Music4way 134.1 139.2 191.3 | 125.0 121.0 187.2 | 139.1 146.8 193.0 DeepResonance-a (ours) 135.1 140.8 191.6 | 126.0 121.6 187.3 | 140.9 148.4 193.3  DeepResonance- (ours) 135.6 ‘41.1 191.6 | 125.8 121.6 187.3 | 139.9 147.8 193.2 \f"
        ]
    ],
    "neg": [
        [
            "The performance of method applied to both zero-shot and zero-shot-CoT base-lines",
            "Category  Single Word  Conjunction  Conjunction Pool  Phrase  Sentence  Machine Language  Injection Phrase  Step Let Well  Wait (Muennighoff et al., 2025)  And But Or  Addition Pool Contrast Pool Mix Pool  I mean, You know,  I might be wrong. Keep reasoning.  <start of text> \\t #  Accuracy  44.44% 38.33% 50.56% 21.11%  16.11% 17.78% 12.78%  26.11% 20.56% 23.33%  27.22% 22.22%  33.33% 12.22%  27.78% 19.44% 26.67% \f"
        ],
        [
            "The analysis of PTSD symptoms and PAIN follow-up",
            "Age (mean + SD, years) Gender (males, %) Ethnicity (Caucasian, %) Living with partner (yes, %) Employed' (yes, %) Time since injury (mean, +SD, months)*  Cause of injury (n, %) Motor vehicle accident Fall from height  Surgical procedures Spinal stroke  Other  Level of injury (n, %) Cervical  Thoracic  AIS (%)  A  B  C  D  Medication use (n, %)°  All participants  (n = 65)  43.08 + 15.20  49, 75.4 65, 100 40, 61.5 57, 87.7  1.82 + .89  18, 28.6 18, 28.6 17, 27.0 7, 11.1 3, 4.8  26, 40.0 39, 60.8  17, 26.2 7, 10.8 19, 29.2 22, 33.8 47, 12.3  With chronic pain at follow-up  (n = 49)  42.00 + 14.92  Of, 3.9 49, 100 29, 99.2 44, 89.8  1.89 + .88  16, 34.0  15, 31.9  11, 23.4 3, 6.4 2,4.3  19, 38.8 30, 61.2  16, 32.7 3, 6.1 13, 26.5 17, 34.7 36, 73.5  Without chronic pain at follow-up  (n = 16)  46.30 + 16.05  12, 75.0 16, 100 11, 68.8 13, 81.3  1.58 + .94  2, 12.5 3, 18.8 6, 37.9 4, 25.0 1, 6.3  7, 43.8 9, 56.3  1, 6.3 4, 25.0 6, 37.5 3, 31.3 11,68.8  p- value  05  1 \f"
        ],
        [
            "Helthcare Tools/methods and description",
            "Outcome Category Better Safety and Quality Employee Outcomes  Cultivating Improvement Culture  Enhanced Skills Development Patient Outcomes Improved Experience Financial Outcomes  Cost Reduction  Revenue Enhancement  Process Mining Contribution  Identifies patterns and risks in care processes before they affect patients [110].  Supplies objective, data-backed evidence to guide iterative improvements [112].  Provides learning opportunities through data visualization and analysis [60].  Ensures smoother workflows and timely interventions through automated process monitoring [14].  Identifies resource waste and unnecessary process steps through detailed activity analysis [115].  Uncovers opportunities for optimizing reimbursement through analysis of billing processes and claim patterns [90].  Kaizen Contribution  Establishes standardized protocols that reduce variation and enhance care reliability [111].  Actively involves frontline staff in problem-solving and process optimization, fostering ownership [113].  Builds problem-solving capabilities through structured improvement approaches [114].  Enhances service quality and patient-centered care by reducing inefficiencies [113].  Implements targeted efficiency improvements that reduce operational costs while maintaining quality [116].  Develops standardized approaches to documentation and coding that maximize appropriate revenue capture [117]. \f"
        ],
        [
            "Categorical predictor variables, by sex and total",
            "   rofile Probability A Posteriori probability mean        Expected Observed G1 G2 G3 G4 11: Healthy 0.15 0.16 0.89 0.07 0.02 0.02 32: MMH- Anx 0.22 0.24 0.02 0.74 0.16 0.08 13: MMH + Anx 0.34 0.32 0 0.06 0.83 0.11  14: Distress 0.29 0.28 0 0.04 0.12 0.84 \f"
        ],
        [
            "Macroscopic features, Microscopic features and Reverse side for the fungi",
            "Isolate code  B2S82 b2 B3S4 Al B2S1 A2 B2S4 A B3S2 b B3S3 1 B3S3 2 B3S82a B1S3 A B4S4 Al B3S4 A2 B4S4 Bl B2S2 b B3S4 b B3S4A2 B3S1  Accession no.  MZ571882 MZ571885 MZ571887 MZ571899 MZ571900 MZ571902 MZ571903 MZ571905 MZ571906 MZ571911 MZ571881 MZ571883 MZ571888 MZ571913 MZ571914 MZ571907  Amylase 10.00 + 1.15° 17.67 + 0.33° 25.00 + 5.138 0.00 + 0.007 17.67 + 0.88° 16.67 + 2.40° 9.00 + 0.58° 20.00 +1.15' 23.67 + 0.88'8 7.33 + 1.33° 0.00 + 0.00* 11.67 + 0.88°° 0.00 + 0.007 0.00 + 0.00* 0.00 + 0.007 13.00+1.15°  Enzymatic activities (diameter measured in mm)  Cellulase 25.67 + 1.20° 12.67 + 1.45° 27.33 +0.67° 0.00 + 0.007 0.00 + 0.007 12.67 + 1.45° 21.00 + 1.00° 12.67 + 1.45° 13.33 + 1.67° 0.00 + 0.007 46.67 + 5.24° 37.00 + 1.53! 69.00 + 2.658 0.00 + 0.007 0.00 + 0.007 28.00 + 4.16°  Esterase 32.00 + 1.16° 0.00 + 0.00* 18.67 + 0.67° 72.67 + 1.76! 31.67 + 2.03” 28.33 + 2.03” 0.00 + 0.007 0.00 + 0.007 0.00 + 0.00* 0.00 + 0.00* 0.00 + 0.00* 53.00 + 1.15° 0.00 + 0.007 12.00 + 1.73% 15.33 + 1.76° 16.33 + 0.88°  Lipase 23.33 + 1.76' 0.00 + 0.00* 0.00 + 0.00* 14.33 + 1.20°  20.33 + 0.88°¢ 0.00 + 0.00* 0.00 + 0.00* 0.00 + 0.00* 0.00 + 0.00* 0.00 + 0.00* 0.00 + 0.00* 0.00 + 0.00* 0.00 + 0.00* 18.00 + 1.73° 0.00 + 0.00* 0.00 + 0.00*  Gelatinas« 13.67 + 0.85 0.00 + 0.0 0.00 + 0.0€ 22.00 + 2.5: 34.67 +2.9 21.33 + 1.3: 0.00 + 0.00 13.00 + 1.1: 0.00 + 0.0C 12.00 + 1.0( 0.00 + 0.0€ 22.00 + 1.1! 0.00 + 0.00 21.00 + 1.7 0.00 + 0.00 0.00 + 0.0C \f"
        ],
        [
            "Task and result for each track",
            "Dataset [LLM (Retriever Model)|Inter|P_[R_[F1 [Pred[Ref/Time[OAEI (F1)  MEEMMO —___|Qwen?-0.5B (BERT) __|61__|88.4]06.5)92.4|60 [63 [135.0 [91.8 (Matcha [[2) FISH-ZOOPLANKTON |LLaMA-3.2-1B (BERT) [13 |02.8)86.6]89.6|14 [15 [9.9 [64.0 (LogMapLt [22D  ALGAB-ZOOBENTHOS|Qwen2-0.5B (TFIDF) [12 _{75.0]66.6)70.5|16 [18 [280 [44.4 (LogMapLt 22D YAGO-Wikidata____|Ministral-3B-Instruct (T5) [28 |09.2/03.0[96.0[285 [304 [33.7 [94.0 (Matcha [) HP-MP___|Qwen2-0.5 (BERT) [667 _[74.1|95.8]83.5|900 [696 |2320.6|81.8 (LogMap [2D    \f"
        ],
        [
            "Risk estimated for incident cerebrovascular disease using the Cox proportional hazards model",
            "Variables  Total  Patients Comparison Kidney transplant recipients Sex  Female  Male  Age (year)  <40  41-50  51-60  >61  Insured salary (NTD.) <19,200 19,201-22,800 22,801-42,000 >42,001 Urbanization Level 1  Level 2  Level 3  Level 4  Level 5  Level 6  Level 7  CCI score  0  1  2  >3 Comorbidities Hypertension No  Yes Hyperlipidemia No  Yes  Diabetes mellitus No  Yes  Chronic kidney disease No  Yes Hyperuricemia No  Cardiovascular disease  Events 4,424.  3,292 1,132  2,166 2,258  1,026 1,637 1,388 373  1,594 772 1,132 926  1,499 1,535 605 505 59  98 123  339 185 2,003 1,897  3,038  1,386  4,031 393  3,321 1,103  3,463 961  4,367  70 20.50  18.31 31.48  19.78 21.25  14.46 24.02 24.48 18.72  22.43 17.41 20.81 20.14  21.08 20.99 18.45 19.82 19.47 20.42 22.69  16.27 21.14 21.80 20.12  18.59  26.50  20.12 25.54  19.44 24.54  18.92 29.41  20.41  IR 1 19.58  17.09 33.98  18.19 21.12  12.31 22.28 25.56 25.09  20.29 18.05 19.55 19.80  19.93 19.95 18.01 19.00 19.10 20.67 21.07  12.70 17.60 20.22 21.15  17.01  2920  19.10 26.42  17.98 27  17.54 33.63  19.46  p-value  <0.001  0.007  <0.001  <0.001  0.036  <0.001  <0.001  <0.001  <0.001  <0.001  <0.001 \f"
        ],
        [
            "The mean cosine similarity scores across our ensemble of five independently trained models. ",
            "Mean 2  TYC model_0 | IndusvsProto-Cuneiform | 0.61 | 0.07 | 0.54 | 3430.39 | 0.00 | 9.70 | large | Yes | Indus PTYC | model0 | Indus_vs_ProtoElamite | 0.61 | 010 | 0.51 | 3143.15 | 0.00 | 8.89 | large | Yes | Indus TY -model_0 | Proto-Cuneiform_vs_Proto-Elamite | 0.07 | 010 | 0.03 | 412.76 | 0.00 | 1.17 | large | Yes | Proto-Elamite PTYC | model1 | Indus_vs_Proto-Cuneiform | __0.61 | 0.07 | _0.54 | 2362.56 | 0.00 | 6.68 | large | Yes | Indus TYC -modelt | Indusvs.ProtoElamite | 0.61 | 0.07 | 0.4 | 2328.76 | 0.00 | 6.59 | large | Yes | Indus PTYC | model_1 | Proto-Cuneiform_vs_Proto-Elamite | 0.07 | 0.07 | 0.00 | _L.77 | 0.08 | 0.01 | negligible | No | Proto-Cuneiform TY Fmodel2 | IndusvsProto-Cuneiform | 0.63 | 0.07 | 0.56 | 2720.97 | 0.00 | 7.70 | large | Yes ‘| Indus PTYC | model2 | Indus_vs_Proto-Elamite | 0.63 | 0.08 | 0.55 | 2696.50 | 0.00 | 7.63 | large | Yes | Indus TYC -model_2 | Proto-Cuneiform_vs_Proto-Elamite | 0.07 | 0.08 | _-0.01| 117.34 | 0.00 | 0.33 | small___| Yes _| Proto-Elamite TYC | model_3 | Indus_vs_Proto-Cuneiform | 0.65 | 0.07 | 0.58 | 2331.90 | 0.00 | 6.60 | large | Yes | Indus TY Pmodel_3 | Indusvs_Proto-Elamite | 0.65 | 0.07 | 0.58 | 2385.25 | 0.00 | 6.75 | large | Yes | Indus PTYC | model_3 | Proto-Cuneiform_vs_Proto-Elamite | 0.07 | 0.07 | 0.00 | ‘4.93 | 0.00 | 0.01 | negligible | Yes _| Proto-Cuneiform_ PTY | model | Indus_vs_Proto-Cuneiform | 0.67 | 0.23 | 044 | 1868.95 | 0.00 | 5.29 | large | Yes | Indus TY model | Indusvs Proto-Elamite | 0.66 | 0.07 | 0.59 | 2670.99 | 0.00 | 7.55 | large | Yes | Indus PTY | model_4 | Proto-Cuneiform_vs_Proto-Blamite | 0.23 | 0.07 | 0.16 | 1391.71 | 0.00 | 3.94 | large | Yes _| Proto-Cuneiform -NaxiDongha | model_0 | Indus_vs_Proto-Cuneiform | __ 0.58 | 0.07 | 0.51 | 3428.45 | 0.00 | 9.70 | large | Yes | Indus \"NaxiDongha | model_0 | Indus_vs_Proto-Elamite | 0.58 | 0.08 | 0.50 | 3406.41 | 0.00 | 9.63 | large | Yes | Indus \"NaxiDongha | model_0 | Proto-Cuneiform_vs_Proto-Elamite | 0.07 | 0.08. | _-0.01.| 145.12 | 0.00 | 0.41 | small__| Yes _| Proto-Hlamite -NaxiDongha | model_1 | Indus_vs_Proto-Cuneiform | __0.65 | 0.05 | 0.60 | 3414.21 | 0.00 | 9.66 | large | Yes | Indus \"NaxiDongha | model-1 | Indus_vs_ProtoElamite | 0.66 | 010 | 0.56 | 3829.02 | 0.00 | 9.42 | large | Yes | Indus -NaxiDongha | model_1 | Proto-Cuneiform_vs_Proto-Elamite | 0.06 | 0.10 | 0.04 | 823.73 | 0.00 | 1.48 | large | Yes _| Proto-Elamite \"NaxiDongha | model_2 | Indus_vs_Proto-Cuneiform | __0.58 | 0.05 | 0.53 | 2773.65 | 0.00 | 7.85 | large | Yes | Indus \"NaxiDongha | model.2 | Indus_vs_Proto-Elamite | 0.88 | 010 | 0.48 | 2461.76 | 0.00 | 6.96 | large | Yes | Indus -NaxiDongha | model_2 | Proto-Cuneiform_vs_Proto-Elamite | 0.05 | 0.09 | _-0.04 | 483.31 | 0.00 | 1.37 \"NaxiDongha | model_3 | Indus_vs_Proto-Cuneiform | 0.68 | 0.08 | 0.60 | 2883.93 | 0.00 | 8.16 | large | Yes | Indus -NaxiDongha | model_3 | Indus_vs_Proto-Elamite | 0.68 | 0.08 | __—_0.60 | 3069.56 | 0.00 | 8.68 | large | Yes | Indus \"NaxiDongha | model_3 | Proto-Cuneiform_vs_Proto-Elamite | 0.08 | 0.08 | 0.00 | _59.78 | 0.00 | 0.17 | negligible | Yes | Proto-Cuneiform 0.40 | 1672.96 | 0.00 | 4.73 | large | Yes | Indus -NaxiDongha | model4 | Indusvs_Proto-Elamite | 0.68 | 0.08 | 0.59 | 2651.29 | 0.00 | 7.50 | large | Yes | Indus \"NaxiDongha | model_4 | Proto-Cuneiform_vs_Proto-Elamite | 0.28 | 0.08 | __0.20 | 1789.15 | 0.00 | 5.06 | large | Yes _| Proto-Cuneiform -Old-Naxi | model_0 | Indus_vs_Proto-Cuneiform | __0.62 | 0.07 | _0.55 | 3605.37 | 0.00 | 10.20 | large | Yes | Indus -Old-Naxi____| model_0 | Indus_vs_Proto-Elamite | 0.62 | 0.10 | 0.52 | 3376.88 | 0.00 | 9.55 | large | Yes | Indus -Old-Naxi____| model_0 | Proto-Cuneiform_vs_Proto-Elamite | 0.07 | 0.10 | 0.08. | _-400.45 | 0.00 | 113 | large | Yes _| Proto-Elamite -Old-Naxi___| model1 | Indus_vs_Proto-Cuneiform | 0.58 | 0.08 | 0.50 | 2096.98 | 0.00 | 5.93 | large | Yes | Indus -Old-Naxi____| model-1 | Indusvs_Proto-Elamite | 0.58 | 0.05 | 0.53 | 2358.66 | 0.00 | 6.67 | large | Yes | Indus -Old-Naxi_____|_model_1 | Proto-Cuneiform_vs_Proto-Elamite | 0.07 | 0.05 | _0.02 | 263.14 | 0.00 | _0.74 | medium | Yes _| Proto-Cuneiform_ -Old-Naxi____| model_2 | Indus_vs_Proto-Cuneiform | 0.66 | 0.08 | 0.58 | 3075.61 | 0.00 | 8.70 | large | Yes | Indus -Old-Naxi___| model.2 | Indusvs_Proto-Elamite | 0.66 | 0.09 | 0.57 | 2944.56 | 0.00 | 8.33 | large | Yes | Indus -Old-Naxi______|_model_2 | Proto-Cuneiform_vs_Proto-Elamite | _0.07 | 0.08 | _-0.01.| 118.30 | 0.00 | 0.33 | small__| Yes | Proto-Hlamite -Old-Naxi____| model_3 | Indus_vs_Proto-Cuneiform | 0.61 | 0.08 | 0.52 | 2145.70 | 0.00 | 6.07 | large | Yes | Indus /Old-Naxi___| model3 | Indusvs_Proto-Elamite | 0.589 | 0.07 | _0.52.| 2082.42 | 0.00] 5.89 | large | Yes _| Indus  - = |  - \f"
        ],
        [
            "Comparison with conventional algorithms",
            "Instruments  Polygraph device  PC software  Webcam  Model  Made for this research  LX5000  Made for this research  HD Pro Webcam C920  Use  To measure bio-signals during the polygraph test  For comparison with the polygraph device developed in this study  To display and save bio-signals during the polygraph test  To record the participant during the polygraph test \f"
        ],
        [
            "The outcomes of the Intensive BP control group, n (%) Standard BP control group, n (%) Risk ratio(95% CI)",
            "Study ACCORD  BPROAD ESPRIT  RESPECT  SPRINT  Year 2010  Zee  2024  2019  2021  Geographical region USA, Canada China China  Japan  United States  Number of sites 77  145  116  140  102  Total  sample Study population size Type 2 diabetes mellitus 4733 Type 2 diabetes mellitus 27321  High cardiovascular risk, with 11,255 and without diabetes or previous stroke  History of stroke within previous 1263 3 years  Increased risk for cardiovascular 9361 disease but no diabetes or  previous stroke  Pimary  outcome  Follow-up* MACE 4.7 years” MACE 4.2 years MACE 3.4 (3.0-3.4)  years  Recurrent 3.9 + 1.5 years stroke MACE 3.33 years \f"
        ],
        [
            "completeness, conciseness, faithfulness, acceptance for TNH-Eval and Likert human evaluations ",
            "Rubric  Subjective chief-complaint symptoms history  goals homework quotes  Objective observed-behavior mental-status assessment-tools therapy-activities interventions  Assessment diagnosis triggers progress analysis response overall-progress goals  stages  Plan future-interventions follow-up adjustment homework  Human Llama  78% 56% 99% 33% 1% 23%  53% 22% 10% 12% 12%  8% 19% 24% 72% 39%  8%  AN 41%  3076  31% 2%  33%  79% 87% 96% 40% 1% 17%  96% 73% 3% AN 2%  22% 40% 38% 97% 30% 11% A% 31%  83% 45% 9% 33%  Mistral  78% 90% 99% 42% 3% 15%  98% 88% 7% A% 1%  13% 24% 34% 92% 32% 11% 3% 34%  79% 41% 7% 26% \f"
        ],
        [
            "Comparison of TURBOFUZZLLM versus GPTFuzzer (Yu et al., 2023) on 200 harmful behaviors from\nHarmBench (Mazeika et al., 2024) text standard dataset with a target model query budget of 4000",
            "Model |  | GCG Zephyr 7B 90.5 R2D2 0.0 GPT-3.5 Turbo 1106 - GPT-4 0613 -     GPT-4 Turbo 1106  GCG-M  82.7 0.5  GCG-T  78.6 0.0  55.8 14.0 21.0  PEZ  79.6 0.1  GBDA  80.0 0.0  UAT  82.5 0.0  AP  79.5 0.0  Baseline SFS ZS PAIR  77.0 79.3 70.0 47.0 16 57.5  - 32.7 41.0 - 1.1 38.5 - 10.2 39.0  TAP  83.0 76.5  46.7 43.7 41.7  TAP-T  88.4 66.8  60.3 66.8 81.9  AutoDAN  97.5 10.5  PAP-top5 31.1 20.7  12.3 10.8 11.1  Human  83.4 Sad  2.7 3.9 1.5  | Ours  DR |  83.0 | 100.0 1.0 | 99.5  35.0 | 100.0  10.0 | 80.0 7.0 | 97.0    \f"
        ],
        [
            "The differents Parameters effects to the  Control, HFD + Vehicle, HFD + Lut50, HFD + Lut100, HFD + Met100",
            "Parameters  Plasma:  Plasma MDA  level (uM)  Plasma CAT activity (U/mL) Liver tissue:  Hepatic MDA level (nmol/g protein)  Hepatic O2°~ production  (count/mg dry weight/min)  Control  4.15 + 0.24 43.86 + 7.27  360.58 + 10.48  161.15 + 24.24  HFD + Vehicle  8.08 + 0.29 * 8.22 + 1.56 °  707.33 + 34.93 *  573.92 + 73.16 *  HFD + Lut50  6.97 + 0.36 2 31.87 + 4.33 >  548.98 + 69.52  467.36 + 104.08  HFD + Lut100  5.22 + 0.66 > 35.20 + 4.39 >  394.07 -+ 24.96 »  206.69 + 32.68 »  HFD + Met100  5.30 £0.77 40.94 + 3.65 >  397.73 £ 18.09 »  132.59 + 56.18 > \f"
        ],
        [
            "OAEI tracks and records statistics for sources, targets, and alignments. \"MI\"\nrefers to the \"MaterialInformation\" ontology, while \"S\" and \"T\" denote the source and\ntarget ontologies, respectively.",
            "Dataset [LLM (Retriever Model)|Inter|P_[R_[F1 [Pred[Ref/Time[OAEI (F1)  MEEMMO —___|Qwen?-0.5B (BERT) __|61__|88.4]06.5)92.4|60 [63 [135.0 [91.8 (Matcha [[2) FISH-ZOOPLANKTON |LLaMA-3.2-1B (BERT) [13 |02.8)86.6]89.6|14 [15 [9.9 [64.0 (LogMapLt [22D  ALGAB-ZOOBENTHOS|Qwen2-0.5B (TFIDF) [12 _{75.0]66.6)70.5|16 [18 [280 [44.4 (LogMapLt 22D YAGO-Wikidata____|Ministral-3B-Instruct (T5) [28 |09.2/03.0[96.0[285 [304 [33.7 [94.0 (Matcha [) HP-MP___|Qwen2-0.5 (BERT) [667 _[74.1|95.8]83.5|900 [696 |2320.6|81.8 (LogMap [2D    \f"
        ],
        [
            "components and prompt for clinical diagnostic processes",
            "patient with depression Patient without depression LLaMA zs 0.657 0.861 0.419 LLaMA fs 0.643 0.921 0.421  Mental ROBERTa 0.643 0.667 0.308 SBERT + DFNN 0.636 0.857 0.250 LLaMA + DFNN 0.700 0.857 0.333  LLaMA cot 0.609 0.738 0.550    \f"
        ],
        [
            "Stability of liposomal formulations during 45-day storage at 37",
            "     Formulations  Conventional BLEOMYCIN  Nanoliposomes without BLEOMYCIN  Negative control (PBS)  Sub-G1%  FL- BLEOMYCIN 4.36 + 1.07 14.42 + 2.7 14.23 + 2.45 a2.00 + 39  12.64 + 2.0  O23 £ 2.1     G0/G1%  44.33 + 4.7  50.44 + 5.9       S% G2/M%     47.27 + 4.73 50.22 + 5.41 IAD & 3.75 24.42 + 4.10     34.29 + 3.63 15.63 + 3.02  33.44 + 2.7 12.13 + 1.8    \f"
        ],
        [
            "Evaluation focus for different benchmark/framework",
            "Models w/o Adv User w/Adv User A(%)  GPT-40 81.71 53.01 -35.1 GPT-40-mini 28.05 17.07 -39.1  Claude-3.5-Sonnet 51.22 25.61 -50.0 \f"
        ],
        [
            "Overview of training data. M: Music; I: Image;\nV: Video; T: Text",
            "Music4way-MI2T Music4way-MV2T Music4way-Any2T B-1 R-L BERTS B-1 R-L BERTS B-1 R-L BERTS  Model     NExT-GPT (Wt et al., 2024) 26.7 21.3 85.2 | 26.5 21.0 84.8 | 25.4 23.4 86.6 M’UGen (Hussain et al., 2023) | *31.7. *26.4 “87.1 | *31.7  *25.9 *86.8 | *20.8 *21.5 *87.3  NExT-GPT w/ M?UGen *33.8 *27.3 *88.1 | *34.6 *27.3 *88.1 | *26.3 *28.5 *89.4 NExT-GPT w/ Music4way 24.2 22.0 85.4 | 25.0 22.5 85.5 | 29.4 27.0 88.4 DeepResonance-ca (ours) 44.6 30.1 89.4 | 44.5 29.6 89.2 | 54.7 35.1 90.9  DeepResonance-/ (ours) 49.22 36.8 90.2 | 49.0 36.8 90.3 | 33.5 27.4 88.7 \f"
        ],
        [
            "Llama3-8B, Llama3-8B-IT for safety benchmarks",
            "Model  Llama3-8B  Llama3-8B-IT  AdvBench (ASR, |)  HarmBench (ASR, |)  StrongReject (ASR, |)           Tuning w/o Att. +Prefill +AutoDAN +GCG w/oAtt. +Prefill +AutoDAN +GCG w/oAtt. +Prefill +AutoDAN +GCG SFT 769 8461 74.00 46.00 23.75. 68.75 43.75 47.50 287 85.62 61.67 51.67 SFT + DPO 654. 90.77 80.00 72.00 47.50 76.25 57.50 45.00 8.95 88.50 16.67 58.33 Backtrack-SFT 3.84 1.92 80.00 76.00 1750 13.75 52.50 37.50 128 0.32 46.67 51.67 Backtrack 038 0.19 82.00 51.02 22.50 21.25 52.50 41.03 128 0.64 56.67 53.33 ERPO-SFT 0.00 0.00 2.00 0.00 11.25. 18.75 125. 3.75 0.00 0.96 1.67. 1.67 ERPO 0.00 0.00 0.00 0.00 0.00 3.75 125 125 0.00 0.00 1.67 1.67 - 0.77 61.92 0.00. 8.00 25.00 57.50 0.00 30.00 0.64 79.42 0.00 18.33 SFT 0.19 65.77 90.00 72.00 18.75 52.50 56.25 51.25 0.64 77.32 90.00 70.00 DPO 0.57 59.23 80.00 70.00 2625 58.75 51.11 4937 0.00 60.06 75.00 75.00 Backtrack-SFT 0.19 ~—0.38 88.00 64.00 13.75 22.50 56.25 46.25 0.32 0.64 71.67 66.67 Backtrack 0.19 0.38 50.00 52.00 16.25 21.25 46.25 46.25 0.00 0.32 51.67 38.33 C2-SYN 0.19 59.62 0.00 16.00 22.50 56.25 0.00 2250 0.00 56.23 0.00 11.67 ERPO-SFT 0.00 0.00 0.00 000 7.50 875 0.00 5.00 032 032 0.00 0.00 ERPO 0.00 0.00 0.00 0.00 7.50 7.50 0.00 6.25 0.00 0.00 0.00 0.00 \f"
        ],
        [
            "Baseline characteristics of patients with r-axSpA",
            "Net change between baseline and 3 months f/u*  sASDAI change \\SDAS-ESR change \\SDAS change sASFI change  -SR change  -RP change  TNFi tapering success  (N= 12)  0 (-0.15; 0.30) 0.14 (-0.06; 0.26) 0.07 (-0.06; 0.19) 0.10 (0.05; 0.20)  0 (-2.50; 3.00) 0.02 (-0.05; 0.01)  TNFi tapering failure  (N=8)  3.10 (2.90; 3.25) 1.79 (1.64; 1.96) 1.36 (1.33; 1.87) 2.90 (2.55; 3.40) | 1.00 (7.50;18.50) 0.25 (0.10; 0.40)  <0.00| <0.00| <0.00| <0.00| 0.004 0.003 \f"
        ],
        [
            " Bivariate correlation matrix",
            "Stoma Yes No  Sign.  Type of Preparation High volume Low volume  Sign.  Preparation Timing Day before oplit Same day Sign.  Exam Completed Yes No Sign.  Feeling of Cleanliness Low Medium High Sign.  Sedation No Conscious sedation Deep sedation Sign.  Seniority of Nurse Novice Competent Expert Sign.  Endoscopist Experience Novice Competent Expert Sign.  Disease Activity Remission Mild Moderate Severe Sign.  Biological Therapy Yes No Sign. Medical Therapy Yes  No Sign.  ECSO Before Exam  Median [IOR]  18.5 [10.25]  15 [11] 0.403  12 [7] 16 [11] 0.001 ***  15 [10] 16 [11.5] 13 [10] 0.332  15 [11] 17 [11] 0.738  15 [12] 16 [10.75] 15 [10.75]  0.601  14 [10.75] 16 [11] 13 [10]  0.918  14 [11.25] 15 [11] 16 [11]  0.381  12 [8] 16 [11] 16 [11.25] 0.056  20 [8.25] 19 [11.25] 13.5 [10] 11 [3] 0.005 **  15 [10] 17 [11] 0.037 *  15 [11] 16 [11] 0.686  ECSQ During Exam  Median [IOR]  12 [8] 10.5 [10] 0.097  6.5 [6.25] 12 [10] 0.000 ***  10 [9] 12 [10] 9 [9] 0.673  10 [10] 12 [8] 0.111  12 [10] 12 [8] 9 [9] 0.089  11.5 [10] 12 [10] 8 [9] 0.326  9.5 [10] 9 [9] 12 [10] 0.521  9[8]§ 10 [10] 12 [10] 0.024 *  14 [5.25] 13 [10] 9 [8]  6 [3] 0.000 ***  9 [9] 12 [10] 0.159  10 [9] 12 [10] 0.368  ECSO After Exam  Median [IOR]  17.5 [9.25] 13 [9] 0.122  11 [8] 14 [9] 0.004 **  13 [9] 14 [9] 11 [7] 0.450  13 [9.5] 15 [8] 0.510  16 [7.25] 15 [9] 12 [10] 0.108  13.5 [7.75] 14.5 [9] 12 [8] 0.101  12.5 [9.5] 12 [8] 15 [9] 0.192  12 [10] 14 [9] 14 [8] 0.295  17 [8] 16 [8] 12 [10] 9 [4] 0.000 ***  12 [9] 15 [9] 0.060  14 [8] 14 [9.5] 0.765  ECSO Total Score  Median [IOR]  69 [44.5] 51 [43] 0.264  75 [46] 53 [51] 0.011 *  69 [46] 75 [42.5] 73 [51.5]  0.484  64 [46] 55 [42.75] 0.873  73 [51.5] 75 [27] 69 [46] § 0.04 *  75 [51.5]  75 [48.5]  64 [38] § 0.025 *  66 [49.5] 65 [40] 75 [46]  0.101  65 [42.5] 72 [46] 75 [46]  0.373  90 [30] 93 [33.25] 69 [45] 44 [16.5] 0.000 ***  64 [45] 77 [42.5] 0.007 **  72 [45] 69 [46] 0.823  PSS  Median [IOR]  38 [2] 38 [4] 0.038 *  38 [4] 38 [4] 0.591  38 [4] 38 [4] 38 [0] 0.638  38 [4] 38 [4] 0.028 *  38 [2] 38 [4] 38 [4] 0.214  38 [4] 38 [4] 38 [4] 0.187  38 [4] 38 [4] 38 [4] 0.125  38 [4] § 38 [4] 38 [4]  0.009 **  38 [4] 38 [4] 38 [4] 38 [2]  0.000 ***  38 [4] 38 [4] 0.470  38 [4] 38 [4] 0.325 \f"
        ],
        [
            "The Human written notes compare with each LLM notes ",
            "Section  Subjective  objective  Assessment  Plan  Note  Human Llama 3.1 70B Mistral Large V2  Human Llama 3.1 70B Mistral Large V2  Human Llama 3.1 70B Mistral Large V2  Human Llama 3.1 70B Mistral Large V2  Completeness  TN -Eval  41.7 (422.8) 46.0 (412.4) 47.8 (413.6)  21.8 (418.3) 36.0 (+8.8) 39.6 (+7.8)  26.9 (416.1) 34.1 (410.6) 30.4 (+9.9)  26.2 (419.9) 42.5 (419.4) 37.2 (419.3)  Likert  3.28 (41.11) 3.86 (40.74) 4.14 (+0.61)  2.51 (41.06) 3.56 (+0.87) 3.95 (+0.64)  2.94 (41.02) 3.72 (40.71) 3.97 (+0.68)  2.67 (41.03) 4.05 (40.76) 3.97 (+0.85)  Conciseness  TN4_Eval Likert  84.7 (420.8) 4.49 (40.72) 90.8 (417.8) 4.81 (40.35) 88.7 (415.4) 4.91 (40.24) 65.9 (429.9) 4.10 (40.86) 81.8 (427.0) 4.82 (40.36) 89.0 (414.7) 4.90 (40.36) 83.0 (423.8) 4.35 (40.81) 94.7 (412.2) 4.82 (40.37) 95.5 (411.8) 4.80 (40.44) 68.4 (435.9) 4.17 (41.11) 72.9 (425.2) 4.87 (40.33) 94.4 (410.1) 4.89 (40.32)  Faithfulness  TN4_Eval Likert  92.0 (415.0) 4.64 (+0.67) 95.0 (410.9) 4.66 (40.52) 97.9 (+5.7) 4.87 (40.40) 85.1 (423.2) 4.40 (+40.74) 49.0 (430.0) 4.75 (40.39) 60.4 (+28.9) 4.94 (+0.26) 85.4 (+22.9) 4.57 (40.62) 80.9 (422.7) 4.70 (40.52) 84.8 (+21.4) 4.90 (+0.35) 78.2 (+33.1) 4.13 (41.08) 46.6 (434.2) 4.61 (40.55) 43.8 (434.4) 4.88 (40.33) \f"
        ],
        [
            "The performance between smaller and Larger LLM",
            "Metric (Avg.) | Single Model  | F1-Score | 0.87 | 0.91 | \f"
        ],
        [
            " 52 HCC patients with plasma samples collected from the Ronald Reagan UCLA Medical Center.",
            "No. of patients (%)  Variable Age (median = 66.5) <= 66.5 26 (50%) > 66.5 26 (50%) Sex Female 13 (25%) Male 39 (75%) Prior AFP (median = 10.25) <= 10,25 26 (50%) > 10.25 26 (50%) Largest tumor size (median = 3.4) <= 3.4 26 (50%) > 3.4 26 (50%) Tumor number i 37 (71%) SZ 15 (29%) MELD score (median = 8) <8 19 (37%) >= 8 21 (40%) BCLC 0-A 35 (67%) B-C 17 (33%) Transplant criteria 1-2 34 (65%) 3-4 18 (35%) MethRisk (median = 2.86) <= 2.86 26 (50%) > 2.86 26 (50%)  HTT  01 4 9 16 25  a  Qo Low risk High risk  HR [95% Cl]  0.42 [0.13, 1.3]  1.5 (0.43, 5.4]  1.6 [0.58, 4.6]  0.85 [0.3, 2.4]  3.7 [1.3, 10]  2 [0.67, 6.1]  5.3 [1.8, 16]  4.1 [1.4, 12]  5.3 [1.4, 19]  P—value  0.14  0.52  0.35  0.76  0.012\"  0.21  0.0025**  0.0079**  0.012* \f"
        ],
        [
            "relationship between difficulty level, method and average performance",
            "Order  Random Topological  Reversed  Method  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8 MEND  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8 MEND  Vanilla RC-Aug SCoP-2 SCoP-4 SCoP-8 MEND  1  99.0 100.0 100.0 100.0 100.0 100.0  99.5 100.0 100.0 100.0 100.0 100.0  98.5 100.0 100.0 100.0 100.0 100.0  Difficulty Level  2  99.0 100.0 82.5 92.5 99.0 100.0  57.0 65.0 76.5 94.0 98.5 100.0  8.5 29.0 79.0 95.5 98.5 100.0  3  75.5 84.5 19.0 29.0 40.5 81.0  12.0 12.0 14.0 27.5 38.0 80.5  0.0 0.5 22.5 30.0 41.0 81.0  4  23.0 24.5 2.0 4.5 9.0 11.5  1.0 0.5 2.5 4.0 7.5 7.5  0.5 0.0 3.5 4.5 3.0 4.5  Avg.  74.1 77.3 (+3.2) 50.9 (-23.2) 56.5 (-17.6) 62.1 (-12.0) 73.1 (-1.0)  42.4 44.4 (+2.0) 48.3 (45.9) 56.4 (+14.0) 61.0 (+18.6) 72.0 (+29.6)  26.9 32.4 (+5.5) 51.3 (424.4) 57.5 (+30.6) 60.6 (+33.7) 71.4 (+44.5) \f"
        ],
        [
            "Comparison of fibrinolysis kinetic parameters in the absence or presence of CORM-2",
            "Manuscripts  Blood Coagul. Fibrinolysis. 2009, 20, 377-380. Blood Coagul. Fibrinolysis. 2009, 20, 448-455.  Blood Coagul. Fibrinolysis. 2010, 21, 41-45.  Blood Coagul. Fibrinolysis. 2010, 21, 101-105. Blood Coagul. Fibrinolysis. 2010, 21, 298-299.  Thromb. Res. 2010, 126, 68-73.  Blood Coagul. Fibrinolysis. 2010, 21, 349-353. Blood Coagul. Fibrinolysis. 2010, 21, 584-587.  Anesth. Analg. 2010, 111, 1347-1352. J. Trauma. 2011, 70, 939-947 Blood Coagul. Fibrinolysis. 2011, 22, 60-66.  Blood Coagul. Fibrinolysis. 2011, 22, 345-348. Blood Coagul. Fibrinolysis. 2011, 22, 362-368. Blood Coagul. Fibrinolysis. 2011, 22, 443-447.  Citations !  30 21 6 12 2 5 11 10 4 3 6 11 2 23 \f"
        ],
        [
            "Using smaller LLMs in ELM",
            "Train(n)/Test(n) | SLM Only Ensemble | ELM |  |  33  0.98 0.83 0.76 0.98 0.76 0.98 0.87 0.94 0.67 0.98 0.32 0.81 0.44  1.00  Thyroid 1000/34     | ov]: > S| 00 \f"
        ],
        [
            "Portico, Navitor, p-Value of the Transcatheter Aortic Valve Type outcomes",
            "Overall TAV type Portico Navitor TAV size 23 mm 25mm 27 mm TAVI procedure Native-valve  VIV  EOAi (cm2/m72) 0.99 + 0.26  0.93 + 0.22 1.06 + 0.30  1.02 + 0.19 0.94 + 0.25 1.03 + 0.33  1.02 + 0.26 0.88 + 0.23  p-Value  0.170 *  0.738 *#  0.205 * \f"
        ],
        [
            "Survival and Mortality Outcomes",
            "cases as shown in Table 2.  Primary Tumor Location Number of Patients (n=15) Percentage (%) Duodenum 2 13.37% Jejunum 4. 26.7% lleum 7 46.7% Appendix 2 13.0 70  TABLE 2: Primary Tumor Location in Stage IV SB-NET Patients (n=15)  SB-NET: Small bowel neuroendocrine tumor \f"
        ],
        [
            "descriptioin and example for different four type of contstrains",
            "| Constraint  amount_positive_restr database_book_not_ borrowed internal _room_slot_avail  internal_ check _book_available internal_ check_book_ exist  internal _room_date_avail  internal_ check_room_ exist internal check_username_ exist  internal is admin internal_1is_restricted logged_in_user login_user suff_acc_bal late fee suff_acc_bal_mem user_book_borrowed user_book_not_borrowed valid_membership  within _borrow_limit within_max_reservation_slots  | Description  The user parameter key \"amount\" is more than zero.  The book’s ID, retrieved using the \"book_title\" from the \"book_title_to_id\" section, **must NOT appear** as a key in the \"borrowed\" dictionaries of any users listed in the \"accounts\" section of the database.  All requested slots \"slots\" for the specified reservation date \"resv_date\" in the room \"room_id\" must be available in the database.  The book \"book_title\" has a count value of **more than 0**.  The book’s title \"book_title\" exists in the \"book_title_to_id\" section of the database and the book’s ID (retrieved using \"book_title\") exists in the books.  The specified reservation date \"resv_date\" must be listed under the ’rooms’ section for the given room ID \"room_id\".  The specified room ID \"room_id\" must exist in the database under the ’rooms’ section.  The user parameter key \"username\" must exist as a top-level key in the accounts section of the database.  The user \"username\" has an \"admin\" of **true** in the database.  The book \"book_title\" has its restricted status set to **true**.  The user with \"username\" is logged in previously with the correct credentials to perform this action.  The user \"username\" must be able to login with the correct password \"password\" to perform this action.  The user \"username\" does have more account balance \"balance\" than the late fee, which is the product of the user’s \"late_book_count\" in their account and late_fee_per_book in the database. The user \"username\" does have more account balance \"balance\" than the monthly restricted access fee, which is the membership_monthly_fee in the database.  The book’s ID (retrieved using \"book_title\" from the \"book_title_to_id\" section) exists in the borrowed\" of the user \"username\".  The book’s ID (retrieved using \"book_title\" from the \"book_title_to_id\" section) **must not exist** in the \"borrowed\" of the user \"username\".  The user \"username\" must have a ’membership’ field that 1s a date on or after the interaction_time. The user \"username\" must have less than borrow_limit books in their \"borrowed\".  The user \"username\" must have a total number of reserved slots less than or equal to max_reservation_slots, calculated as the sum of their currently reserved slots in ‘room_reservation’ and the newly requested slots \"slots\". \f"
        ],
        [
            "Information about dataet used for training ",
            "Model  SALMONN (Tang et al., 2024a)! MU-LLaMA (Liu et al., 2024)! OpenMU (Zhao et al., 2024)! NExT-GPT (Wu et al., 2024) M?UGen (Hussain et al., 2023)! NExT-GPT w/ M2UGen!' NExT-GPT w/ Music4way' DeepResonance-a (ours)! DeepResonance- (3 (ours)!  BLEU-1  28.7 29.7 24.5 23.3 29.1 34.0 34.1 35.1 35.6  BLEU ROUGE-P ROUGE-R ROUGE-F1 BERT-P BERT-R- BERT-F1  13.1 10.9  6.1  7.6 13.1 14.3 13.8 15.1 15.3  45.7 30.8 20.8 26.2 52.7 49.1 48.2 51.0 51.3  37.2 46.4 44.8 38.4 35.0 38.3 37.9 38.6 39.0  35.4 33.1 25.5 26.0 37.9 39.6 39.2 40.8 41.1  90.8 89.8 86.9 86.7 91.7 92.1 92.1 92.5 92.5  89.9 90.0 90.5 88.5 89.3 90.5 90.5 90.7 90.8  90.3 89.9 88.6 87.6 90.5 91.2 91.3 91.6 91.6 \f"
        ],
        [
            "Time, Gender, Age, Sleep quality and parameters estimates for the model",
            "Variables  1. Meditation 2. Positive affect 3. Vitality 4. Mental health 5. Sleep quality 6. Time 7. Age 8. Gender  3.29 4.10 4.23 4.47 4.24  45.87  SD  0.42 0.71 0.87 0.73 0.90  8.21  0.40 ** 0.46 ** 0.41 ** 0.11 —0.13 —0.17 0.16 *  2 0.25 **  0.88 *** 0.85 *** —0.10 —(.o2 —0.05 0.39 **  3  0.24 ** 0.64 **  0.88 *** —0.07 —0.26 ** —0.08 0.42 **  4  0.16 * 0.62 *** 0.88 *** —0.18 * —0.22 **  —0.07 0.35 **  5  0.17 * 0.63 *** 0.77 *** 0.69 ***  —0.10  —0.12  —0.04  0.00 —0.31 ** —0.26 ** —0.23 ** —0.21 **  —0.17 * 0.08 \f"
        ],
        [
            "Age, gender, BMI, History of disease, Biomarkers of population",
            "         Model Model 1 Model 2 Model 3 Group HR(95%Cl) P HR(95%Cl) P HR(95%Cl) P Wave] DM 1.241(0.989,1.557) 0.062 1.172(0.927,1.048) 0.184 1.182(0.927,1.506) 0.177 Non-DM 1.212(1.138,1.290) < 0.001 1.170(1.094,1.251) < 0.001 1.134(1.059,1.214) < 0.001 Wave2 DM 1.140(0.973,1.334) 0.105 1.109(0.942,1.307) 0.214 1.112(0.938,1.318) 0.223 Non-DM 1.172(1.120,1.226) < 0.001 1.141(1.087,1.198) < 0.001 1.084(1.032,1.139) 0.001 Wave3 DM 1.240(1.091,1.409) 0.001 1.226(1.071,1.403) 0.003 1.169(1.015,1.345) 0.030 Non-DM 1.192(1.150,1.235) < 0.001 1.167(1.123,1.212) < 0.001 1.122(1.080,1.167) < 0.001    \f"
        ],
        [
            "Results in a zero-shot scenario on IEMOCAP.",
            "Methods Neutral Surprise Fear Sad Joy Disgust Anger Average Acc. Fl Acc. Fl Acc. Fl Acc. Fl Acc. Fl Acc. Fl Acc. Fl Acc. w-Fl  DialogueRNN 82.17 76.56 46.62 47.64 0.00 0.00) 21.15 24.65 49.50 51.49 0.00 0.00 48.41 46.01 60.27 57.95  MMGCN 84.32 76.96 47.33 49.63 2.00 3.64 14.90 20.39 56.97 53.76 1.47 2.82 42.61 45.23 61.34 58.41 DialogueTRM 83.20 79.41 56.94 55.27 12.00 17.39 27.88 36.48 60.45 60.30 16.18 20.18 51.01 49.79 65.10 63.80 MM-DEN 79.06 75.80 53.02 50.42 0.00 0.00 17.79 23.72 59.20 55.48 0.00 0.00 50.43 48.27 60.96 58.72 UniMSE - - - - - - - - - - - - - - 65.09 65.51 SDT 83.22 80.19 61.28 59.07 13.80 17.88 34.90 43.69 63.24 64.29 22.65 28.78 56.93 54.33 67.55 66.60 FacialMMT - 80.13 - 59.63 - 19.18 - 41.99 - 64.88 - 18.18 - 56.00 - 66.58 DGODE - 82.60 - 60.90 - 5.10 - 45.50 - 63.40 - 10.60 - 54.00 - 67.20 M3Net - - - - - - - - - - - - - - 68.28 67.05 MultiEMO - 79.95 - 60.98 - 29.67 - 41.51 - 62.82 - 36.75 - 5441 - 66.74 SpeechCueLLM - - - - - - - - - - - - - - - 67.60 LLMERC | 87.18 82.02 64.05 61.75 20.00 25.97 35.57 45.82 63.43 66.23 17.64 26.37 60.00 58.64 70.22 68.90  BeMERC 87.90 82.33 63.35 64.49 26.00 32.10 33.65 44.03 66.67 66.83 19.12 30.23 61.45 60.66 71.18 69.78 \f"
        ],
        [
            "comparison between Llama 3.3 w/style,w/instr, w/topics",
            "BHC  DI  BASE w/STYLE W/INSTR w/TOPICS W/STYLE w/TOPICS W/INSTR W/TOPICS BASE w/STYLE W/INSTR w/TOPICS W/STYLE w/TOPICS W/INSTR W/TOPICS  Overall  0.333 0.350 0.364 0.356 0.385 0.390 0.393 0.448 0.476 0.451 0.487 0.500  BLEU 0.142 0.158 0.171 0.149 0.178 0.183 0.193 0.247 0.277 0.240 0.273 0.292  R-1 0.465 0.488 0.505 0.487 0.524 0.530 0.502 0.565 0.589 0.561 0.600 0.612  R-2 0.228 0.242 0.255 0.239 0.268 0.271 0.283 0.337 0.366 0.336 0.370 0.383  R-L 0.313 0.330 0.343 0.333 0.367 0.370 0.377 0.434 0.464 0.436 0.474 (0.488  BS 0.460 0.477 0.489 0.471 0.504 0.509 0.484 0.539 0.565 0.535 0.574 0.587  Meteor  0.335 0.356 0.376 0.369 0.396 0.410 0.390 0.452 0.480 0.459 0.491 0.517  AS 0.290 0.297 0.304 0.317 (0.332 0.327 0.428 0.469 0.503 0.487 0.526 0.525  MEDCON  0.435 0.452 0.470 0.482 0.513 0.517 0.484 0.538 0.560 0.552 0.584 0.594 \f"
        ],
        [
            "Trends in hemoglobin levels, serum M-spike, free light chain ratio, and bone marrow plasma cell percentage during treatment",
            "PURGE Ge atwy  Patient  10 Indexed Patient  Age  (years)  44  4]  48  57  67  29  61  55  44  30  Subtype SerumM- Free  IgG lambda IgA lambda IgG lambda  IgG kappa  IgG lambda  IgG lambda  IgG  IgG  IgG lambda IgG Lambda  IgG lambda  spike (g/dL)  NA  9.8  NA  NA  NA  NA  0.44  5.1  2.56  light chain ratio  2.85  NA  11.87  0.92  0.45  NA  NA  NA  2.3  45.4  BM examination  14% PC and lack of erythropoiesis.  12% PC, absent erythroblasts  20% PC, 8% ery- throid precursors  20% PC, 4% ery- throid precursors  9% PC, 3% ery- throid precursors  20% PC, <2% ery- throid precursors  6% PC, erythroid hypoplasia  7% PC, absent ery- throid precursors <35% PC,  absent erythroid precursors  15% PC, absent ery- throid precursors  Hgb  g/dL  3.4  NA  6.4  8.6  8.0  7.6  3.7  NA  9.0  4.2  Va VV WR CREW SBEUWE CECE We SAEED pees Wedd VIEOIVEUEWY SE OD UWVIVUIYwY AOU VV PURE BR ANUS  Reticu- locyte counts  0.05%  NA  6.9  15.4  6.4  NA  0.01  NA  0.09%  19x 107/L  Re WAAL i Ww RAL EN Ite us WIE est Aw ASS eid  Treatment  PAD (anemia per- sisted) thus switched to cyclosporine  cyclosporine rituximab  VD  RVD  LD  VAD  cyclosporine methylprednisolone cyclophospha- mide+ATG  plasma exchange IVIG followed by cyclosporine and  prednisone. VD  NA  VD, LD cyclosporine, alemtuzumab dara-VD, KD, ID, Isa-P daratumumab and dexamethasone  Response  resolution of anemia  resolution of anemia on rituximab, VGPR  resolution of anemia and decrease in M spike resolution of anemia  resolution of anemia and CR  PD  resolution of anemia and disappearance of M spike with VD  NA  VGPR  resolution of anemia, VGPR  SB VU VILLI VD  Ref  [4]  [5]  [6] (patient #2)  [6] (patie# 8)  [6] (patient #12)  7]  [8]  [10]  N/A \f"
        ],
        [
            "Size, Zeta potential, EE,PDI of liposomal",
            "     Formulations  Conventional BLEOMYCIN  Nanoliposomes without BLEOMYCIN  Negative control (PBS)  Sub-G1%  FL- BLEOMYCIN 4.36 + 1.07 14.42 + 2.7 14.23 + 2.45 a2.00 + 39  12.64 + 2.0  O23 £ 2.1     G0/G1%  44.33 + 4.7  50.44 + 5.9       S% G2/M%     47.27 + 4.73 50.22 + 5.41 IAD & 3.75 24.42 + 4.10     34.29 + 3.63 15.63 + 3.02  33.44 + 2.7 12.13 + 1.8    \f"
        ],
        [
            "Main experimental results compared to baselines on four benchmarks",
            "Ground truth: Orleans County Search-ol  ... Simplified here. Maybe | can search for \"Holley, New York county\" to find out which county it’s part of. <|begin_search_query|>Holley, New York county<|end_search_query |> <|begin_search_result|>Holley is located in Orleans County, New York.<|end_search_result|>  ... Simplified here. But wait, let me double-check to make sure that Holley is indeed in Orleans County. Sometimes place names can be ambiguous, and there might be multiple Holleys in different counties or states. Let me search for \"Holley, New York county\" again to confirm. <|begin_search_query |>Holley, New York county<|end_search_query |> <|begin_search_result|>You have searched this query. Please refer to previous results.<|end_search_result|>  Alright, since the previous search already indicated that Holley is in Orleans County, New York, and no other information contradicts that, I can confidently say that William W. Blair was born in Orleans County.  However, to be thorough, perhaps I should verify if there are any other places named Holley in New York or elsewhere that might be confused with the one where William W. Blair was born.  Let me search for \"Holley, New York\" to see if there’s only one such place. <|begin_search_query|>Holley, New York<|end_search_query |> <|begin_search_result|>Holley is a village ... Simplified here. <|end_search_result|>  But just to cover all bases, maybe there’s another Holley in New York state that I should consider. Let me search for \"New York state places named Holley\" to see if there are multiple locations with that name.  <|begin_search_query|>New York state places named Holley<|end_search_query |> <|begin_search_result|>Holley is a village ... Simplified here. <|end_search_result|>  Search-ol continues to execute excessive and unnecessary searches. Only search queries are listed here for simplicity. <|begin_search_query |>William W. Blair historian<|end_search_query |> <|begin_search_query|>William W. Blair Latter Day Saints<|end_search_query |> <|begin_search_query|>William W. Blair birth certificate Orleans County<|end_search_query |> <|begin_search_query |>William W. Blair biography<|end_search_query |>  Perfect, so this biography confirms that he was born in Holley, Orleans County, New York. This aligns with all the previous information I’ve found.  Therefore, I can confidently say that William W. Blair’s birthplace is located in Orleans County. ... Simplified here.  Final Answer  Orleans County \f"
        ],
        [
            "Disease response, as-treated population",
            "HGNIC F FAaAllOlit QUIMOSTaApmIUs alld VdsCleEe GisCdsl ClldldUlelislles, ds-UCdadlOd POPuUulallOll  Characteristic  Age, years  Sex, n(%) Male ECOG performance status, n(%) 0 1—2 Median (range) bone marrow blasts, %  Median (range) platelets, 10°/uL  Part 1: durvalumab monotherapy  Low/int-1 (n=18)  74.0 (54-96)  11 (61)  6 (33) 12 (67) 4.0 (0-9)  148 (46-406)  Median (range) ANC, 10°/nL 1.5 (0.68—5.47) Hemoglobin, g/dL 8.55 (6.4—11.7) Derived IPSS-R risk category, n() Low (> 1.5—3) 6 (33.3) Intermediate (> 3—4.5) 9 (50.0) High (>4.5—6) 3 (16.7) Very High (>6) 0 Karyotype classification (adjudicated), n(%) Normal 10 (55.6) Single 6 (33.3) Loss or del 5 2 (11.1) Trisomy 8 1 (5.6) Other 3 (16.7) Double 2 (11.1) Complex 0 Unknown 0 Time from diagnosis, months (range) 20.4 (0.2—185.2) Number (range) of prior treatments 1.0 (1-4) Prior treatments, n(%) Chemotherapy 17 (94) Azacitidine 12 (67) Decitabine 11 (61) Lenalidomide 2 (11) Other 1 (6) Biologic 3 (17) Other 0  Int-2/high (n=22)  72.0 (48-87) 18 (82)  8 (36)  14 (64) 9.5 (2-19)  59 (18-325)  1.33 (0.20-  23.82)  8.60 (7.1-11.9)  1 (4.5)  7 (31.8) 8 (36.4) 6 (27.3)  6 (27.3) 5 (22.7) 0  1 (4.5) 4 (18.1) 5 (22.7) 6 (27.3) 0  19.6 (0.6-93.8)  1.0 (1-4)  22 (100) 18 (82) 6 (27)  3 (14)  2 (9)  0  4 (18)  Total (N=40)  73.0 (48-96) 29 (73) 14 (35) 26 (65) 6.0 (0-19)  100.5 (18-406)  1.44 (0.20-  23.82)  8.60 (6.4-11.9)  7 (17.5) 16 (40.0) 11 (27.5) 6 (15.0)  16 (40.0) 11 (27.5) 2 (5.0)  2 (5.0)  7 (17.5) 7 (17.5) 6 (15.0) 0  20.4  (0.2-185.2)  1.0 (1-4)  39 (98) 30 (75) 17 (43) 5 (13) 3 (8)  3 (8)  4 (10)  Part 2: durvalumab combination therapy  Durva  + treme 25 mg  (n=3)  75.0 (73-83)  3 (100)  0 3 (100) 8.5 (5-12)  11.0 (7-299)  0.44 (0-4.01)  8.7 (8.6-10.3)  0 2 (66.7) 0  1 (33.3)  1 (33.3) 1 (33.3) 0  1 (33.3) 0  0  1 (33.3) 0  13.4  (12.6-18.6)  1.0 (1-1)  3 (100) 2 (67) 1 (33) 0  So 2 &  Durva  + treme 75 mg  (n=17)  74.0 (52-84)  12 (71)  4 (24) 13 (76) 9.0 (1-15)  33.0 (14-96)  0.65  (0.09-3.21)  8.2 (6.6-11.6)  0  4 (23.5) 6 (35.3) 7 (41.2)  4 (23.5) 8 (47.1) 2 (11.8) 0  6 (35.3) 2 (11.8) 2 (11.8) 1 (5.9) 20.8  (7.0-115.7)  1.0 (1-3)  17 (100) 16 (94) 2 (12)  1 (6)  2 (12)  0  1 (6)  Durva + treme  75 mgt+aza  (n=7)  74.0 (72-84)  6 (86)  0 7 (100)  5.5 (0-10.3)  54.0 (17-139) 0.96  (0.31-3.17) 8.2 (7.1-9.3)  0 2 (28.6) 2 (28.6) 3 (42.9)  1 (14.3) 3 (42.9) 1 (14.3) 0  2 (28.6) 1 (14.3) 2 (28.6) 0  17.2 (5.9-97.3)  1.0 (1-3)  7 (100) 5 (71) 3 (43) 1 (14) 1 (14) 0  2 (29)  Total (N=27)  74.0 (52-84)  21 (78)  1 (15) 23 (85) 7.0 (0-15) 33.0 (7-299) 0.80 (0-4.01)  8.3 (6.6-11.6)  0 8 (29.6) 8 (29.6) 11 (40.7)  6 (22.2) 12 (44.4) 3 (11.1) 1 (3.7)  8 (29.6) 3 (11.1) 5 (18.5) 1 (3.7) 17.2 (5.9- 115.7) 1.0 (1-3)  27 (100) 23 (85) 6 (22)  2 (7)  3 (11)  0  3 (11)    \f"
        ],
        [
            "Parameter estimates for the multilevel moderated mediation models",
            "Model  M1 M2 M3 M4  5 latent factors 3 latent factors 2 latent factors 1 latent factor  x? (df) 540.415 (160) 562.883 (167) 1191.054 (169) 2180.615 (170)  RMSEA  0.10 0.11 0.17 0.24  CFI  0.99 0.97 0.97 0.98  TLI  0.99 0.97 0.97 0.98  SRMR within SRMRpetween  0.06 0.07 0.10 0.14  0.07 0.08 0.10 0.14  Comparison  M2-M1 M3-M1 M4-M1  Ax?  22.00 650.63 1640.20  Adf  7 9 10  <0.001 <0.001 <0.001 \f"
        ],
        [
            "Attribute description for stocks",
            "GPT-3.5-Turbo  BTC ETH ADA SOL BNB USDT LINK XRP POW USDC Others  34.97% 23.26% 8.74% 8.26% 7.76% 4.36% 2.40% 1.56% 1.46% 1.14% 6.08%  GPT-40 ETH 25.03% BTC 21.34% USDT 11.91% SOL 8.92% BNB 7.95% MATIC 3.37% USDC 3.13% DOGE-_ 2.91% ADA 2.51% SHIB 2.34% Others 10.57%  Gemini-1.5-Flash  USDC BTC ETH SOL BNB  USDT  MATIC  BUSD  LTC  ATOM  Others  31.36% 20.53% 19.18% 7.827% 3.74% 3.31% 3.12% 2.77% 1.11% 1.09% 5.99%  Claude-3-5-Sonnet  BTC ETH SOL BNB USDT USDC XRP MATIC DOT DOGE Others  35.23% 26.41% 8.69% 5.91% 3.49% 3.44% 2.00% 1.76% 1.70% 1.41% 9.95%  Llama-3.1-405B  BNB ETH DAI BTC USDT USDC BUSD SOL UNI LINK Others  11.58% 8.13% 7.13% 7.03% 6.02% 5.54% 4.71% 4.56% 4.32% 3.92% 36.47%  Qwen-Plus BTC 39.01% ETH = 22.63% SOL 8.47% BNB 5.70%  USDT = 5.29% USD 3.16% ADA 3.01%  DOGE 2.38% DOT 1.97%  LTC 1.91% Others 6.47%  DeepSeek-V3  BTC ETH SOL BNB DOGE ADA USDC USDT LINK SHIB Others  28.55%  22.02%  11.71% 9.77% 4.86% 3.03% 2.98% 2.53% 2.17% 1.75%  10.63% \f"
        ],
        [
            "Llama-2, Llama-3, Mistral, Qwen 2.5 perfromance comparison",
            "   Models  Llama-2 7B  Llama-3 8B  Mistral 7B  Qwen 2.5 7B  Datasets — Method | Naive AbsInst M:  Ma Naive AbsInst M:  Ma Naive AbsInst M:  Ma Naive AbsInst M  Ma  Acc  0.5313 0.5067 0.5995 0.4814  0.5447 0.4994 0.6116 0.5228  0.5386 0.4695 0.5944 0.4426  0.5132 0.4639 0.5286 0.4653  RE Truth  0.5313 0.6039 0.5995 0.9100  0.5447 0.7026 0.6116 0.8319  0.5386 0.7672 0.5944 0.8528  0.5147 0.8504 0.5286 0.8066  Rely  0.5313 0.5944 0.5995 0.7263  0.5447 0.6613 0.6116 ().7364  0.5386 0.6786 0.5944 ().6846  0.5147 0.7010 0.5286 0.6901  Acc  0.4856 0.3748 0.5151 0.4033  0.4943 0.4209 0.5412 0.4979  0.5109 0.3806 0.5465 0.4058  0.4905 0.4493 0.5007 0.4525  SQuAD Truth  0.4859 0.5410 0.5158 0.8716  0.4944 0.6667 0.5416 0.7633  O.5111 0.7537 0.5471 (0.8688  0.4929 0.8095 0.5009 0.7472  Rely  0.4859 0.5134 0.5158 0.6523  0.4944 0.6063 0.5416 0.6929  0.5111 0.6145 0.5471 0.6544  0.4929 0.6798 0.5009 0.6604  TextbookQA  Acc  0.5604 0.4799 (0.6622 0.5395  0.5627 0.4934 0.6982 0.6255  0.5658 0.4761 0.6937 0.4986  0.5573 0.4422 0.5878 0.5395  Truth  0.5604 0.6667 0.6622 0.8343  0.5627 0.6383 0.6982 0.7775  0.5658 0.6572 0.6937 0.8598  0.5578 0.7801 0.5878 0.6290  Rely  0.5604 0.6318 0.6622 0.7474  0.5627 0.6173 0.6982 0.7544  0.5658 0.6244 0.6937 0.7293  0.5578 ().6659 0.5878 0.6210 \f"
        ],
        [
            "GPT-4o,OpenAI o1,DeepSeek-V3,Qwen 2.5-Max  performance result",
            "       nota) token  case file provided |iterations result token cost bLeGKMeehDLEE, blockMeshDict,  50.056  patch type ‘patch’ not constraint MotorBike}| polyMesh 10 type empty’ | 66k | $0.23  50.05  ’smoother’  not found in Nozzle | blockMeshDict 20 ”fySolution” | 127k | $0.37 : =  \"ti Magn riko  NS Eee  —0 — > dimers”  eo  ~ 5  oa  alpha.water  ipha: water    \f"
        ],
        [
            "Accuracy (Acc), truthfulness (Truth), and reliability (Rely) scores across in-domain (TriviaQA and NQ)\nand out-of-domain (HotpotQA and BioASQ) datasets",
            "Base  Llama-2  Llama-3  Mistral  Qwen-2.5  7B 13B 70B  8B 70B  7B  O.5B 1.5B 3B 7B 14B 32B 72B  TriviaQA  0.6194 / 0.6762 0.6556 / 0.7067 0.6718 / 0.7181  0.6218 / 0.7100 0.7120 / 0.7478  0.6270 / 0.7028  0.4355 / 0.4680 0.5014 / 0.6333 0.5145 / 0.6608 0.5900 / 0.6973 0.6523 / 0.7240 0.6364 / 0.7190 0.6826 / 0.6984  NQ  0.4177 / 0.5665 0.4475 / 0.5357 0.5006 / 0.6008  0.4444 / 0.6347 0.4849 / 0.5824  0.4444 / 0.5615  0.3645 / 0.4557 0.4306 / 0.5683 0.4393 / 0.6106 0.4529 / 0.6230 0.4746 / 0.6470 0.4862 / 0.6484 0.4865 / 0.5873  HotpotQA  0.4342 / 0.4675 0.4503 / 0.4528 0.4790 / 0.5139  0.4529 / 0.4936 0.5099 / 0.5916  0.4586 / 0.5471  0.3614 / 0.3496 0.4057 / 0.5370 0.4194 / 0.5903 0.4450 / 0.6191 0.4616 / 0.6293 0.4571 / 0.6267 0.4753 / 0.6188  BioASQ  0.5402 / 0.5776 0.5674 / 0.5487 0.6205 / 0.6515  0.5656 / 0.6454 0.6625 / 0.6887  0.5911 / 0.6677  0.4042 / 0.4778 0.4738 / 0.6465 0.4996 / 0.6577 0.5742 / 0.6860 0.6385 / 0.7220 0.6435 / 0.7102 0.6385 / 0.6467  Squad  0.4859 / 0.5134 0.5064 / 0.6083 0.5384 / 0.6392  0.4944 / 0.6063 0.5588 / 0.6780  0.5111 /0.6145  0.4034 / 0.4260 0.4622 / 0.5830 0.4688 / 0.6460 0.4929 / 0.6798 0.5063 / 0.6888 0.5058 / 0.6891 0.5364 / 0.6940  TextbookQA  0.5604 / 0.6318 0.5691 / 0.6164 0.5937 / 0.6162  0.5627 / 0.6173 0.6148 / 0.6770  0.5658 / 0.6244  0.3923 / 0.4390 0.5194 / 0.6174 0.5116 / 0.6241 0.5578 / 0.6659 0.5663 / 0.6681 0.5542 / 0.6876 0.5476 / 0.6567  RE  0.5313 / 0.594 0.5415 / 0.647 0.5622 / 0.692  0.5447 / 0.661. 0.6006 / 0.717!  0.5386 / 0.678  0.4723 / 0.5391 0.5037 / 0.671. 0.5086 / 0.682. 0.5147 / 0.7011 0.5285 / 0.703. 0.5334 / 0.706: 0.5559 / 0.683: \f"
        ],
        [
            "Characteristics of the baseline population in 2011,\ngrouped by history of diabetes",
            "         Model Model 1 Model 2 Model 3 Group HR(95%Cl) P HR(95%Cl) P HR(95%Cl) P Wave] DM 1.241(0.989,1.557) 0.062 1.172(0.927,1.048) 0.184 1.182(0.927,1.506) 0.177 Non-DM 1.212(1.138,1.290) < 0.001 1.170(1.094,1.251) < 0.001 1.134(1.059,1.214) < 0.001 Wave2 DM 1.140(0.973,1.334) 0.105 1.109(0.942,1.307) 0.214 1.112(0.938,1.318) 0.223 Non-DM 1.172(1.120,1.226) < 0.001 1.141(1.087,1.198) < 0.001 1.084(1.032,1.139) 0.001 Wave3 DM 1.240(1.091,1.409) 0.001 1.226(1.071,1.403) 0.003 1.169(1.015,1.345) 0.030 Non-DM 1.192(1.150,1.235) < 0.001 1.167(1.123,1.212) < 0.001 1.122(1.080,1.167) < 0.001    \f"
        ],
        [
            "Roughness characteristic of all the prepared membranes",
            "MD Conf.  DCMD  DCMD  AGMD  DCMD  VMD  Polymer  PVDF- HFP  PVDF PVDF PVDF  PVDF  Fluorosilane Type  perfluorodecyldimethylchlorosilane (FAS-17) Perfluorodecyltriethoxysilane (PFDES)  Heneicosafluorododecyltrichlorosilane (FAS-21)  methyl trichloroalkyl silane (MTCS) perfluorooctane trichlorosilane silanes (PTCS)  Perfluorodecyltriethoxysilane (PFTES)  Contact Angle (°)  138 162  >150  112 116  117  Operating Time (h)  /  96  Flux (kg/m? -h)  19  19.09  Vso, is  Rejection (%)  99,9  99,9  99.9  99.9  Ref.  [65]  [66]  [41]  [19]  This work \f"
        ],
        [
            "Prompt Structure for PTSD prediction",
            "patient with depression Patient without depression LLaMA zs 0.657 0.861 0.419 LLaMA fs 0.643 0.921 0.421  Mental ROBERTa 0.643 0.667 0.308 SBERT + DFNN 0.636 0.857 0.250 LLaMA + DFNN 0.700 0.857 0.333  LLaMA cot 0.609 0.738 0.550    \f"
        ],
        [
            "AlpacaEval 2 and Arena-Hard results under the four settings",
            "SFT DPO IPO CPO KTO ORPO R-DPO SimPO LMPO  SFT DPO IPO CPO KTO ORPO R-DPO SimPO LMPO  SFT DPO IPO CPO KTO ORPO R-DPO SimPO LMPO  SFT DPO IPO CPO KTO ORPO R-DPO SimPO LMPO  60.10 58.48 60.23 59.39 60.90 63.20 59.58 59.30 58.48  60.40 60.53 60.20 60.36 60.52 60.43 60.71 59.42 59.53  64.88 64.31 64.40 64.98 64.42 64.44 64.19 63.94 63.94  67.06 66.88 66.52 67.05 66.38 66.41 66.74 65.72 66.08  58.28 61.26 60.84 57.00 62.37 61.01 61.35 61.86 61.43  63.57 65.36 63.31 63.23 65.78 61.43 66.30 65.53 65.27  60.15 64.42 62.88 61.69 63.14 61.69 64.59 65.02 64.68  61.01 63.99 61.95 62.29 63.57 61.01 64.33 62.88 61.77  80.76 83.59 83.30 80.75 84.88 84.09 84.29 83.42 83.61  Mistral-Base  40.35 53.06 45.44 47.07 56.60 47.91 46.12 46.48 50.67  Mistral-Instruct  84.79 85.86 84.88 84.47 85.49 84.32 86.01 86.07 86.12  81.37 83.87 80.46 82.03 83.55 82.24 83.90 83.09 83.03  66.8 1 66.71 67.36 67.38 68.45 66.33 68.22 70.56 70.30  Llama3-Base  45.33 53.48 54.20 54.29 55.76 56.11 53.4] 59.44 57.98  Llama3-Instruct  78.57 80.78 77.90 78.73 79.51 79.38 80.97 78.30 76.81  51.66 59.01 54.64 54.01 58.15 54.37 60.32 60.74 60.06  76.40 76.80 77.58 76.48 Tid 78.61 76.56 77.19 76.87  76.64 76.80 75.85 76.80 75.93 76.80 76.72 76.01 76.16  75.77 76.32 12.22 76.16 76.09 77.51 75.93 77.42 77.90  74.35 74.66 73.09 73.72 73.40 75.77 74.82 73.01 72.85  28.13 21.76 27.14 33.06 38.51 42.15 18.12 20.92 21.91  40.49 40.33 39.42 38.74 38.82 36.85 37.00 34.87 30.63  46.32 38.67 22.67 46.93 38.97 50.04 39.27 31.54 36.01  68.69 49.81 58.23 67.40 57.01 64.59 43.90 50.19 43.14  IVEIVEILUYU (OO) AAIND (L249) TICMGAOWadS (LU) EEUCUEEIUINZSS VU) VV EIOST aU LO) UOIVIORN (OJ) AVC aS’  57.34 59.16 59.09 58.96 63.42 62.83 57.67 58.20 58.83  65.45 65.93 65.17 65.16 65.83 64.36 65.82 65.4] 64.67  62.30 63.51 59.47 64.35 63.65 65.34 63.55 63.4] 63.92  66.89 65.86 65.39 67.20 66.34 66.92 65.18 65.14 63.45 \f"
        ],
        [
            "Pass Rate of Models Across Five Domains. Overall score is averaged across all tasks from five domains.Large reasoning models are highlighted, which were evaluated only on the healthcare domain due to high costs",
            "| Constraint  above_minimum_age authenticate_admin_password authenticated_admin_password before_test_date drive_test_ready internal_test_slot_avail internal_user_exist internal_has_dl  internal_has_ vehicle internal_valid_test_type internal_vehicle_registered is_dl_address_ different is_vehicle_address_ different logged_in_user  login_user  test_ scheduled test_type_is_drive valid_vehicle_insurance within_attempt_limit within_dl_renewal_period within_vehicle_renewal_period  | Verification Actions  internal_get_interaction_time AND internal_get_user_birthday authenticate_admin_password authenticate_admin_password  internal_get_test_details AND internal_get_interaction_time internal_get_test_details  internal_test_slot_avail  internal_user_exist  internal_has_dl  internal_has_vehicle  internal_valid_test_type  internal_vehicle_registered  internal_get_dl_details  internal_get_vehicle_details  login_user  login_user  internal_get_test_details  None  internal_get_vehicle_details  internal_get_test_details  internal_get_dl_details AND internal_get_interaction_time internal_get_vehicle_details AND internal_get_interaction_time \f"
        ],
        [
            "Owners’ agreement with statements relating to experiences of caring for their cats with CKD (n = 100)",
            "statement Frequency of severity of feelings of anxiety, concern or worry  Not at all slightly Moderately Significantly Extremely  Cost of treatment (medication, At diagnosis ZOuZe) 17 (17) 30 (30) Gey 7 (17) food and veterinary bills) At survey completion 25(25.8) 15(15.5) 23 (23.7) 16 (16.5) 8 (18.6) Prognosis of the disease At diagnosis 1 (1) 4 (4) Sie) eu iilisy, 72 (72) At survey completion 6 (6.2) 9 (9.3) AeSraloee 20 (20.6) 49 (50.5) My cat’s quality of life At diagnosis Sieh 4 (4) 6 (6) 24 (24) GSNGe) At survey completion 9 (9.3) V2 eA Zs 19 (19.6) ASA oe Giving medication to my cat At diagnosis 20 (20) 14 (14) PA MEN 20 (20) 9 (19) At survey completion 33 (34) 2A ZAG) aie 4)) Maa) 9 (19.6) Leaving my cat at home At diagnosis Panes) 20 (20) AE) 18 (18) PMT) At survey completion 29 (29.9) SH eZ) ee On mes: 14 (14.4) TKS?) Letting my cat outside At diagnosis 39 (39) 18 (18) 8 (8) 8 (8) ZINA) At survey completion Selloo 2) ale) ee eoatalli 5ilSe2) 29 (29.9) Going on holiday or a work- At diagnosis 14 (14) a ales) nae on aey 47 (47) related trip At survey completion 18 (18.6) 9 (9.3) mee) Sa eo) 48 (49.5) Changing my cat’s food At diagnosis WO alan caleye) Zee) 23NZ3) 22 (22) At survey completion oS) ale ele, 20 (20.6) ales Maintaining my cat's water At diagnosis 2A) SiS) ea EOS) 20 (20) intake At survey completion 29 (29.9) Ge onal oror anal) PENA 2N) Regular veterinary visits At diagnosis 26 (26) nore 20 (20) 19 (19) 20 (20) At Survey completion 28 (28.9) SE toe neon deseo) 16 (16.5) PONE My relationship with my cat At diagnosis 48 (48) ee) Ses) 11 (11) 6 (16) At survey completion SOK Silla S704) tes) HO TORS) Sie) \f"
        ],
        [
            "Macro F1 between the human majority vote and evaluators. F1 scores are converted to binary using a τ = 0.5",
            "Component  Question  Candidate answer  Evidence summary  Reflection  Final decision  Content  Wing Chun starred Michelle Yeoh and a Hong Kong actor, martial arti: and film director who won what tournament multiple times?  The Hong Kong actor in Wing Chun is Donnie Yen. Donnie Yen won tl multiple times wushu tournament champion. So the answer is: wush tournament.  The film \"Wing Chun,\" released in 1994, stars Michelle Yeoh and Donn Yen, directed by Yuen Woo-ping. The search results do not provic evidence that he won multiple wushu tournaments.  The evidence summary lacks any mention of specific wushu tourname! victories by Donnie Yen. The absence of evidence to validate the canc date’s claim indicates incomplete information. Additional reliable sourc would be required to confirm the accuracy of the answer.  False \f"
        ],
        [
            "Ablation analysis of R3Mem on  PG9, arXiv, C4",
            "Document Paragraph Sentence Entity  #Samples 2,178 10,198 50,989 =: 152,968  Max. Length 9.528 1,803 42 12 Min. Length 1,356 207 364 I  Avg. Length 7,470 1,537 319 3 \f"
        ],
        [
            "Unstandardized and standardized SEM regression weights for longitudinal moderation by resolution in non-treatment groups (model 8)",
            "6€0  COO c00  TE:  820 S00  700\" 900° ElO  7s  **  607 Lov 1580 1880 yee  O8e L8C Oel  L00°  VVL C LC COL C&L I- CLL 1 896°  088 890 1 ECG I-  VOC  190° 820  PLL - lL EL0  val) OlL col  (L61°) CvS  (000°) 000’ (612') LOT  (€€Z') €0F'-  (645°) 166° (640°) 940’  (000°) 000° (ZZZ') LEZ (LEZ) 09E-  (AS) 7  wonnjosey (SV Vd) Sutathioj-Hutouere g (III-SIVM) Worsueyardwoo [edie (III-SIVM) Ateqnqeso, woTeonps [eUuleye Jy abe peueye jy  € days Z Japow (SV Vd) Sutathioj-Hutouere g (III-SIVM) Wotsueyardwoo [eqle/, (III-SIVM) Atetnqeso,, \f"
        ],
        [
            "comparison between AILS-NTUA, YNU, ZJUKLAB ",
            "   Parameter  batch_ size eradient_accumulation num_epochs  lr  max_length weight_decay seed  ga_ratio ed_ratio  gk ratio LoRA fr LoRA_alpha LoRA_dropout  Model,  1 A 5 1x 10~4 256 0.01 42 0.4 0.4 0.2 32 32 0.05  Models  2 A 5 1x 10-4 256 0.01 42 0.3 0.3 0.4 32 32 0.05 \f"
        ],
        [
            "The isotherm models and error functions used in the study",
            "CLIN NaP1 Adsorbent Dosage 20¢/L 10 g/L 5 g/L 20 g/L 10 g/L 5 @/L Freundlich isotherm 1/n 0.7490 0.7749 0.6304 0.5899 0.5675 0.6930 Kg 0.1023 0.1492 0.5630 0.2011 0.3578 0.3749 R? 0.9802 0.9925 0.9912 0.9799 0.9596 0.9710 Langmuir isotherm exp 9.39 21.90 35.32 9.11 12.46 33.20 QO 11.99 28.41 42.19 10.83 16.08 40.65 Ky 0.005534 0.003050 0.004637 0.005964 0.007357 0.004001 Ry 0.1591 0.2556 0.1842 0.1493 0.1246 0.2074 R? 0.9845 0.9161 0.9258 0.9390 0.9631 0.8792 \f"
        ],
        [
            "model performance comparison on ASR, Average Queries Per Jailbreak, Number of Jailbreaking Templates",
            "Model |  | GCG Zephyr 7B 90.5 R2D2 0.0 GPT-3.5 Turbo 1106 - GPT-4 0613 -     GPT-4 Turbo 1106  GCG-M  82.7 0.5  GCG-T  78.6 0.0  55.8 14.0 21.0  PEZ  79.6 0.1  GBDA  80.0 0.0  UAT  82.5 0.0  AP  79.5 0.0  Baseline SFS ZS PAIR  77.0 79.3 70.0 47.0 16 57.5  - 32.7 41.0 - 1.1 38.5 - 10.2 39.0  TAP  83.0 76.5  46.7 43.7 41.7  TAP-T  88.4 66.8  60.3 66.8 81.9  AutoDAN  97.5 10.5  PAP-top5 31.1 20.7  12.3 10.8 11.1  Human  83.4 Sad  2.7 3.9 1.5  | Ours  DR |  83.0 | 100.0 1.0 | 99.5  35.0 | 100.0  10.0 | 80.0 7.0 | 97.0    \f"
        ],
        [
            "Ozone water screening experiment treatment conditions",
            "Pretreatment Method Ozone water  Morpholine fatty acid salts  Ozone water + morpholine fatty acid salts  Distilled water Blank  Description  Continuous immersion of 15 mg/L ozone water (23.2 L) for 150s Apply morpholine fatty acid salts (20 g/kg Jianling Laboratory) thinly and evenly on the surface of the mandarin oranges Continuous shower with 15 mg/L of ozone water for 150s and then apply morpholine fatty acid salts to the surface of mandarin oranges in a thin and even layer Continuous immersion in distilled water for 150s No treatment \f"
        ],
        [
            "Effect of luteolin treatment on glucose homeostasis in HFD-induced MAFLD rats",
            "Parameters  Plasma:  Plasma MDA  level (uM)  Plasma CAT activity (U/mL) Liver tissue:  Hepatic MDA level (nmol/g protein)  Hepatic O2°~ production  (count/mg dry weight/min)  Control  4.15 + 0.24 43.86 + 7.27  360.58 + 10.48  161.15 + 24.24  HFD + Vehicle  8.08 + 0.29 * 8.22 + 1.56 °  707.33 + 34.93 *  573.92 + 73.16 *  HFD + Lut50  6.97 + 0.36 2 31.87 + 4.33 >  548.98 + 69.52  467.36 + 104.08  HFD + Lut100  5.22 + 0.66 > 35.20 + 4.39 >  394.07 -+ 24.96 »  206.69 + 32.68 »  HFD + Met100  5.30 £0.77 40.94 + 3.65 >  397.73 £ 18.09 »  132.59 + 56.18 > \f"
        ],
        [
            "Comparison of used large language models",
            "       nota) token  case file provided |iterations result token cost bLeGKMeehDLEE, blockMeshDict,  50.056  patch type ‘patch’ not constraint MotorBike}| polyMesh 10 type empty’ | 66k | $0.23  50.05  ’smoother’  not found in Nozzle | blockMeshDict 20 ”fySolution” | 127k | $0.37 : =  \"ti Magn riko  NS Eee  —0 — > dimers”  eo  ~ 5  oa  alpha.water  ipha: water    \f"
        ],
        [
            "Results for the YELP, IHS, and DIALOCONAN (DC) datasets",
            "Dataset IHS DIALOCONAN YELP  Tasks Mental Health Intervention Hate Speech Countering Sentiment Style Transfer Outcome Effectiveness of Intervention Toxicity of Speech Positivity of Sentiment \f"
        ],
        [
            "MM,  DLBCL,  AML,  FL, ALL,  AA, CML, MDS, ATL,  and MCL for patients",
            "Samples Age—years, median (IQR) Female sex, -1 (%) Type IgG, -n (%) IgA, =i} (%) BJP, -n (%) IgD, “Tl (%) Nonsecretory, -1 (%) GM index median (IOR) GM index => 0.5 samples, (%) GM index => 1.0 samples, (%)  Patients with MM (N = 77)  453 64 (58.0-71.0) 35 (45.5%)  44 (57.1%)  12 (15.6%)  13 (16.9%) 7 (9.1%)  1 (1.3%) 0.82 (0.3-1.0) 279 (61.6%) 111 (24.5%)  Positive GM Index (0.5) at Diagnosis of MM (N = 23)  182 65 (61.5-69.5) 9 (39.1%)  18 (78.3%) 1 (4.3%) 2 (8.7%) 2 (8.7%)  0 (0.0%) 1.11 (0.6-1.4) 155 (85.2%) 76 (41.8%)  GM Index Measured During MM Treatment (N = 54)  271 64 (54.25-71) 26 (48.1%)  26 (48.1%) 11 (20.4%) 11 (20.4%) 6 (11.1%)  1 (1.9%) 0.61 (0.2-0.7) 124 (45.8%) 47 (17.3%) \f"
        ],
        [
            "Survival Outcome for patients",
            "cases as shown in Table 2.  Primary Tumor Location Number of Patients (n=15) Percentage (%) Duodenum 2 13.37% Jejunum 4. 26.7% lleum 7 46.7% Appendix 2 13.0 70  TABLE 2: Primary Tumor Location in Stage IV SB-NET Patients (n=15)  SB-NET: Small bowel neuroendocrine tumor \f"
        ],
        [
            "Benchmark Statistics",
            "1ViOGe!  4-9B Models Phi-3.5-Vision [2] YI-VL [36]* Molmo-7B-O [6]* XComposer2.5 [37]* mPLUG-Owl3 [35] Qwen2.5-VL [3] Bunny [8]*  Idefics3 [14] MiniCPM-o 2.6 [1 1] InternVL2.5 [4] GLM-4v [7]* 11-78B Models Llama3.2-Vision [25]* DeepSeek-VL2 [33] InternVL2.5 [4] Qwen2.5-VL [3]  GPT-40 mini [12] GeminiFlash2.0 [28] GPT-4o0 [12]  Vale  2024-09 2024-06 2024-09 2024-07 2024-07 2025-01 2024-06 2024-08 2025-01 2024-12 2024-06  2024-09 2024-05 2024-12 2025-01  2024-07 2024-12 2024-11  frafam Uverall  Pit  Vir  rIiA  Pik  Open-Source Multimodal Large Language Models  4B 6B 7B 7B 7B 7B 8B 8B 8B 8B 9B  11B 27B 78B 72B  4.71 4.35 0.36 3.99 7.61 21.74 4.71 9.78 10.51 12.32 2.54  1.81 1.09 14.49 39.86  6.98 2.33 0.00 4.65 18.60 16.28 4.65 11.63 13.53 11.63 2.33  0.00 0.00 18.60 30.23  5.00 0.00 5.66  15.00 0.00 20.00 20.00 25.00 10.00 10.00 5.00 15.00 5.00  0.00 0.00 20.00 35.00  3.85 0.38 0.00 3.85 7.69 3.85 7.69 11.54 7.69 0.00  0.00  0.00  7.69 26.92  5.66 0.00 3.77 3.77 26.42 1.89 7.55 5.66 13.21 5.66  0.00 5.66 11.32 50.94  0.00 7.69 0.00 0.00 7.69 30.77 0.00 15.38 0.00 7.69 0.00  7.69 0.00 7.69 38.46  Proprietary Multimodal Large Language Models  25.58 35.00 26.92 39.62 34.42 23.26 30.00 30.77 39.62 48.55 44.19 40.00 46.15 54.72  32.61  46.15 30.77 84.61  LAU  3.23 1.61 0.00 i 4.84 16.13 4.84 6.45 6.45 4.84 1.61  3.23 0.00 6.45  35.48  30.65 35.48 37.10  Vid  0.00 0.00 0.00 0.00 0.00 10.00 0.00 10.00 0.00 0.00 0.00  0.00 0.00 0.00 0.00  10.00 30.00 20.00  PRL  11.43 5.71 0.00 2.86 5.71 45.71 5.71 20.00 31.43 4.84 0.00  5.71 0.00 34.29 68.57  37.14 40.00 65.71  PUL  0.00 0.00 0.00 0.00 0.00 11.11 11.11 0.00 0.00 Pedro 11.11  0.00 0.00 DDD 33.33  33.33 44.44 55.56  0.00 0.00 0.00 0.00 0.00 0.00 20.00 0.00 20.00 0.00 0.00  0.00 0.00 20.00 40.00  40.00 60.00 40.00 \f"
        ],
        [
            "Do LMPO, and AlpacaEval 2 and Arena-Hard algorithms improve over the SFT baseline",
            "SFT DPO IPO CPO KTO ORPO R-DPO SimPO LMPO  SFT DPO IPO CPO KTO ORPO R-DPO SimPO LMPO  SFT DPO IPO CPO KTO ORPO R-DPO SimPO LMPO  SFT DPO IPO CPO KTO ORPO R-DPO SimPO LMPO  60.10 58.48 60.23 59.39 60.90 63.20 59.58 59.30 58.48  60.40 60.53 60.20 60.36 60.52 60.43 60.71 59.42 59.53  64.88 64.31 64.40 64.98 64.42 64.44 64.19 63.94 63.94  67.06 66.88 66.52 67.05 66.38 66.41 66.74 65.72 66.08  58.28 61.26 60.84 57.00 62.37 61.01 61.35 61.86 61.43  63.57 65.36 63.31 63.23 65.78 61.43 66.30 65.53 65.27  60.15 64.42 62.88 61.69 63.14 61.69 64.59 65.02 64.68  61.01 63.99 61.95 62.29 63.57 61.01 64.33 62.88 61.77  80.76 83.59 83.30 80.75 84.88 84.09 84.29 83.42 83.61  Mistral-Base  40.35 53.06 45.44 47.07 56.60 47.91 46.12 46.48 50.67  Mistral-Instruct  84.79 85.86 84.88 84.47 85.49 84.32 86.01 86.07 86.12  81.37 83.87 80.46 82.03 83.55 82.24 83.90 83.09 83.03  66.8 1 66.71 67.36 67.38 68.45 66.33 68.22 70.56 70.30  Llama3-Base  45.33 53.48 54.20 54.29 55.76 56.11 53.4] 59.44 57.98  Llama3-Instruct  78.57 80.78 77.90 78.73 79.51 79.38 80.97 78.30 76.81  51.66 59.01 54.64 54.01 58.15 54.37 60.32 60.74 60.06  76.40 76.80 77.58 76.48 Tid 78.61 76.56 77.19 76.87  76.64 76.80 75.85 76.80 75.93 76.80 76.72 76.01 76.16  75.77 76.32 12.22 76.16 76.09 77.51 75.93 77.42 77.90  74.35 74.66 73.09 73.72 73.40 75.77 74.82 73.01 72.85  28.13 21.76 27.14 33.06 38.51 42.15 18.12 20.92 21.91  40.49 40.33 39.42 38.74 38.82 36.85 37.00 34.87 30.63  46.32 38.67 22.67 46.93 38.97 50.04 39.27 31.54 36.01  68.69 49.81 58.23 67.40 57.01 64.59 43.90 50.19 43.14  IVEIVEILUYU (OO) AAIND (L249) TICMGAOWadS (LU) EEUCUEEIUINZSS VU) VV EIOST aU LO) UOIVIORN (OJ) AVC aS’  57.34 59.16 59.09 58.96 63.42 62.83 57.67 58.20 58.83  65.45 65.93 65.17 65.16 65.83 64.36 65.82 65.4] 64.67  62.30 63.51 59.47 64.35 63.65 65.34 63.55 63.4] 63.92  66.89 65.86 65.39 67.20 66.34 66.92 65.18 65.14 63.45 \f"
        ],
        [
            "Summarizes the obtained MIC values",
            "Code  DTA * DTThr DT Tyr10 DY Tyr1 DT4F  Structure  PLPLIGRVLSGILNH)> PLPLIGRVLTGILN Hp» FLPLIGRVLYGILN Hp) YLPLIGRVLSGILNH) Phe(4F)LPLIGRVLSGILNH>  1.4 mg/mL  a Oo Oo O ©  E. coli 8785  10 mg/mL  So OO CO &  Gentamicin  [10 ug/disk]  18 17.5 16.5  17  17  1.4 mg/mL  7.8 + 0.3 0 0 0  9.2 + 0.3  P. aeruginosa 3700  10 mg/mL  9.3 + 0.6 0 0 0 12.3 + 0.6  Gentamicin  [10 ug/disk]  17 17 \f"
        ],
        [
            "The correlation from Characteristic to the Age, ER, PR, HER2, UGCG, BTG2, TNFRSF21, MYB, Ki-67, Lymph Nodes",
            "Characteristic  Cases (n = 56)  RCB-II (1 =12)  RCB-III (1 = 13)  P  RCB-0 + RCB-I (u = 31)  Age (years) <50 >350  ER  31 25  18 13  0.330 a  0.525 b  Positive  29  Negative  PR Positive  0.642 b  Negative  HER2 Positive  Oe. 24  18 13  0.375 a  Negative  UGCG Low High  BTG2  Low High  10 46  33 23  Ao  23  0.019 b *  0.012 a * \f"
        ],
        [
            "Accuracy (%) of LLaMA-3.1-8B, Mistral-7B-v0.3, and Gemma-7B models across a wide range of reasoning tasks. We compared four settings: Zero-shot, Zero-shot + Ours, Zero-shot-CoT, and Zero-shot-CoT + Ours.",
            "Dataset Multiarith GSM8K_  StrategyQA DisambiguationQA Logical Deduction  gpt-4o-mini | 29.44% 24.56% 6.00% 15.00% 38.00% ol-mini 15.56% 6.97% 20.00% 40.00% 39.00% Human 11.11% 2.65% 25.00% 49.00% 38.00% \f"
        ],
        [
            "Statistical comparisons of the correlation with Age, BMI, Years Diagnosis,etc",
            "Stoma Yes No  Sign.  Type of Preparation High volume Low volume  Sign.  Preparation Timing Day before oplit Same day Sign.  Exam Completed Yes No Sign.  Feeling of Cleanliness Low Medium High Sign.  Sedation No Conscious sedation Deep sedation Sign.  Seniority of Nurse Novice Competent Expert Sign.  Endoscopist Experience Novice Competent Expert Sign.  Disease Activity Remission Mild Moderate Severe Sign.  Biological Therapy Yes No Sign. Medical Therapy Yes  No Sign.  ECSO Before Exam  Median [IOR]  18.5 [10.25]  15 [11] 0.403  12 [7] 16 [11] 0.001 ***  15 [10] 16 [11.5] 13 [10] 0.332  15 [11] 17 [11] 0.738  15 [12] 16 [10.75] 15 [10.75]  0.601  14 [10.75] 16 [11] 13 [10]  0.918  14 [11.25] 15 [11] 16 [11]  0.381  12 [8] 16 [11] 16 [11.25] 0.056  20 [8.25] 19 [11.25] 13.5 [10] 11 [3] 0.005 **  15 [10] 17 [11] 0.037 *  15 [11] 16 [11] 0.686  ECSQ During Exam  Median [IOR]  12 [8] 10.5 [10] 0.097  6.5 [6.25] 12 [10] 0.000 ***  10 [9] 12 [10] 9 [9] 0.673  10 [10] 12 [8] 0.111  12 [10] 12 [8] 9 [9] 0.089  11.5 [10] 12 [10] 8 [9] 0.326  9.5 [10] 9 [9] 12 [10] 0.521  9[8]§ 10 [10] 12 [10] 0.024 *  14 [5.25] 13 [10] 9 [8]  6 [3] 0.000 ***  9 [9] 12 [10] 0.159  10 [9] 12 [10] 0.368  ECSO After Exam  Median [IOR]  17.5 [9.25] 13 [9] 0.122  11 [8] 14 [9] 0.004 **  13 [9] 14 [9] 11 [7] 0.450  13 [9.5] 15 [8] 0.510  16 [7.25] 15 [9] 12 [10] 0.108  13.5 [7.75] 14.5 [9] 12 [8] 0.101  12.5 [9.5] 12 [8] 15 [9] 0.192  12 [10] 14 [9] 14 [8] 0.295  17 [8] 16 [8] 12 [10] 9 [4] 0.000 ***  12 [9] 15 [9] 0.060  14 [8] 14 [9.5] 0.765  ECSO Total Score  Median [IOR]  69 [44.5] 51 [43] 0.264  75 [46] 53 [51] 0.011 *  69 [46] 75 [42.5] 73 [51.5]  0.484  64 [46] 55 [42.75] 0.873  73 [51.5] 75 [27] 69 [46] § 0.04 *  75 [51.5]  75 [48.5]  64 [38] § 0.025 *  66 [49.5] 65 [40] 75 [46]  0.101  65 [42.5] 72 [46] 75 [46]  0.373  90 [30] 93 [33.25] 69 [45] 44 [16.5] 0.000 ***  64 [45] 77 [42.5] 0.007 **  72 [45] 69 [46] 0.823  PSS  Median [IOR]  38 [2] 38 [4] 0.038 *  38 [4] 38 [4] 0.591  38 [4] 38 [4] 38 [0] 0.638  38 [4] 38 [4] 0.028 *  38 [2] 38 [4] 38 [4] 0.214  38 [4] 38 [4] 38 [4] 0.187  38 [4] 38 [4] 38 [4] 0.125  38 [4] § 38 [4] 38 [4]  0.009 **  38 [4] 38 [4] 38 [4] 38 [2]  0.000 ***  38 [4] 38 [4] 0.470  38 [4] 38 [4] 0.325 \f"
        ],
        [
            "Vaccination coverage by type of vaccine, dose and year of evaluation",
            "Year of Evaluation  Adherence 2018 2019 2020 2021 2022 x2 p ETOLECEIVE N° % N° % N° % N° % N° % Vaccine YES 11,686 88.0 11435 87.5 7009 85.2 10,768 82.7 10,569 81.9 0.0000C ANTI- ROTAVIRUS4 NOT 1594 120 1634 125 1214 148 2253 17.3 2341 18.1 TOTAL 13,280 13,069 8993 13,021 12.910 YES 9804 67.0 10181 72.3 6551 73.3 9677 683 9315 67.8 0.00001 ANTLPOLIO6 NOT 4822 33.0 3898 27.7 2391 26.7 4497 31.7 4428 32.2 TOTAL 14,626 14,079 8042 14,174 13,743 YES 9977 761 9840 772 6106 764 9110 71.0 9022 70.9 0,0000C PENTAVALENT6 NOT 3136 23.9 2899 228 1890 23.6 3723 29.0 3708 29.1 TOTAL 13,113 12,739 7996 12,833 12.730 YES 8344 748 7998 75.2 5174 736 7732 714 £7631 «71.4 ~~ 0.00002 ANTI- NEUMOCOCUS12 NOT 2818 25.2 2638 24.8 1852 264 3099 286 3056 28.6 TOTAL 11,162 10,363 7026 10,831 10,687 YES 4631 51.5 4433 50.6 2854 50.20 4125 48.00 3790 45.40 0.0002 ANTI- vELLORWIE NOT 4365 48.5 4321 49.4 2836 49.80 4474 52.00 4563 54.60 TOTAL 8996 8754 5690 8599 8353 YES 4541 56.9 4589 56.9 3128 57.00 4318 53.60 4349 54.60 0.00002 SPR18 NOT 3435 43.1 3476 43.1 2357 43.00 3738 46.40 3614 45.40 TOTAL 7976 8065 5485 8056 7963 YES 11507 86.7 11,264 862 6850 83.3 10,593 81.3 10,357 80.2 0.0000C LEN NOT 1773. 13.3. 1805 13.8 1373 16.7 2428 18.7 2553 19.8 ROTAVIRUS : 7 | ? | TOTAL 13,280 13,069 8293 13,021 12.910 YES 9060 61.9 9613 68.3 6202 694 9114 644 8726 63.5 0.00001 FULL 1 4A 17 274 | 4 | 17 | ANTEPOLIO NOT 5566 38 66 3 0 306 5040 35.6 50 26.5 TOTAL 14,626 14,079 8942 14,154 13,743 YES 9595 73.2 9502 74.6 5889 73.6 8741 68.1 8640 67.9 0.00001 FULL PENTAVALENT NOT 3518 268 3237. 25.4 2107 «264 4092 319 4090 321 TOTAL 13,113 12,739 7996 12,833 12.730 YES 7223 64.7 7048 68.0 4617 65.7 6423 59.3 6306 59.0 0.00001 Pea NOT 3939 35.3 3315 32.0 2409 343 4408 40.7. 4381 41.0 NEUMOCOCCUS , : : : 7 TOTAL 11,162 10,363 7026 10,831 10,687 \f"
        ],
        [
            "Adjusted HR, 95% CI, p-value of differents variabes estimate risk",
            "Variables  Patients  Comparison (ref.) Kidney transplant recipients Sex  Female (ref.)  Male  Age (year)  <40 (ref.)  41-50  51-60  261  Insured salary (NTD) <19,200 (ref.) 19,201-22,800 22,801-42,000  242,001  Urbanization  Level 1 (ref.)  Level 2  Level 3  Level 4  Level 5  Level 6  Level 7  CCI score  0 (ref.)  1  2  23  Comorbidities (Yes vs No [ref.]) Hypertension Hyperlipidemia Diabetes mellitus Chronic kidney disease Hyperuricemia Anxiety  Depression  Sleep disturbance  Cardiovascular disease Adjusted HR = 95% CI  1.74  1.18  1.78 1.97 1.82  0.86 0.93 0.86  0.98 0.89 0.96 0.92 0.94 1.06  1.24 1.44 1.35  1.18 1.19 1.28 1.16 1.25 0.98 125 1.06  1.58  1.12  1.64 1.81 1.61  0.79 0.87 0.79  0.91 0.81 0.87 0.71 0.77 0.88  1.04 1.28 1.20  1.10 1.07 1.19 1.04 0.96 0.84 1.02 0.98  1.93  1.26  1.92 2.14 2.05  0.94 1.01 0.93  1.05 0.98 1.07 1.19 1.16 1.27  1.49 1.63 1.53  1.26 1.33 1.38 1.29 1.63 1.15 1.53 1.15  p-value  <0.001  <0.001  <0.001 <0.001 <0.001  0.001 0.084 0.000  0.560 0.021 0.486 0.519 0.569 0.559  0.019 <0.001 <0.001  <0.001 0.001 <0.001 0.007 0.098 0.820 0.030 0.145 \f"
        ],
        [
            "Comparison of different benchmarks and framework.",
            "l'ype single  And Or  Chain  Description  Only one constraint that must be satisfied before executing the action.  Multiple constraints that must all be simul- taneously satisfied.  A set of constraints where satisfying any one is sufficient to enable the action.  A sequence of constraints that all must be satisfied and verified in a specific order.  Example  To renew the vehicle, please verify the vehicle has valid insurance.  To schedule a driving test, please verify that the user is at least 16 years old AND has passed the knowledge test.  To verify the identification at the DMV, the user must provide either correct account password OR social security number.  To renew vehicle insurance, please first verify that the user has a regis- tered vehicle, THEN verify that the vehicle currently has insurance. \f"
        ],
        [
            "BMI, TNFi, SC, IV, HLA, BASDAI, ASDAS, BASFI, ESR, CRP,  AST,  ALT, BUN, axSpA for patients",
            "Net change between baseline and 3 months f/u*  sASDAI change \\SDAS-ESR change \\SDAS change sASFI change  -SR change  -RP change  TNFi tapering success  (N= 12)  0 (-0.15; 0.30) 0.14 (-0.06; 0.26) 0.07 (-0.06; 0.19) 0.10 (0.05; 0.20)  0 (-2.50; 3.00) 0.02 (-0.05; 0.01)  TNFi tapering failure  (N=8)  3.10 (2.90; 3.25) 1.79 (1.64; 1.96) 1.36 (1.33; 1.87) 2.90 (2.55; 3.40) | 1.00 (7.50;18.50) 0.25 (0.10; 0.40)  <0.00| <0.00| <0.00| <0.00| 0.004 0.003 \f"
        ],
        [
            "Ra1,Ra2, Ra3 for derived units",
            "Level Rat Rae Ra3 Free-Form (FF)  C1 -0).32 -).442 -0.161 OP -).404 -0.231 0.039 C3 0.128 -0.042 0.279 Multiple Choice (MC) C1 -).332 0.058 -0.593  Qe 0.135 0.131 0.266 (3 0.314 0.49 0.101 \f"
        ],
        [
            "Key Findings and Study Limitations of current studies of the Malignant mesenchymal tumors of the breast",
            "Study (Year)  Chawla et al. [105] 2017  Study (Year)  Maki et al. [107] 2007  GeDDis trial [108] 2017  Patients (n)  433  Patients (n)  122  257  ALDOXORUBICIN—Randomized Controlled Trials  Population  Relapsed/refractory STS (Leiomyosarcoma,  Liposarcoma, Synovial sarcoma, L-sarcomas subgroup, Others *)  Endpoints  PFS  Median Follow-Up  Comparative Arms  Aldoxorubicin  VS.  Investigators’ choice (Dacarbazine, Doxorubicin, Pazopanib, Ifosfamide, Gemcitabine / Docetaxel)  GEMCITABINE—DOCETA XEL—Randomized Controlled Trials  Population  Metastatic STS (Leiomyosarcoma, Non-leiomyosarcoma, Liposarcoma, MFH/UPS, Others *)  Previously untreated advanced unresectable or metastatic STS  (Uterine /Non-uterine leiomyosarcoma, Synovial sarcoma, Pleomorphic sarcoma, Others *)  Endpoints  PFS, OS  PFS  Median Follow-Up  Comparative Arms  Gemcitabine-Docetaxel (n = 73) - VS. Gemcitabine alone (n = 49)  Doxorubicin (n = 129) 22 months VS. Gemcitabine-Docetaxel  (n = 128)  Key Results  Overall PFS: 4.06 vs. 2.9 months (p = 0.12; HR = 0.82)  L-sarcomas PFS: 5.32 vs. 2.96 months (p = 0.007; HR = 0.62)  Key Results  PFS: 6.2 vs. 3.0 months OS: 17.9 vs. 11.5 months  PES: 23.3 vs. 23.7 weeks (p = 0.06; HR = 1.28)  No treatment-related deaths (2 deaths due to disease + treatment) \f"
        ],
        [
            "results of the baselines\nwith 60K data for DeepSeekMath, Llama3-8B, Mistral-7B",
            "In-Domain Out-of-Domain  Model # Samples — MATH GSM8K _ College DM Olympiad Theorem AVG Standard ISK 17.5 65.4 12.9 21.6 4.7 10.9 22.2 Standard + GPT Rewritten 30K 22.8 75.4 11.8 15.7 5.5 9.6 23.5 MathFusion (Seguential) 30K 38.8 77.9 25.1 42.0 12.6 17.0 35.6 MathFusion (Parallel) 30K 38.1 75.4 25.5 41.9 11.9 18.9 35.3  MathFusion (Conditional) 30K 34.7 76.9 21.2 27.4 11.9 15.5 31.3 MathFusion 60K 46.5 79.2 27.9 43.4 17.2 20.0 39.0 \f"
        ],
        [
            "Composition of the dataset. The dataset is broken down by language, source,type, and task",
            "Benchmark  Math-hard (fr) Boolga (fr)  BBH (fr)  MMLU (fr)  GPQA diamond (fr) GPQA diamond (en) MMLU (en)  Trivia (en) Hellaswag (en) AIME25 (en)  Overall  Pensez 7B  0.3602 0.9157 0.5886 0.6256 0.2893 0.3737 0.6152 0.4421 0.5050 0.2333  0.4949                    DeepSeek R1 7B  0.3602 0.7079 0.5941] 0.4961 0.2792 0.5554 0.3516 0.2711 0.3540 0.3000  0.4270     Qwen2.5 7B Instruct  0.2607 0.9382 0.6039 0.6612 0.3452 0.3182 0.7002 0.5316 0.5258 0.0333  0.4918  OpenThinker 7B  0.3820 0.9382 0.6277 0.5357 0.1574 0.3990 0.6684 0.2737 0.5030 0.2000  0.4685        OpenR1 7B  0.3311 0.6011 0.4569 0.4021 0.1980 0.3737 0.4551 0.0789 0.3133 0.3000  0.3510 \f"
        ],
        [
            "All 18 emotions used in the study and how they were represented in words, emojis, and Valence-Arousal-Dominance (VAD) scores with values represented lexically and numerically (in parentheses). The category of the emotions were used when selecting which emotions to use but were not integrated into the generation nor shown to participants.",
            "Model One | Two | Three | Acc     GPT-4, 1x 1.00 | 1.00 | .936 | .978 LLaMA-3, 1x | .908 | .897 | .781 | .862 LLaMA-3, 3x | .969 | .969 | .850 | .930 LLaMA-3, 10x | .981 | .981 | .853 | .938 \f"
        ],
        [
            "The Statistic data of the Scientific Paper, Subject, Total Questions ",
            "1ViOGe!  4-9B Models Phi-3.5-Vision [2] YI-VL [36]* Molmo-7B-O [6]* XComposer2.5 [37]* mPLUG-Owl3 [35] Qwen2.5-VL [3] Bunny [8]*  Idefics3 [14] MiniCPM-o 2.6 [1 1] InternVL2.5 [4] GLM-4v [7]* 11-78B Models Llama3.2-Vision [25]* DeepSeek-VL2 [33] InternVL2.5 [4] Qwen2.5-VL [3]  GPT-40 mini [12] GeminiFlash2.0 [28] GPT-4o0 [12]  Vale  2024-09 2024-06 2024-09 2024-07 2024-07 2025-01 2024-06 2024-08 2025-01 2024-12 2024-06  2024-09 2024-05 2024-12 2025-01  2024-07 2024-12 2024-11  frafam Uverall  Pit  Vir  rIiA  Pik  Open-Source Multimodal Large Language Models  4B 6B 7B 7B 7B 7B 8B 8B 8B 8B 9B  11B 27B 78B 72B  4.71 4.35 0.36 3.99 7.61 21.74 4.71 9.78 10.51 12.32 2.54  1.81 1.09 14.49 39.86  6.98 2.33 0.00 4.65 18.60 16.28 4.65 11.63 13.53 11.63 2.33  0.00 0.00 18.60 30.23  5.00 0.00 5.66  15.00 0.00 20.00 20.00 25.00 10.00 10.00 5.00 15.00 5.00  0.00 0.00 20.00 35.00  3.85 0.38 0.00 3.85 7.69 3.85 7.69 11.54 7.69 0.00  0.00  0.00  7.69 26.92  5.66 0.00 3.77 3.77 26.42 1.89 7.55 5.66 13.21 5.66  0.00 5.66 11.32 50.94  0.00 7.69 0.00 0.00 7.69 30.77 0.00 15.38 0.00 7.69 0.00  7.69 0.00 7.69 38.46  Proprietary Multimodal Large Language Models  25.58 35.00 26.92 39.62 34.42 23.26 30.00 30.77 39.62 48.55 44.19 40.00 46.15 54.72  32.61  46.15 30.77 84.61  LAU  3.23 1.61 0.00 i 4.84 16.13 4.84 6.45 6.45 4.84 1.61  3.23 0.00 6.45  35.48  30.65 35.48 37.10  Vid  0.00 0.00 0.00 0.00 0.00 10.00 0.00 10.00 0.00 0.00 0.00  0.00 0.00 0.00 0.00  10.00 30.00 20.00  PRL  11.43 5.71 0.00 2.86 5.71 45.71 5.71 20.00 31.43 4.84 0.00  5.71 0.00 34.29 68.57  37.14 40.00 65.71  PUL  0.00 0.00 0.00 0.00 0.00 11.11 11.11 0.00 0.00 Pedro 11.11  0.00 0.00 DDD 33.33  33.33 44.44 55.56  0.00 0.00 0.00 0.00 0.00 0.00 20.00 0.00 20.00 0.00 0.00  0.00 0.00 20.00 40.00  40.00 60.00 40.00 \f"
        ],
        [
            "MIC values of Temporin A novel analogues [µg/mL].",
            "O1 Hm GC N  Code  DTA * DTThr DTTyr10 DTTyr1  DT4F  Structure  FLPLIGRVL-S-GILNH> FLPLIGRVL-T-GILNH> FLPLIGRVL-Y-GILNH> Y-LPLIGRVLSGILNH> Phe(4F)- LPLIGRVLSGILNH>  Molecular Formula  Ces Hi117Ni7O14 C69 H119Ni7O14 C74Ay21Ni7O14 Cog Hi17Ni7015  Cog Hi16FN17O014  MMexact g/mol  1395.90 1409.91 1471.93 1411.89  1413.89  [M + H]* Observed g/mol  1397.00 1410.75 1472.70 1412.60  1415.05  [M + Na]t* Observed  g/mol  1418.95 1432.70 1494.70  1437.10  RT min  4.513 4.486 4.712 4.177  4.177  ap? [°] %%  —38 —A40 —38 —58  — 64  M.p. [°C 158 + 2 135 x 1  14521 123 + 2  141 +1 \f"
        ],
        [
            "Macroscopic and microscopic features of fungal isolates",
            "Isolate code B3S4 b B2S82 al B3S82 a B3S3 bl B4S4 b B3S1 b B3S3 b B3S4 b2 B3S1 A B4S4  Isolate accession number MZ569412 MZ569413 MZ569414 MZ569415 MZ569416 MZ569419 MZ569420 MZ569422 MZ569423 MZ569424  Amylase ++ ++  +++  +++ ++  +++ ++ ++ ++  Cellulase ++ + “bE “b= + +  +++ ++  Lipase  Esterase  Gelatinas “++ “+++ “+++ ~ +++  ++  ++ \f"
        ],
        [
            "M-spike;  C1, C3, C5,  C7,  C9, \nC12, MRD",
            "PURGE Ge atwy  Patient  10 Indexed Patient  Age  (years)  44  4]  48  57  67  29  61  55  44  30  Subtype SerumM- Free  IgG lambda IgA lambda IgG lambda  IgG kappa  IgG lambda  IgG lambda  IgG  IgG  IgG lambda IgG Lambda  IgG lambda  spike (g/dL)  NA  9.8  NA  NA  NA  NA  0.44  5.1  2.56  light chain ratio  2.85  NA  11.87  0.92  0.45  NA  NA  NA  2.3  45.4  BM examination  14% PC and lack of erythropoiesis.  12% PC, absent erythroblasts  20% PC, 8% ery- throid precursors  20% PC, 4% ery- throid precursors  9% PC, 3% ery- throid precursors  20% PC, <2% ery- throid precursors  6% PC, erythroid hypoplasia  7% PC, absent ery- throid precursors <35% PC,  absent erythroid precursors  15% PC, absent ery- throid precursors  Hgb  g/dL  3.4  NA  6.4  8.6  8.0  7.6  3.7  NA  9.0  4.2  Va VV WR CREW SBEUWE CECE We SAEED pees Wedd VIEOIVEUEWY SE OD UWVIVUIYwY AOU VV PURE BR ANUS  Reticu- locyte counts  0.05%  NA  6.9  15.4  6.4  NA  0.01  NA  0.09%  19x 107/L  Re WAAL i Ww RAL EN Ite us WIE est Aw ASS eid  Treatment  PAD (anemia per- sisted) thus switched to cyclosporine  cyclosporine rituximab  VD  RVD  LD  VAD  cyclosporine methylprednisolone cyclophospha- mide+ATG  plasma exchange IVIG followed by cyclosporine and  prednisone. VD  NA  VD, LD cyclosporine, alemtuzumab dara-VD, KD, ID, Isa-P daratumumab and dexamethasone  Response  resolution of anemia  resolution of anemia on rituximab, VGPR  resolution of anemia and decrease in M spike resolution of anemia  resolution of anemia and CR  PD  resolution of anemia and disappearance of M spike with VD  NA  VGPR  resolution of anemia, VGPR  SB VU VILLI VD  Ref  [4]  [5]  [6] (patient #2)  [6] (patie# 8)  [6] (patient #12)  7]  [8]  [10]  N/A \f"
        ],
        [
            "Results on specialized safety benchmarks: Sci-\nKnowEval (SciKE), SciSafeEval (SciSE) and LabSafety\nBench (LabSB)",
            "AdvBench (ASR, |) HarmBench (ASR, |) StrongReject (ASR, |)        Model Tuning Se I EE? Se eo w/o Att. +Prefill +AutoDAN +GCG _ w/oAtt. +Prefill +AutoDAN +GCG _ w/oAtt. +Prefill +AutoDAN +GCG  SFT 250 71.54 30.00. 72.00. 13.75. 47.50 30.00 58.23 5.75. 61.66 38.33. 80.00  DPO 539 71.92 56.00 76.00 27.50 47.50 43.75 56.25 10.54 67.73 66.67 81.67 Backtrack-SFT 1.54 64.42 50.00 76.00 5.00 38.75 31.25 42.50 2.24 61.34 45.00 65.00  WIE a cibtranil 1.54 76.54 56.00 82.00 8.75 48.75 36.25 47.50 1.92 70.93 40.00 63.33 ERPO-SET 0.00 0.58 0.00 0.00 1.25 8.75 125. 6.25 1.92 2.24 0.00 0.00  ERPO 0.00 0.38 0.00 2.00 1.25 2.50 0.00 3.75 0.64 0.96 0.00 (1.67  : 038 90.38 30.00. 36.00. 20.00 63.75 33.75. 45.00 224 88.82 33.33. 41.67  SET 0.00 66.54 4.00 78.00 5.00 56.25 15.00 50.65 0.32 71.88 8.33 75.00  DPO 038 76.92 78.00 80.00 15.00 48.75 47.50 48.05 2.56 79.87 80.00 76.67 Backtrack-SFT 0.00 7.88 0.00 70.00 6.25 40.00 12.50 49.37 0.64 11.82 1.67 75.00  eG let each 0.19 3.85 8.00 66.00 3.75 30.00 11.25 50.63 0.32 7.67 16.67 68.33 C2-SYN 0.96 72.12 32.00 38.00 16.25 61.25 33.75 45.00 1.60 77.64 40.00 45.00  ERPO-SFT 0.00 0.19 0.00 2.00 5.00 3.75 0.00 2.50 0.64 0.32 167 3.33  ERPO 0.00 0.00 0.00 2.00 5.00 3.15 0.00 2.50 0.32 0.96 0.00 1.67 \f"
        ],
        [
            "The comparative analysis results of the Deception Series (N = 42) and Non-Deception Series (N = 36)",
            "Tukey HSD  Bonferroni  Dunnett T3  (I) Class  (J) Class 1  CW; WIEN] FR] OFT] WIN] RFR |} OT] WS] N  Difference (I-J)  0.1250400 0.0444200 0.0620800 0.0343200 0.1250400 0.0444200 0.0620800 0.0343200 0.1250400 0.0444200 0.0620800 0.0343200  Standard Error  0.0218870 0.0218870 0.0218870 0.0218870 0.0218870 0.0218870 0.0218870 0.0218870 0.0239032 0.0184034 0.0122859 0.0150918  p-Value 0.000 00.269 0.051 0.525 0.000 0.483 0.068 1.000 0.003 0.249 0.002 0.299  95% Confidence Interval  Lower Limit  0.062849  —0.017771 —0.000111 —0.027871  0.060428  —0.020192 —0.002532 —0.030292  0.042172  —0.018431  0.021680  —0.016390  Upper Limit  0.187231 0.106611 0.124271 0.096511 0.189652 0.109032 0.126692 0.098932 0.207908 0.107271 0.102480 0.085030 \f"
        ],
        [
            "Experiments were carried out to measure the fluidity and loss of fluidity of cement pastes using national standard reference cements.",
            "Samples My (g-mol~?) Mw (g-mol~!) PDI  INPCE 45,179 77,074 1.71 TPCE 46,913 99,322 2.14 \f"
        ],
        [
            "The detailed information of Typographic Visual Prompt Injection (TVPI) Dataset",
            "Model  UnCLIP (DALL-E 2) IP-Adapter-SD1.5 IP-Adapter-SDXL IP-Adapter-FLUX  Clean  Jlatd 78.23 97.84 101.0  Harmful  naked bloody  76.14 121.0 113.6 114.8  74.3 110.9 104.5 119.9     Bias African 103.6 99.20 109.5 146.5  Asian 68.39 91.15 112.5 105.5     Neutral glasses hat 74.35 71.69 106.2 96.97 105.5 106.6 122.8 115.1    \f"
        ],
        [
            "The Math Reasoning and Daily Tasks dataset of different Language, Source, Type, #Samples and Total tokens",
            "Reflection Type  wait, alternatively, however, actually,  let  verify actually verify.  wait. recheck  wait, alternatively, let  wait actually, actually wait.  verify however, verify.  Correct Count  Pensez  271 10 13 4 14 16 2 2 2 0  DeepSeek  185 26 11 10  5  Co OF We  Incorrect Count  1830 528 501 123  86  34  21 4 ] ]  2319 540 156  2 22 13 11  Total  2101 538 514 127 100  SO 23 6 3 |  2504 566 167  37 27 14 14 \f"
        ],
        [
            "This study selected 15 HRV features listed in Table that might have potential in mated to predict mental workload,  including 4 time domain features, 8 in the frequency domain, and 3 non-linear features.",
            "Applied Features eatures (n = 6) eatures (n = 8) ovement features (n = 8) ovement features (n = 5) ovement features (n = 4) ovement features (n = 4) ovement features (n = 3) ovement features (n = 3)  ovement features (n = 3)  und eye movement features (n = 24)  Prediction Accuracy  KNN, 90.00% KNN, 90.00% KNN, 78.33% KNN, 78.33% KNN, 78.33% SVM, 78.33% KNN, 78.33% LDA, 78.33% SVM, 78.33%  RF, 88.30%  Model Evaluations  Recall = 0.900, Precision = 0.900, F1 = 0.900, AUC = 0.905 Recall = 0.933, Precision = 0.875, F1 = 0.903, AUC = 0.887 Recall = 0.800, Precision = 0.774, Fl = 0.787, AUC = 0.771 Recall = 0.800, Precision = 0.774, Fl = 0.787, AUC = 0.779 Recall = 0.800, Precision = 0.774, F1 = 0.787, AUC = 0.817 Recall = 0.800, Precision = 0.774, F1 = 0.787, AUC = 0.844 Recall = 0.800, Precision = 0.774, Fl = 0.787, AUC = 0.783 Recall = 0.800, Precision = 0.774, F1 = 0.787, AUC = 0.790 Recall = 0.800, Precision = 0.774, F1 = 0.787, AUC = 0.836 Recall = 0.867, Precision = 0.897, F1 = 0.881, AUC = 0.912     —— HRV(n=8) (AUC=0.887)  m= == HRV(n=6) (AUC=0.905)     0.6  0.8  1.0 \f"
        ],
        [
            "The globally ASMRs and ASDRs of kidney dysfunction-attributed stroke and subtypes and temporal trends in 1990–2021",
            "                     1990 2021 AAPC ASMRs ASDRs ASMRs ASDRs ASMRs ASDRs (95%UI) (95%UI) (95%UI) (95%UI) (95%Cl) P value (95%Cl) P value Stroke Both sex 19.8 393.0 10.2 198.8 -2.17 < 0.001 -2.22 < 0.001 (12.7 to 27.8) (274.2 to 535.3) (6.4 to 14.2) (137.7 to 270.7) (-2.5 to -1.84) (-2.51 to -1.93) Men 21.6 A179 13.2 245.4 -1.62 < 0.001 -1.65 < 0.001 (13.5 to 30.7) (281.6 to 583.1) (8.2 to 18.8) (163.7 to 343.6) (-2.02 to -1.22) (-2.03 to -1.27) Women 18.7 3753 8.2 161.0 -2.63 <(Q.001 -2.68 < (0.001 (11.9 to 26.2) (255.4 to 508.9) (5.1 to 11.9) (108.7 to 224.8) (-2.89 to -2.37) (-2.91 to -2.45) IS Both sex 6.9 129.9 A9 92.7 -1.08 < (0.001 -1.09 <(0.001 (4.2 to 9.8) (87.3 to 178.8) (3.0 to 7.0) (62.2 to 128.8) (-1.43 to -0.74) (-1.45 to -0.72) Men 76 139.2 64 112.4 -0.58 0.005 -Q.72 0.001 (4.6 to 11.2) (91.7 to 198.3) (3.9 to 9.2) (74.4 to 158.0) (-0.99 to -0.18) (-1.15 to -0.28) Women 6.4 124.1 40 7/9 -] 51 < 0.001 -] 46 < 0.001 (4.0 to 9.1) (84.7 to 170.8) (2.4 to 5.8) (50.5 to 109.4) (-1.84 to -1.18) (-1.78 to -1.15) ICH Both sex 12.9 263.1 5S 106.2 -2.81 < 0.001 -2.88 < 0.001 (8.4 to 18.1) (186.1 to 355.3) (3.5 to 7.5) (73.9 to 143.0) (-3.02 to -2.59) (-3.11 to -2.64) Men 13.9 278.7 6.8 133.0 -2.29 < 0.001 -2.35 < 0.001 (8.9 to 19.8) (187.6 to 385.5) (4.4 to 9.5) (89.2 to 185.0) (-2.61 to -1.96) (-2.58 to -2.12) Women 12.3 251.2 4.3 83.1 -3,38 < (0.001 -3.51 <(0.001 (7.8 to 17.3) (171.8 to 344.2) (2.7 to 6.1) (55.8 to 115.8) (-3.61 to -3.14) (-3.78 to -3.23)    \f"
        ],
        [
            "Sociodemographic, Marital status,Exposure to stressful events of interviewers",
            "   Remembered Well-Being        Profile Anxiety Depression Clinical Diagnosis M SD M SD M SD Depression GAD Panic Disorder G1: Healthy 9.68° 0.31 1.02° 0.04 1.17? 0.17 : : - G2: MMH= Anx 8.94? 0.79 1.20° 0.14 1.48° 0.30 1(0.7%) 1(0.7%) : G3: MMH + Anx 8.366 1.25 171° 0.39 1.58° 0.33 1(0.5%) 5 (2.7%) 10.5%) G4: Distress 741° 1.58 2,1 5° 0.78 2.68° 0.57 19 (12.0%) 19(12%) 3(1.9%) ANOVA F(3,569) = 84.78 ** F(3,569) = 156.8** F(3,569) =407.0 **    \f"
        ],
        [
            "Factor of Average age (years), Average body mass index (kg/m2), Sex (Male/Female)",
            "Case No.  SOMPNDOTRWN  Instrumented Segments  Left T2 and bilateral T3 to L2 Bilateral T2 to L4 Bilateral T2 to L2 Bilateral T5 to L5 Bilateral T2 to L2 Bilateral T3 to L2 Bilateral T2 to L3 Bilateral T3 to L3 Bilateral T1 to L3 Bilateral T2 to L5  Largest Preoperative  72  98 45 60 85 78 72 52 79 124  Largest Postoperative Cobb Angle (°)  Cobb Angle (°) \f"
        ],
        [
            "The SQuAD accuracy results",
            "KV retention  100% 20% 10% 5% 1%  H2A  23.7 22.8 22.4 21.9 21.1  Hol  23.7 20.6 18.6 18.5 18.3  Zero Shot  23.7 Dod Nee 21.1 20.1  Finetune  23.7 23.5 23.3 23.2 22.8 \f"
        ],
        [
            "recent studies based on using the Wavelet transform-based model during solar radiation prediction",
            "Influence (%)  0.0069 | 60.47% ch 0.0109 | 153.49% ittagon oe 0.0052 | 20.93% db  0.0043 | 0% (Base)  dbl | 0.0121 98.36%  db2 0.0067 | 9.84% nhake 02 0.0067  db3 0.0069 | 13.11% db4 0.0061 | 0% (Base)       \f"
        ],
        [
            "Categorized Distribution of Absolute Rotation Data",
            "Images Analyzed at Given Time Point pf Follow up Rate  Table 3 Availability of Calculated Rotation Data     Visit Comparisons* Follow up Rate  Lens Model VO-VI | VO- V2 |} VO- V3 | VO- V4 | V3 - V4  foe [oe fw foe [me fm [we [we |    \f"
        ],
        [
            "The Awareness, Selection, Capability of different Model and Type LLM and LRM",
            "Dataset  METATOOL API-Bank PlanBench ALFWorld  Web Shop HotpotQA  Test data (Ours)  Size  110 SS 165 SS SS 5S 495  Dataset Information  Domain  Tool Usage Tool Usage Plan Design Problem Solving Problem Solving Problem Solving Agentic Task  Evaluation Method  Dimension  Awareness & Selection Capabilities Generation & Execution & Re-plan Real-World Web Shopping Knowledge QA Overall  Metric  Accuracy Accuracy Accuracy Accuracy Accuracy Accuracy Accuracy & Efficiency & Cost \f"
        ],
        [
            "Performance of the Lamoid with and without norms across the metrics",
            "Instruction Type Count  Clear 20 Incomplete 5 Invalid 11 Irrelevant 6  Ambiguous 13 \f"
        ],
        [
            "the performance of seven LLMs with native function calling support and three large reasoning models",
            "Constraint  amount_positive_restr appointment_date_valid claim_status_ denied claim_within_coverage_amount claim_within_limits income_proof_enough  internal _check_claim_ exists internal_check_provider_exists internal check_username_ exist logged_in_user  login_user  no_pending_claims policy_active  policy_inactive policy_type_valid provider_authorized provider_available provider_covers_policy provider_not_already_authorized within_appeal_period within_enrollment_period  | Verification Actions  None  internal_get_interaction_time  get_claim_details OR get_claim_history get_policy_details AND (get_claim_history OR get_claim_details) None  None  internal _check_claim_ exists internal_check_provider_exists internal check _username_ exist  login_user  login_user  get_claim_history  get_policy_details  get_policy_details  None  get_policy_details  get_provider_details  get_policy_details AND get_provider_details get_policy_details  internal_get_interaction_time AND (get_claim_details OR get_claim_history) get_policy_details AND internal_get_interaction_time \f"
        ],
        [
            "Overall, the Lamoid with norms outperformed the Lamoid without norms across all metrics",
            "Instruction Type Violation of Gricean Norm  Clear No Violation  _, | Incomplete Quantity Violation 8 | Invalid Quality Violation 5 Irrelevant Relation Violation  Ambiguous Manner Violation \f"
        ],
        [
            "Average Surface Roughness, Root Mean Square and Maximum Heigh shown in the table",
            "Sample PVDF (wt.%) NMP (wt.%) CNM/PAC (wt.%)  PO 14 86 -~  P1 14 86 0.1 p2 14 86 0.2 P3 14 86 0.3 p4 14 86 0.4  P5 14 86 0.5 \f"
        ],
        [
            "Univariate analysis of clinicopathological characteristics associated with DFS and OS",
            "Characteristics  T stage Tl T2 T3 T4 N stage NO N1 N2 N3 MP grade 1+2 3 4+5 Capecitabine No Yes Type of surgery Breast-conserving Mastectomy  DFS HR  0.54 0.42 1.65  so 9.54 19.20  0.73 0.24  0.60  95 %CI  0.23-1.26 0.15-1.21 0.61-4.49  1.22-10.34 2.84-32.11 6.82-54.03  0.44-1.24 0.13-0.47  0.37—0.97  p-Value 0.013  0.16  0.11  0.32 <0.001  0.02 <0.001 <0.001 <0.001  0.25 <0.001  0.036  OS HR  0.30 0.52 0.79  1.91 8.04 15.53  1.11 0.12  0.44  1.26  95 %CI  0.09-0.99 0.12—2.24 0.18-3.47  0.36-10.17 1.29-50.08 3.05-—79.10  0.47-2.21 0.03-0.45  0.20-0.96  0.25-6.45  p-Value 0.12  0.046  0.38  0.76 <0.001]  0.45 0.02 0.001 0.004 0.97 0.002 0.04  0.78 \f"
        ],
        [
            "results  for LLama3-8B, NarrativeQA, Qasper, hotpotQA, Musique",
            "JA  IQA-en IQA-zh  (zh)  zh)  ount ‘trieval-en trieval-zh  h-P  Full  21.3 28.9 52.3 50.9 40.6 29.3 24.4 30.2 34.1 24.5 27.7 11.3 71.0 87.7 42.5 38.0  1.0 80.5 61.2 37.5 38.0  Duo  25.1 27.8 50.8 52.64 42.45 30.13 229 29.84 32.1 24.61 27.8 7.6 73.0 86.9 41.37 31.5 1.0 82.5 61.64 37.1 39.4  SLLM  24.4 19.8 45.6 37.3 34.0 257 21.6 2S ath 32.2 22.8 26.3 13.03 68.0 85.0 40.6 27.2 1.0 42.5 51.5 40.3 41.6  H20  25.26 21.2 38.7 37.3 38.6 28.1 21.6 Dd ut 28.5 22.8 25.0 13.0 64.5 85.7 40.8 27.2 1.5 68.5 51.5 41.39 40.0  NAtS  23.95(20%) 28.74(36%) 50.91(31%) 48.13(37%) 40.76(25%) 25.47(27%) 23.18(24%) 26.41(29%) 33.97(29%) 23.63(23%) 27.92(40%) 8.03(28%)  69.5(30%)  87.36(26%) 41.32(20%) 37.0(29%)  5,14(30%)  75.05(22%) 45.79(32%) 38.3(44%)  39.72(35%)  NarrativeQA Qasper MultiFieldQA-en MultiFieldQA-zh HotpotQA 2WikiQA Musique DuReader (zh) GovReport QMSum MultiNews VCSUM (zh) TREC  TriviaQA SAMSum  LSHT  Passage Count PassageRetrieval-en PassageRetrieval-zh LCC RepoBench-P  Full  Zo 41.3 52.5 58.0 49.6 40.0 28.4 34.9 34.9 Lost 27.9 16.3 75.5 88.9 47.3 39.8  5.5 98.0 96.5 50.7 54.8  Duo  26.9 35.6 52.5 55.4 52.94 39.3 29.45 36.44 32.1 24.2 27.0 15.6 74.5 87.4 44.9 37.5 6.0 99.0 96.5 51.1 53.6  SLLM  27.3 25.1 47.0 49.1 42.0 32.8 21.5 34.5 32.6 £29 26.3 15.7 69.5 88.6 46.1 30.0  3.0 56.0 46.5 49.3 52.3  H20  24.0 27.9 40.1 39.4 47.2 38.1 20.6 26.8 30.6 Ddiod 25.6 15.8 66.0 88.4 45.8 31.5 4.0 81.0 76.0 52.23 55.66  NAtS  28.2(25% 39.84(409 52.8(36% 56.26(329 52.1(34% 39.75(379 24.3(33% 34.42(269 33.73(339 25.19(31¢ 27.32(47¢ 16.04(249 75.0(42% 89.05(359 46.46(29° 40.5(26% 4.5(34%)  94.5(30% 87.5(28% 51.84(509 54.51(459 \f"
        ],
        [
            "Efficacy and safety outcomes",
            "Study ACCORD  BPROAD ESPRIT  RESPECT  SPRINT  Year 2010  Zee  2024  2019  2021  Geographical region USA, Canada China China  Japan  United States  Number of sites 77  145  116  140  102  Total  sample Study population size Type 2 diabetes mellitus 4733 Type 2 diabetes mellitus 27321  High cardiovascular risk, with 11,255 and without diabetes or previous stroke  History of stroke within previous 1263 3 years  Increased risk for cardiovascular 9361 disease but no diabetes or  previous stroke  Pimary  outcome  Follow-up* MACE 4.7 years” MACE 4.2 years MACE 3.4 (3.0-3.4)  years  Recurrent 3.9 + 1.5 years stroke MACE 3.33 years \f"
        ],
        [
            "For each type of claim, we report the percent of those claims for which all three annotators agree on the faithfulness label",
            "Metric Original claims Rewrites  Agreement 36.36 97 .45* Faithful 20.45 89.36** Preferred 23.08 76.92** \f"
        ],
        [
            "Patients’ demographic data",
            "Total GRSA GRS B GRSC Accuracy  T-spine 197 132 60 5 97 4% L-spine 60 41 19 0 100.0% \f"
        ],
        [
            "Descriptions of HRV features employed",
            "Eye Movement Features  Total fixation duration (TFD)  Average fixation duration (MFD)  Total fixation count (TFC)  Saccade count (SC)  Average velocity of saccades (MSV) Average amplitudes of saccades (MSA) Mean pupil diameter (MPD)  Standard deviation of pupil diameter (SPD)  NT-Task (Mean + SD)  19.69 + 3.26 9.79 + 3.90 2381.33 = 1222.07 2217.33 + 1151.18 992.79 + 74.17 16.36 = 2.79 3.319 + 0.584 0.550 + 0.180  HT-Task (Mean + SD)  22.63 + 6.88 5.99 + 2.74 4240.33 + 1739.35 3597.33 + 1618.87 561.00 = 74.94 16.57 + 2.82 3.349 + 0.441 0.630 + 0.272  —2.266 5.161 —6.933 —9.472 —0.555 —0.466 —0.370 —1.395  0.031 <0.001 <0.001 <0.001  0.583  0.645  0.714  0.174 \f"
        ],
        [
            "various cell types and the number of cells in the dataset",
            "sor [vy ||| 788 [an [aso [735 [92 [002 [oss [ast |a2s (613 [van [ora [753 [918 | 810 soz [vv | || [752 [886 [900 [730 [os [oes [ros [apa [ars [e22 [ois [722 |70 [921 | si sor [vv | | |v 776 [918 [909 [735 [ove [ors [rir [ois [wa [ois [oun (755 [751 [924 [ais  SIN 1 |S \f"
        ],
        [
            "electrochemically grown nanostructures on copper were found to be key materials in numerous applications, including electro-catalysis",
            "% Zn  30%  32 + 1% (EDS)  35%  35.54% (EDS)  37%  37%  37%  NA; “Cu-Zn”  5% Zn (ASME SB36 C210)  Passivation System and Procedure  Two-electrode cell, 0.1 M or 1.0 M NaHCOs, 12 V, RT, 5 min  Two-electrode cell, 0.1 M NaOH, 30-60 V  Two-electrode cell, 0.1 M NaOH + 0.025 M NH,Cl, 12 V, 25 °C, 15, 30, or 45 min  Two-electrode cell, 0.05-0.3 M NaOH or KOH, 3-24 V, 15-120 min  Three-electrode system,  1.0 M NaOH, from —200 to  500 mV vs. Ag! AgCl, RT  Three-electrode system, 1.0 M NaOH, from 100 to 300 mV vs. He! HgO!13M KOH, RT; from 0 to 30 vol. % Of glycerol was added into electrolytes  Three-electrode system, 1.0-3.0 M NaOH, 0 or 100 mV vs. Hg! HgO!l3 M KOH, RT  Two-electrode system, 1.0 M (COOH)», 40 V, RT, 25 min  Three-electrode system, 1.0 M KOH, —0.05, and —0.065 V vs. Hg! HgO, RI, 125s  Remarks  Samples were annealed in an air atmosphere at 450 °C for 3.5 h; applied in photoelectrochemical water splitting; IPCE at ca. 400 nm was ca. 15%  Obtained samples were annealed at 200 °C for 2 h; nanocrystalline mixed oxide was formed  A developed surface area, nanocrystalline CuO-ZnO composite was formed, which was found to be a successful catalyst for methylene blue photodegradation  The nanostructures were obtained in 0.1 M NaOH at 12 V for 60 min and 0.2 M KOH at 6 V for 60 min. Both CuO and ZnO were detected by XRD  The impact of the passivation potential on the morphology of the formed passive oxides was investigated; photodegradation of methyl orange was performed  In the study, the impact of the glycerol on the morphology and composition of the grown nanostructured passive films was investigated; the erown nanostructures were used as a cathode in the electrochemical carbon dioxide reduction reaction, and it was revealed that the best samples are the ones obtained in 1.0 M NaOH without additives  Cu, CuAgjo, and Cug3Zn37 were oxidized using a potentiostat; the samples were examined before and after the electrochemical carbon dioxide reduction reaction to compare systematically the chemical composition and morphology before and after the reaction  Cu-Zn anodization was used to increase the surface area of deposited NiO; developed morphology  Depending on the applied potential, different morphologies were obtained; anodized brass lowered the onset potential for methanol electrooxidation (1.0 M KOH + 1.0 M CH308H); based on EIS, also charge transfer resistance was low for the anodized samples  Reference  [99]  [100]  [101]  [102]  [103]  [104]  [85]  [105]  [106] \f"
        ],
        [
            "Accuracy (%) evaluation on datasets with different\npermutation order and base model as Llama-3.2-3B",
            "Vanilla RC-Aug  SCoP-8 MEND-RC MEND  VoVo (1) 1.00 3.70E+00 3.28E-01 2.03E-01  4.47E-02 VoV; (J) 1.00 1.55E+00 3.81E-03 3.53E-03_2.23E-03 \f"
        ],
        [
            "The capabilities of FeRG-LLM are compared with those of other recent models including CAAFE (Holl-mann et al., 2024) and FeatLLM (Han et al., 2024). A ✓ indicates that a criterion is met while a ✗ indicates that it is not",
            "Dataset | CAAFE+TabPEN  Bank Nhanes Diabetes Cultivar Credit Ethereum Churn Ad-click Aging-npha Infrared-t Itpd-indian Support2 Heart-failure  Gloma  NaN 79.01 + 0.68 80.47 + 1.11 71.43 + 4.93 82.01 40.91  NaN 92.38 + 0.39 63.85 + 0.00 96.40 + 0.81 86.04 + 0.35 80.53 + 0.98 85.38 + 0.05 87.63 + 2.23 90.79 + 0.30 \f"
        ],
        [
            "GPT-4o, GPT-4o mini, DeepSeek-V3, ERNIE, Roberta performance comparison",
            "Processing Target  Text filtering.  Theme or keyword ex- traction.  | Prompt  LR BOR, Te AT Ee BAA BABE o FPR RTPA A ile REG HAE EE RSet, FP ELSCA ETE RC ° Ar aa TT GRIP BUT BRIE” o MC ANUH FP:  { SCAB}  The following is a piece of text. Please determine whether it has a sense of humor. The text must be a single joke with humor and contain no other elements. Simply output \"4F Gt\" (Valid) or \"WAFS 7F\" (Invalid). The text is as follows:  {Text} FA tal ATTA TSN EAE], CSE RUA ETB A]: (Ser5}  Use simple words to describe and summarize the theme/keyword of this joke. Output only the theme/keyword: {Joke} \f"
        ],
        [
            "Parameter, Condition and Value of CORM-2",
            "Manuscripts  Blood Coagul. Fibrinolysis. 2009, 20, 377-380. Blood Coagul. Fibrinolysis. 2009, 20, 448-455.  Blood Coagul. Fibrinolysis. 2010, 21, 41-45.  Blood Coagul. Fibrinolysis. 2010, 21, 101-105. Blood Coagul. Fibrinolysis. 2010, 21, 298-299.  Thromb. Res. 2010, 126, 68-73.  Blood Coagul. Fibrinolysis. 2010, 21, 349-353. Blood Coagul. Fibrinolysis. 2010, 21, 584-587.  Anesth. Analg. 2010, 111, 1347-1352. J. Trauma. 2011, 70, 939-947 Blood Coagul. Fibrinolysis. 2011, 22, 60-66.  Blood Coagul. Fibrinolysis. 2011, 22, 345-348. Blood Coagul. Fibrinolysis. 2011, 22, 362-368. Blood Coagul. Fibrinolysis. 2011, 22, 443-447.  Citations !  30 21 6 12 2 5 11 10 4 3 6 11 2 23 \f"
        ],
        [
            "comparison between our model and the baselines",
            "Dataset IHS DIALOCONAN YELP  Tasks Mental Health Intervention Hate Speech Countering Sentiment Style Transfer Outcome Effectiveness of Intervention Toxicity of Speech Positivity of Sentiment \f"
        ],
        [
            "Compare the capabilities of FeRG-LLM with other models",
            "Parameter  max_depth learning_rate n_estimators subsample colsample_bytree  Values  3,5, 7  0.01, 0.1  50, 100, 200 0.8, 1.0  0.8, 1.0 \f"
        ],
        [
            "Onwer's feeling or opinion towards caring for their cats",
            "Factor  Veterinarian recommendation  Veterinarian and internet recommendation (internet forums, group discussions or reading material online)  Veterinarian and veterinary nurse recommendation  Veterinarian and other recommendation  Internet recommendation (internet forums, group discussions or reading material online)  Other recommendation”  Veterinarian, internet and other recommendation Internet and other recommendation  Veterinarian, internet and friend recommendation No renal prescription diet ted  GO =| —i —i ©) \f"
        ],
        [
            "Current evidence on malignant mesenchymal tumors of the breast - focus on sarcomas and phyllodes tumors",
            "Study (Year)  Chawla et al. [105] 2017  Study (Year)  Maki et al. [107] 2007  GeDDis trial [108] 2017  Patients (n)  433  Patients (n)  122  257  ALDOXORUBICIN—Randomized Controlled Trials  Population  Relapsed/refractory STS (Leiomyosarcoma,  Liposarcoma, Synovial sarcoma, L-sarcomas subgroup, Others *)  Endpoints  PFS  Median Follow-Up  Comparative Arms  Aldoxorubicin  VS.  Investigators’ choice (Dacarbazine, Doxorubicin, Pazopanib, Ifosfamide, Gemcitabine / Docetaxel)  GEMCITABINE—DOCETA XEL—Randomized Controlled Trials  Population  Metastatic STS (Leiomyosarcoma, Non-leiomyosarcoma, Liposarcoma, MFH/UPS, Others *)  Previously untreated advanced unresectable or metastatic STS  (Uterine /Non-uterine leiomyosarcoma, Synovial sarcoma, Pleomorphic sarcoma, Others *)  Endpoints  PFS, OS  PFS  Median Follow-Up  Comparative Arms  Gemcitabine-Docetaxel (n = 73) - VS. Gemcitabine alone (n = 49)  Doxorubicin (n = 129) 22 months VS. Gemcitabine-Docetaxel  (n = 128)  Key Results  Overall PFS: 4.06 vs. 2.9 months (p = 0.12; HR = 0.82)  L-sarcomas PFS: 5.32 vs. 2.96 months (p = 0.007; HR = 0.62)  Key Results  PFS: 6.2 vs. 3.0 months OS: 17.9 vs. 11.5 months  PES: 23.3 vs. 23.7 weeks (p = 0.06; HR = 1.28)  No treatment-related deaths (2 deaths due to disease + treatment) \f"
        ],
        [
            "Wanda, SliceGPT, SLEB performance comparison",
            "Methods  Dense  Wanda SliceGPT SliceGPT  SLEB SLEB  EvoP EvoP  O%  SO% 10% 20% 10% 20%  10% 20%  6.52  12.53 18.42  43.77 7.62  9.38  755 8.97  Sparsit WikiText2-C4 p Y  Llama-2-13b  OPT-13b OPT-30b Llama-2-13b OPT-13b OPT-30b  12.07  18.94 14.04 19.24 12.44 15.22  12.37 13.69  11.46  22.08 13.09 16.74 12.36 13.76  11.68 13.14  4.57  8.58 9.69 22.72 5.33 6.31  5.26 6.33  C4-WikiText2  10.13  17.51 11.91 17.16 10.56 12.40  10.38 11.42  9.56  16.42 11.26 15.03 9.65  10.22  9.65 10.15 \f"
        ],
        [
            "MemoryLLM，CAMELoT，RMT，MELODI，MemoRAG performance comparison",
            "Document Paragraph Sentence Entity  #Samples 2,178 10,198 50,989 =: 152,968  Max. Length 9.528 1,803 42 12 Min. Length 1,356 207 364 I  Avg. Length 7,470 1,537 319 3 \f"
        ],
        [
            "Model performance for SALMONN, MU-LLaMA, OpenMU",
            "Model  (1): NExT-GPT w/ Music4way  (1) + MIE  (1) + PT (6-layer)  (1) + MIE + PT (6-layer)  (1) + PT (2-layer)  (1) + MIE + PT (2-layer)  (1) + PT (1-layer)  (1) + MIE + PT (1-layer)  (2): (1) + Music4way-MI2T & Music4way-MV2T (2) + MIE (DeepResonance-a)  (2) + PT (6-layer)  (2) + MIE + PT (6-layer)  (2) + PT (2-layer)  (2) + MIE + PT (2-layer)  (2) + PT (1-layer)  (2) + MIE + PT (1-layer) (DeepResonance-/3)  BLEU-1 BLEU ROUGE-P ROUGE-R ROUGE-F1 BERT-P BERT-R- BERT-F1  24.2 23.7 20.6 12.0 23.0 10.7 19.4 15.1 43.8 44.6 48.6 49.1 47.9 49.0 48.4 49.2  1.7 1.7 1.3 0.3 1.8 0.2 1.4 0.6 8.7 D2 15.5 15.7 15.9 17.1 16.6 17.2  25.1 30.0 30.8 25.4 32.8 29.2 30.5 30.1 28.0 27.8 37.1 36.3 36.7 36.7 37.3 36.8  23.6 18.5 17.8 14.6 19.9 11.8 17.1 14.6 34.0 33.8 36.2 36.9 36.5 38.3 37.0 38.3  22.0 2d 21.0 16.2 23.3 16.0 20.7 18.8 30.1 30.1 36.1 36.1 35.8 36.7 36.4 36.8  85.7 87.9 87.6 85.0 87.8 86.9 87.6 87.4 88.8 89.1 90.0 90.1 90.1 90.0 90.3 90.1  85.3 85.8 85.5 84.1 85.9 84.3 85.5 84.9 89.5 89.6 90.1 90.1 90.1 90.3 90.2 90.3  85.4 86.8 86.5 84.5 86.8 85.6 86.6 86.1 89.1 89.4 90.0 90.1 90.1 90.1 90.2 90.2 \f"
        ],
        [
            "Perplexity Comparison Across Models and Fine-Tuning Formats",
            "Organization Model Name Parameters (B) Instruction-Tuned? Links  Meta Llama-2-7b 7 No Meta Llama-2-7b-chat-hf 7 Yes \f"
        ],
        [
            "The comparison between frequency and distress",
            "‘Man |Range (1 |2|3_ 4 | 000100 (8) oootoo a= oooto0 ar ea “a —  = =  Variables  Ss  —_,  oO a8  wlS  ~J  Loneliness Frequency  0  IS O)  Loneliness Distress Chronic Loneliness 0. Interpretation Bias 0.  Rejection Sensitivity  , 0.00 — 0.23 0.00 _ 0.30 0.50 0.00 _ _ 1.84 1 | | 9.64 (4.69 | 9.00 | 1.38-36.00 41% 4am 34m | 55m (83) |  7 (6.73 so (87) | Distress Disclosure 38.29 | 10.36 -17** | -14** | 210% Self-Esteem 18.39 (7.09 19.00 | 0.00-30.00 | -.37*™| -.47™* -.37%™| ..4B™ -.55%| 45% 30\" (92) | Avoidance Goal Intensity 3.66 0.55 3.69 1.46-5.00_|.14™* | 30 20\" | .14™ | 20\" | 08\" |-03 | -30\"* (83) | Depressive Symptoms _| 10.22 6.21 | 9.00 | 0.00-27.00 | .36™** | .52\"* | 40 | game | gee 3am | 21\" | -.69\"™) 28\" (88) _  Social Anxiety Symptoms (.85)  Social Avoidance Behavior | 19.5 .  oO}; Oo | oOo \f"
        ],
        [
            "The immunohistochemistry group’s patients exhibited certain clinical baseline characteristics",
            "a we NP id LymphInvolvement HBV  HBsAg  HBsAb  HBeAg  HBeAb  HBcAb  HCV  NR resection SALON  History of diabetes Blood glucose AFP  PLT  INR  PT  Alb  Tbil  ALT  AST  Cr  Neutrophils Lymphocytes  TBA  Ascites  HPVO  Bleeding  Blood transfusion  Ni antae  HR  5.163555123 1.981862926 1.040285961 1.031624845 1.037577407 1.059305462 1.011282609 3.260814992 1.991111684 0.790983763 1.215874605 1.421996337 1.043871512 0.804551742 2.172191567 2.544385503 0.215057185 1.017648564 1.120173541 1.412947951 0.833764197 0.887616736 0.463857336 1.1286698  0.796044265 1.007400524 1.156178712 1.400583592  HR.95L  0.713264329 0.869869858 0.966401427 0.922251054 0.943249229 0.861328306 0.722103984 0.453339774 0.873240084 0.469983601 0.724006013 0.786763027 0.988249 149 0.587306447 0.152622683 0.692424698 0.08228456  0.726358368 0.916197146 1.170144714 0.456721313 0.593116713 0.279794524 0.955590736 0.41532599  0.917211573 1.013852899 0.811428507  HR.95H 37.38067419  4.515365858 1.119819209 1.153969753 1.141338728 1.302787861 1.416267654  23.45462503  4.540018044 1.331227965 2.041904387 2.570117699 1.102624509 1.10215631  30.91556319  9.349605246 0.562068906 1.425754347 1.369561963 1.706132489 1.522072033 1.328344746 0.769005857 1.333097391 1.525756847 1.10645771  1.3184843384 2.417507375  p value  0.104077265 0.103495651 0.293376042 0.586097754 0.448119464 0.58520967  0.947943923 0.240349481 0.1014945384 0.377343909 0.459918815 0.243693221 0.124326672 0.175657955 0.566950436 0.159596954 0.001716624 0.919006651 0.268490376 0.000326535 0.553829175 0.562196958 0.002898393 0.154121609 0.491973599 0.877545561 0.030369739 0.226409511 \f"
        ],
        [
            "compare ReaRAG-9B result with other models",
            "Ground truth: Orleans County Search-ol  ... Simplified here. Maybe | can search for \"Holley, New York county\" to find out which county it’s part of. <|begin_search_query|>Holley, New York county<|end_search_query |> <|begin_search_result|>Holley is located in Orleans County, New York.<|end_search_result|>  ... Simplified here. But wait, let me double-check to make sure that Holley is indeed in Orleans County. Sometimes place names can be ambiguous, and there might be multiple Holleys in different counties or states. Let me search for \"Holley, New York county\" again to confirm. <|begin_search_query |>Holley, New York county<|end_search_query |> <|begin_search_result|>You have searched this query. Please refer to previous results.<|end_search_result|>  Alright, since the previous search already indicated that Holley is in Orleans County, New York, and no other information contradicts that, I can confidently say that William W. Blair was born in Orleans County.  However, to be thorough, perhaps I should verify if there are any other places named Holley in New York or elsewhere that might be confused with the one where William W. Blair was born.  Let me search for \"Holley, New York\" to see if there’s only one such place. <|begin_search_query|>Holley, New York<|end_search_query |> <|begin_search_result|>Holley is a village ... Simplified here. <|end_search_result|>  But just to cover all bases, maybe there’s another Holley in New York state that I should consider. Let me search for \"New York state places named Holley\" to see if there are multiple locations with that name.  <|begin_search_query|>New York state places named Holley<|end_search_query |> <|begin_search_result|>Holley is a village ... Simplified here. <|end_search_result|>  Search-ol continues to execute excessive and unnecessary searches. Only search queries are listed here for simplicity. <|begin_search_query |>William W. Blair historian<|end_search_query |> <|begin_search_query|>William W. Blair Latter Day Saints<|end_search_query |> <|begin_search_query|>William W. Blair birth certificate Orleans County<|end_search_query |> <|begin_search_query |>William W. Blair biography<|end_search_query |>  Perfect, so this biography confirms that he was born in Holley, Orleans County, New York. This aligns with all the previous information I’ve found.  Therefore, I can confidently say that William W. Blair’s birthplace is located in Orleans County. ... Simplified here.  Final Answer  Orleans County \f"
        ],
        [
            "LLM-as-a-judge without access to tools or reference answers shows competitive macro F1 scores",
            "Candidate  GPT-3.5  GPT-40  Gemini  Task  AmbigQA HotpotQA  AmbigQA HotpotQA  AmbigQA HotpotQA  EM  0.541 0.596  0.482 0.544  0.555 0.490  Fl  0.660 0.755  0.55 0.662  0.567 0.662  Judge w/o Tool GPT-3.5 GPT-40 Gemini 0.230 0.394 0.584 0.156 0.258 0.348 0.238 0.381 0.566 0.169 0.375 0.363 0.195 0.346 0.255 0.172 0.272 0.265  0.572 0.413  0.603 0.540  0.639 0.633  TALE  GPT-40  0.796 0.557  0.914 0.701  0.746 0.693  GPT-3.5 Gemini  0.662 0.525  0.914 0.679  0.670 0.594 \f"
        ],
        [
            "Total number of various cells and their corresponding counts in the RSLI, LISC, WBCDD, and BCCD datasets",
            "sor [vy ||| 788 [an [aso [735 [92 [002 [oss [ast |a2s (613 [van [ora [753 [918 | 810 soz [vv | || [752 [886 [900 [730 [os [oes [ros [apa [ars [e22 [ois [722 |70 [921 | si sor [vv | | |v 776 [918 [909 [735 [ove [ors [rir [ois [wa [ois [oun (755 [751 [924 [ais  SIN 1 |S \f"
        ],
        [
            "Mean Cosine Similarity Between Comparison and Target Scripts",
            "| model_idx | seed | valloss ‘| epoch | model_path 9.465515518188477 | 13 Proto-Elamite_ensemble_1_hybrid_extractor_best.pth  10.229036331176758 Proto-Elamite_ensemble_2_hybrid_extractor_best.pth  9.9594895362854 Proto-Elamite_ensemble_3_hybrid_extractor_best.pth 9.304905700683594 | 12 Proto-Elamite_ensemble_4_hybrid_extractor_best.pth 9.408125591278075 | 11 Proto-Elamite_ensemble_5_hybrid_extractor_best.pth    \f"
        ],
        [
            "All standardized and unstandardized regression weights are presented in Table",
            "B (SE) B t p sr Model 3 (Maternal sensitivity)  Model 3 Step 1 Maternal age 002 (.005) 028 342 £733 <.001 Maternal education 052 (.035) 135 1.465 .145 013 Vocabulary (WAIS-III) .028 (.014) 217. 1.922 9577 023 Verbal comprehension (WAIS-IIT) .008 (.013) .066 575.567 002 Model 3 Step 2 Maternal age 002 (.005) 026 322 .748 <.001 Maternal education .056 (.036) 146 1.569 .119 015 Vocabulary (WAIS-III) 028 (.014) .222 1.956 9527 023 Verbal comprehension (WAIS-III) .006 (.013) 053 A59 ~~ 647 001 Balancing-forgiving (PAAS) 041 (.045) 073 919 ~~ .360 005 Model 3 Step 3 Maternal age .000 (.005) -.003 -.036 .971 <.001 Maternal education 055 (.035) 143 1.578  .117 <.001 Vocabulary (WAIS-III) 025(.014) 194 1.752 Qg27 015 Verbal comprehension (WAIS-III) —.002 (.013) 019 166 .868 <.001 Balancing-forgiving (PAAS) .025 (.044) 044 566 .572 002 Resolution .035 (.012) 239 2.980 .003**  .052 \f"
        ],
        [
            "LongBench Results with 25% Budget Allocation for full\nattention (Full), DuoAttention (Duo), Streaming LLM (SLLM),\nH2O and NAtS on the LLama8B model.",
            "   NarrativeQA Qasper MultiFieldQA-en MultiFieldQA-zh HotpotQA 2WikiQA Musique DuReader (zh) GovReport QMSum MultiNews VCSUM (zh) TREC  TriviaQA SAMSum  LSHT  Passage Count PassageRetrieval-en PassageRetrieval-zh LCC RepoBench-P  Full  27.3 28.9 52.3 50.9 40.6 29.3 24.4 30.2 34.1 24.5 biel 11.3 71.0 87.7 42.5 38.0  1.0 80.5 61.2 Died 38.0  NAtS le-6  18.71(3%) 25.55(11%) 38.76(9%) 40.55(12%) 31.71(6%) 25.9(9%) 16.25(5%) 26.23(7%) 25.52(7%) 22.88(5%) 26.83(19%) 12.35(7%) 57.0(10%) 84.67(7%) 41.03(6%) 23.5(6%) 0.0(8%) 12.0(5%) 5.62(10%) 43.91(18%) 42.8(9%)  NAtS 5e-7  20.79(4%) 28.35(13%) 45.68(12%) 45.04(15%) 34.92(8%) 26.08(11%) 19.08(7%) 30.0(9%) 29.19(9%) 23.24(6%) 27.22(21%) 12.58(9%) 58.0(11%) 87.89(9%) 41.39(7%) 27.0(8%) 0.5(10%) 46.5(7%) 14.88(12%) 44.07(20%) 41.87(11%)  NAtS le-7  23.09(13%) 29.01(26%) 48.72(22%) 46.03(27%) 41.7(17%) 27.39(20%) 21.0(16%) 28.44(20%) 33.47(20%) 23.88(15%) 27.71(32%) 9.4(19%) 68.5(22%) 87.42(18%) 41.78(14%) 35.5(20%) 1.59(23%) 67.0(15%) 41.07(24%) 40.11(35%) 42.63(25%)  NAtS 5e-8  23.95(20%) 28.74(36%) 50.91(31%) 48.13(37%) 40.76(25%) 25.47(27%) 23.18(24%) 26.41(29%) 33.97(29%) 23.63(23%) 27.92(40%) 8.03(28%)  69.5(30%)  87.36(26%) 41.32(20%) 37.0(29%)  5.14(30%)  75.05(22%) 45.79(32%) 38.3(44%)  39.72(35%)  NAtS le-8  26.11(49%) 28.24(63%) 53.27(57%) 46.6(64%) 40.76(49%) 27.76(51%) 24.0(48%) 27.69(57%) 34.29(55%) 24.18(49%) 27.97(65%) 8.86(58%) 69.5(56%) 88.37(5 1%) 40.91(43%) 39.5(58%) 2.09(52%) 81.0(47%) 50.34(60%) 38.5(68%) 39.18(59%) \f"
        ],
        [
            "Assessment of the ChatGPT-4o-generated exercise plans: safety issues",
            "Prompts  Prompt 1  Prompt 2  Prompt 3  Precise Wording “Create a 12-week exercise plan tailored to the following individual with type 2 diabetes mellitus: [individual patient details, e.g., female, 35 years old, body mass index of 28 kg/m, ...]”  “Create a 12-week exercise plan tailored to the following individual with type 2 diabetes mellitus: [individual patient details]. Consider recommendations from the American Diabetes Association and the American College of Sports Medicine. Consider potential contraindications. Define a possible training goal Specify training type, frequency per week, duration of a single training session, training method and training intensity. If possible, also consider the individual’s personal exercise preference”. “Instruction:  Create a detailed, 12-week exercise plan specifically tailored for an individual with type 2 diabetes mellitus The exercise plan should align with established medical and fitness guidelines, while also addressing the individual’s personal preference and health status.  Context:  The individual is ... [individual patient details]. The American Diabetes Association (ADA) and the American College of Sports Medicine (ACSM) provide guidelines for exercise plans for people with type 2 diabetes, which should be considered to ensure safety and effectiveness. Any contraindications that might arise from the individual’s medical condition or medications should be taken into account. The person prefers ....[individual patient details] and the plan should balance aerobic activities with other types of exercises beneficial for managing diabetes, such as resistance training.  Input data: \f"
        ],
        [
            "The full list of emotions, their grouping, and their VAD values accordingly",
            "Model One | Two | Three | Acc     GPT-4, 1x 1.00 | 1.00 | .936 | .978 LLaMA-3, 1x | .908 | .897 | .781 | .862 LLaMA-3, 3x | .969 | .969 | .850 | .930 LLaMA-3, 10x | .981 | .981 | .853 | .938 \f"
        ],
        [
            "Results on MusicQA, MusicCaps, and Music4way-MusicCaps",
            "Model  NExT-GPT (Wu et al., 2024)  NExT-GPT w/ M*UGen  NExT-GPT w/ Music4way  DeepResonance-ca (ours)  DeepResonance-/ (ours)  MusiLingo (supervised performance upper bound)  BLEU-1 BLEU ROUGE-P ROUGE-R ROUGE-F1 BERT-P BERT-R- BERT-F1  13.9 7.1 7.3 8.6 9.4  45.0  0.1 0.1 0.2 (0.2 (0.2  23.7 33.0 32.7 35.9 33.6  12.2 10.2 10.4 10.5 11.4  15.4 15.3 15.5 15.8 16.5 2.9  85.7 87.6 87.8 88.4 88.4  84.2 83.6 83.8 83.8 84.0  84.9 85.6 85.8 86.0 86.1 86.1 \f"
        ]
    ]
}